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DEVELOPMENT AND IMPLEMENTATION OF A HOMOGENEOUS AND 
HETEROGENEOUS ANTHROPOMORPHIC END TO END QUALITY 
ASSURANCE AUDIT SYSTEM PHANTOM FOR MAGNETIC RESONANCE 
GUIDED RADIOTHERAPY MODALITIES RANGING FROM 0.35 T TO 1.50 T 
 
Angela Kay Steinmann, M.S. 
Supervisory Professor: David S. Followill, Ph.D. 
Abstract 
Introduction: Magnetic resonance (MR) guided radiation therapy (MRgRT) is 
an emerging field that integrates an MR imager with either a linear accelerator or three 
radioactive cobalt-60 sources. Before institutions participate in multi-institutional NCI-
sponsored clinical trials, they are required to perform a credentialing test provided by 
IROC-Houston. During the credentialing test, end-to-end phantoms are used to evaluate 
the institution’s ability to perform consistent and accurate radiation treatments. IROC-
Houston’s conventional anthropomorphic phantoms are not visible in MR, thus they are 
insufficient for MRgRT systems. The purpose of this work was to create an 
anthropomorphic thorax and a head and neck (H&N) phantom for MRgRT systems 
with magnetic fields ranging from 0.35T to 1.5T.   
Methods: Over 80 synthetic materials were examined as potential materials 
used to construct the MRgRT thorax and H&N phantoms. Materials were characterized 
by: 1) measuring Hounsfield units, 2) visualizing in MR and CT imagers and 3) 
evaluating their dosimetric characteristics. Once materials were selected for the 
MRgRT phantoms, radiochromic film and double-loaded TLDs were then characterized 
in a 1.5T and a 0.35T MR environment. Reproducibility measurements on double-
loaded TLDs were performed by using an acrylic block and irradiating it in 0T/1.5T 
and 0T/0.35T configurations on the Unity system and the MRIdian Cobalt 60 system, 
viii 
 
respectively. Geometrical thorax and H&N phantom slabs were designed to mimic 
similar interface conditions seen in anthropomorphic phantoms, but were simplified to 
reduce manufacturing time. The geometrical phantoms were designed with a 
rectangular tumor centrally located around surrounding tissue. These two phantoms 
were used to characterize radiochromic EBT3 film and TLDs by comparing beam 
profiles and point dose measurements irradiated with and without magnetic fields, 
respectively. GEANT4 Monte Carlo simulations validated the detectors in both Unity 
0T/1.5T and MRIdian 0T/0.35T configurations.  Two MRgRT anthropomorphic (H&N 
and thorax) phantoms were designed, manufactured and evaluated. A reproducibility 
and feasibility study was conducted to evaluate the phantom’s performance on MRgRT 
systems.    
Results: This study found four materials which were tissue equivalent and 
visible on both MR and CT. Additionally, this study showed negligible difference in 
dose response between TLDs and radiochromic film when irradiated in 0.35T and 1.5T 
magnetic field environments. Two anthropomorphic phantoms were constructed and 
evaluated. The anthropomorphic thorax and H&N phantoms passed IROC-Houston’s 
7%/5mm and 7%/4mm gamma passing criteria, respectively.  
Conclusions:  An anthropomorphic thorax and an H&N phantom were tissue 
equivalent, compatible with MR and CT workflows and could be used as end-to-end 
QA tools for MRgRT systems with magnetic fields ranging from 0.35T to 1.5T.  
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Chapter 1: Introduction 
 
 
1.1 BACKGROUND 
1.1.1 Imaging Guidance in Radiation Therapy  
Most modern radiotherapy systems are equipped with image-guided radiotherapy 
(IGRT) devices to verify patient setup and manage intrafraction and interfraction 
motion1-3. IGRT devices can broadly be categorized into either radiation or non-radiation 
based systems. Some radiation-based systems include: electronic portal imaging device 
(EPID), Computed Tomography (CT) on rails, Megavoltage CT (MVCT), and cone beam 
CT (CBCT); common non-radiation based IGRT devices are ultrasound and camera-
based systems. Modern treatment vaults can be equipped with either a single IGRT 
system or multiple IGRT systems used in conjunction with one another. 
Gantry-mounted electronic portal imaging systems, commonly known as EPID 
systems, are equipped with a flat-panel imager mounted parallel to an in-field linear 
accelerator. These systems are used to verify patient setup from the treatment field’s 
orientation by capturing a single two-dimensional (2D) MV image. Modern EPID 
systems are readily available since they use the same beam path and energy as the linear 
accelerator. Compton interaction dominates during MV imaging. Consequently, these 2D 
images produce poor contrast between tissues that have similar effective atomic numbers 
(Zeff)4. Structure interfaces that have large Zeff deviations, such as bony anatomy or 
fiducial markers next to soft tissue, will have high contrast delineation in MV images. 
Therefore, EPID images are primarily used to verify patient setup by comparing gross 
anatomy (i.e., bony anatomy) to CT images. While EPID systems are convenient and use 
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the same photon beam, they are a limiting IGRT system since they mostly are used to 
align rigid structures. EPID systems (unless imaged multiple times) are also limited since 
they only capture a 2D image at a single point in time.  
Another IGRT system, known as MVCT, captures a three-dimensional (3D) 
image by using an in-field MV beam parallel to a fan beam detector. Helical 
TomoTherapy is the most commonly known MVCT system used in the clinic and was 
specially designed to alleviate 2D setup errors. During imaging acquisition, the beam 
energy is reduced from 6 MV to 3.5 MV and both detector and beam rotate around a 
single isocenter as a treatment couch travels through the bore. The reduced beam energy 
allows for greater soft tissue contrast compared to a normal 6 MV image and eliminates 
streaking artifacts caused in lower KV images5. While MVCT soft tissue contrast is 
enhanced, acquired images have poor delineation between tumor and surrounding 
tissues. Additionally, MVCT requires more time to acquire an image and can only 
capture a single-frame image6. 
To produce diagnostic-quality images, a conventional CT can be installed inside 
the treatment vaults. Commonly referred to as, CT on rails, a treatment couch is rotated 
180 degrees where a mobile diagnostic CT scanner slides across a pair of rails and 
captures a 3D image which is then used to verify patient setup3.  Diagnostic-quality 3D 
CT images permit better soft tissue contrast than MV generated images, thus improving 
soft tissue localization. CT on rails has a few limitations: 1) images are only captured pre 
or post treatment, 2) large vaults are required to hold both systems, and 3) CT on rails is 
incapable of tracking intrafraction motion. 
CBCT is currently a popular IGRT system which is typically mounted onto the 
treatment gantry and installed orthogonal to the treatment beam. This system is equipped 
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with a retractable x-ray tube parallel to a flat panel imager7.  KV energies are used to 
acquire a single-frame volumetric image by rotating the gantry around the treatment 
couch2-4.  CBCT images produce superior soft tissue contrast compared to common MV 
IGRT systems. While CBCT is currently considered the most universal 3D IGRT system 
used for pre-treatment setup verification, there are limitations prevent CBCT from being 
the absolute universal IGRT system3. The cone beam geometry in CBCT contributes to 
larger radiation scatter which consequently affects the image quality. Therefore, 
diagnostic-quality CT images are not captured in CBCT imagers. This degrade in image 
quality can impair soft-tissue delineation that is required to accurately verify treatment 
setup. Similar to other IGRT systems, CBCT is limited to only capturing a single-frame 
image and is unable to track intrafraction motion without capturing multiple images that 
would then increase patient dose.  
Ultrasound imaging can also be used as an IGRT system for radiotherapy. In-
room ultrasound image guidance is inexpensive, non-ionizing and is used as a site-
specific tumor localization method. Ultrasound captures a 2D image which is used to 
localize soft tissue organs such as a liver, a breast or a prostate. In-room ultrasound image 
guidance verifies patient setup by mapping a 2D ultrasound image to the treatment 
room’s coordinate system3-5.  Other than being restricted to soft tissue organs, there are 
two limiting factors: 1) inter-user variability and 2) the inability to capture real-time 
images4; 5. Ultrasound images are hard to reproduce since the acquisition is highly 
dependent on the transducer’s angle relative to the patient. Secondly, images are not 
captured during treatment since these systems are not automatized and therefore require 
a sonographer to operate the equipment. Since the transducer is required to be close to 
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the patient, any automated system would generally be within the treatment field and 
ultimately might alter the dose deposition. 
Camera-based systems are another non-ionizing radiation imaging technique. 
These systems are used to verify setup positions through visible or infrared cameras. In-
room camera based systems are relatively cheap to install and have a live feedback 
mechanism used to correct setup errors occurring at any point during treatment7. Some 
of these systems are used for site specific locations. These systems mostly commonly are 
used to account for intrafraction motion by implying either gating or external surrogating 
techniques. The major limitation of camera-based systems is the lack of visualizing 
internal structures such as the disease site and surrounding normal tissues. Camera-based 
systems assume exterior surface motion directly correlates with tumor motion. For some 
tumors, measured surface movements do not accurately resemble the same motion a 
tumor experiences. Inability to visualize internal soft tissues prevents the system from 
accurately track tumor motion, and internal organ deformations7; 8. 
 
1.1.1.1 Benefits of On-board MR imaging 
Current IGRT systems have greatly improved dose delivery accuracy in radiation 
therapy by reducing interfraction setup errors; however, these systems all have 
limitations that either are incapable of distinguishing the disease site from surrounding 
normal tissue, visualizing the tumor in real-time or capturing images to be used for online 
adapted radiotherapy. Recently, there have been attempts to mitigate these limitations by 
integrating a magnetic resonance (MR) system with either a linear accelerator or a 
radioactive cobalt 60 source. MR provides superior soft tissue contrast compared to 
images acquired from either KV or MV imagers. This improved ability to visualize soft 
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tissue would consequently increase the accuracy of delineating the tumor boundary from 
normal tissue (Figure 1)9. Better target delineation could be used to reduce margins or 
increase the gross tumor volume (GTV) radiation boost, which could potentially increase 
local tumor control and reduce normal tissue toxicities. Another advantage is that MR 
does not contribute to the absorbed dose; so, a patient is not restricted to a single-frame 
setup image but rather could be image during the entire treatment. Fast sequence 
protocols used in on-board MR scanners enable 2D and 3D cine images during treatment. 
This eliminates the need for external surrogates and improves gating techniques by 
tracking the disease site in real-time. Online adapted radiotherapy could be implemented 
in the clinic since images with superior contrast would be used to localize the disease 
site. The newly captured MR image would then be used to adjust the treatment plan to 
the disease site’s current location. On-board MR imagers could potentially be used to 
capture functional imaging information which then could be used to quantify and 
evaluate the overall tumor progression during treatment. Therefore, on-board MR 
imagers could revolutionize radiation treatment by improving the certainty of delivering 
radiation.  
 
Figure 1: A comparison between abdominal images captured on a 0.35T on-board MR 
imager (left) and CBCT (right). The low field MRI provides high soft tissue contrast to 
distinguish between a pancreas tumor and surrounding organs, whereas the CBCT shows 
insignificant contrast between the two9. 
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1.1.2 MR guided Radiation Therapy Systems 
 
Magnetic resonance guided radiotherapy (MRgRT) is a rapidly emerging field 
which integrates a fully functional MR imager in conjunction with either a linear 
accelerator or a radioactive Cobalt 60 (60Co) source. Presently, there are a total of six 
different MRgRT prototypes:  two are still in the research stage and four have been fully 
implemented into the clinic10-16.  Pre-clinical MRgRT systems are: the Australian MR-
Linac (Ingham Institute, Liverpool, Australia) and Aurora RT (MagnetTx Oncology 
Solutions, Alberta, Canada) and clinically implemented MRgRT systems are:  MRgRT 
suite (Varian, Palo Alto, California, USA and Siemens, Erlangen, Germany), Unity 
(Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands). MRIdian 60Co 
(ViewRay, Oakwood Village, Ohio), and MRIdian Linac (ViewRay, Oakwood Village, 
Ohio).  
In short, the Australian MRI-Linac is an inline MRgRT system equipped with a 
6 MV linear accelerator and a 1.0 T open bore magnet11. This system was designed to 
have a fixed 6 MV beam with a mobile treatment couch that was capable of rotating 360 
degrees inside the bore11; 17.  The Aurora RT system was first designed to have a 6 MV 
beam only; however, additional research has been performed to create a versatile MRgRT 
system that has four possible (4 MV, 6 MV, 8 MV and 10 MV) discrete energies13; 18-20. 
This system was designed such that a linear accelerator can rotate around a biplanar 0.5T 
magnet, thus allowing a photon beam to transmit in either parallel or perpendicular 
directions from the magnetic field13; 21. The first MRgRT system used to treat patients 
was developed at the Princess Margaret Cancer Centre and is commonly known as the 
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MRgRT suite. This suite interconnects three rooms which allow a Siemen’s MRI on rails 
system to travel to either a Varian TrueBeam vault or a Nucletron brachytherapy suite10. 
Elekta’s Unity system started treating patients in 2017 and is equipped with a 7 MV linear 
accelerator located above a modified 1.5T Philip’s MR scanner. The ViewRay system 
currently has two models: ViewRay MRIdian and ViewRay MRIdian Linac, both of 
which are FDA cleared and have been fully implemented into the clinic to treat patients. 
The MRIdian system, which started treating patients in 2014, is equipped with three 60Co 
radioactive head sources located in between a split 0.35T magnet. The MRIdian Linac, 
which started treating patients in 2017, is a modification to the original 60Co MRIdian 
system22. In this upgraded MRgRT system, the three radioactive sources were replaced 
with a single 6 MV beam. Table 1 is a summary of all MRgRT systems and their technical 
specifications. 
While there are several different emerging MRgRT devices (Table 1), the only 
systems currently used within the United States are the Elekta/Philip’s Unity, the 
ViewRay’s MRIdian 60Co, and the ViewRay’s MRIdian Linac MRgRT system. Both 
MRIdian and Unity systems are capable of intrafractional and interfractional monitoring, 
cine images during treatment, and adaptive radiation therapy15; 23. These systems were 
used to develop and characterize the Imaging and Radiation Oncology Core Quality 
Assurance Center in Houston’s (IROC-Houston) MRgRT QA phantoms. These three 
MRgRT systems’ configurations will further be discussed in the following subsections.  
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MRgRT 
Systems 
Energy 
Magnetic 
Field 
Strength 
Bore 
Diameter 
Beam 
Direction to 
Magnetic 
Field 
First 
Treated 
Patients 
Australian 
MRI-Linaca 
6 MV 1.0T 82 cm 
Parallel or 
Perpendicular 
n/a 
Aurora RTb 
4, 6, 8 
and 10 
MV 
0.5 T 60 cm 
Parallel or 
Perpendicular 
n/a 
MRI on 
Railsc 
6 MV 1.5T 70 cm n/a 
2014 
(Princess 
Margret 
Cancer Centre, 
Canada) 
Unityd 7 MV 1.5T 70 cm Perpendicular 
2017 
(UMC Utrecht, 
Netherlands) 
MRIdiane 3 Co-60 0.35T 70 cm Perpendicular 
2014 
(Washington 
University, 
USA) 
MRIdian 
Linace 
6 MV 0.35T 70 cm Perpendicular 
2017 
(Henry Ford 
Health Systems, 
USA) 
a: Ingham Institute, Liverpool, Australia b: MagnetTx Oncology Solutions, Alberta, Canada c: Varian, Palo Alto, 
California, USA and Siemens, Erlangen, Germany d: Elekta, Crawley, United Kingdom and Philips, Amsterdam, 
Netherlands e: ViewRay Oakwood Village, Ohio, USA  
 
Table 1:  Summary of the current MRgRT systems. Among all MRgRT systems, two are in 
the clinical development stage (Australian MRI-Linac and Aurora RT) and four have been 
used to treat patients (MRI on Rails, Unity, MRIdian, and MRIdian Linac).  
 
1.1.2.1 Elekta Unity System  
The Unity system was equipped with a flattening filter free (FFF) 7 MV standing 
waveguide attached to a slip ring gantry centrally located above a modified 1.5T MR 
system (Figure 2). The magnet was redesigned to have a 15 cm gap free of coils in the 
center of the magnet. Additionally, active shielding was modified to create a low field 
toroidal (<10-3T magnetic field) in the center of the magnet24; 25. The 7 MV linear 
accelerator was centrally installed above the magnet, where both systems could be 
magnetically decoupled from one another. The MR component works independently of 
the linear accelerator and can be used to capture real-time diagnostic-quality 2D and 3D 
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images at 8 frames per second. The linear accelerator was designed to have a 160-leaf 
multi-leaf collimator (MLC) system and could be extended to have a maximum field size 
of 57 cm (sagittal) by 22 cm (axial) 23; 26. The Unity system is presently not FDA cleared 
to treat patients in the United States; however, the first patient treated on the Unity system 
was at The University Medical Center Utrecht in 201723.  
 
 
 
1.1.2.2 ViewRay MRIdian System 
The ViewRay MRIdian is the first single-room integrated MRgRT system to 
simultaneously treat and image patients. The MRIdian system was FDA cleared in 2012 
and began treating patients in 2014. The MRIdian system (Figure 3) delivers modulated 
radiation therapy using three independent 60Co head sources equally spaced 120-degrees 
from each other. The radioactive sources are centrally located in between a split 0.35T 
Figure 2: Elekta’s Unity system, which is the first high magnetic field (1.5T) 
system integrated with a 7 MV linear accelerator.  
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superconducting magnet27. All three 60Co head sources simultaneously rotate 240-
degrees around a ring gantry to provide 360-degree coverage and can be used 
individually or simultaneously with one another. The head sources can be used together 
to provide a dose rate comparable to a typical 6 MV linear accelerator (550 cGy/min at 
installation) 15; 28. Each source was equipped with a 60 leaf double-focus MLC to provide 
comparable penumbras that are typically seen in a 6 MV linear accelerator15; 28. Using 
radioactive head sources in between a split magnet eliminated the need for electronics, 
which allowed the two systems to work independently of one another. 
 
Figure 3:  ViewRay’s first MRgRT system.  The MRIdian Co-60 is comprised of three 
equally spaced cobalt 60 head sources centrally located in between a spilt 0.35T 
semiconducting magnetic. In 2014, the first patient was treated on the MRIdian Co-60 
system at Washington University School of Medicine in St. Louis, Missouri, USA27. 
 
The MRIdian Linac (Figure 4) is an upgraded MRgRT system that replaced three 
radioactive 60Co sources with a single compact inline S-band 6 MV standing 
waveguide29; 30. Similar to ViewRay’s first generation MRgRT system, the linear 
accelerator is centrally located in between a split 0.35T superconducting magnet. The 
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compact linear accelerator is enclosed around a magnetic and RF shield, thus allowing 
the two systems to work independently of each other30. The FFF linear accelerator was 
designed to produce dose rates greater than 600cGy/min and was constructed with 138-
leaf double-focused double-stacked MLC system. The two sets of MLC are used to create 
a sharp penumbra and to reduce interleaf leakage30. The MRIdian Linac was granted 
FDA clearance in early 2017 and started treating patients that summer22. 
 
Figure 4: ViewRay’s upgraded MRgRT system.  The MRIdian Linac is comprised of a 6 MV 
linear accelerator centrally located in between a spilt 0.35T semiconducting magnetic. The 
first patient treated on the MRIdian Linac was in 2017 at Henry Ford Health Center, Gross 
Point, Michigan, USA29. 
 
Both MRIdian and MRIdian Linac systems use a Monte Carlo based treatment 
planning system known as the ViewRay System Treatment Planning and Delivery 
Software (VR-TPDS). The VR-TPDS is capable of creating 3D conformal radiation 
therapy (3D-CRT), intensity modulated radiation therapy (IMRT), stereotactic body 
radiation therapy (SBRT), stereotactic radiosurgery (SRS) and IGRT plans. At 4 frames 
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per second, both systems can acquire a single sagittal image using a single true fast 
imaging with a steady state precession MR sequence31. 
1.1.3 Dosimetric Challenges in MRgRT systems 
Secondary electrons, set into motion from photon interactions, are affected by 
magnetic field environments. This phenomenon can be explained by the Lorentz force 
(Equation 1). When charge particles (q) with a velocity (v) experience a magnetic field 
(B), the Lorentz force causes the charge particle’s trajectory to curve perpendicularly 
from the magnetic field direction and velocity direction.   
𝑭 = 𝑞(𝒗 × 𝑩) (Eq.1) 
 
The magnetic field affects the trajectories of secondary electrons which, specific 
to radiotherapy, will consequently affect dose being deposited into a tissue. Figure 5 
visually describes how a single electron’s point spread kernel is affected in different 
magnetic field strengths perpendicular to a 6 MV photon beam inside a homogenous 
water phantom32. In low magnetic field environments (i.e., 0.2T), the electron’s trajectory 
is generally unaffected by the magnetic field and creates similar radiation deposition seen 
in zero magnetic field environments. In high field environments (i.e., 3.0T), the electron’s 
trajectory is greatly influenced by the magnetic field and, as a result, deposits dose in an 
arc-shape pattern. The radius of an electron’s arc-shape trajectory is proportional to the 
electron’s energy and inversely proportional to the experienced magnetic field strength32.  
Therefore, the point spread kernels are more asymmetrically pronounced for higher 
magnetic fields and lower electron energies. 
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Figure 5: Point spread kernels for a single electron trajectory in a homogenous medium 
under a 6MV beam perpendicular to (a) 0T, (b) 0.2T, (c) 0.75T, (d) 1.5T and (e) 3T magnetic 
field strengths. Point spread kernels become more asymmetric in larger magnetic field 
environments32.  
 
 
Secondary electrons traveling through heterogeneous materials in the presence of 
a magnetic field will experience what is known as the electron return effect (ERE). The 
ERE is most prominent at interfaces with high density variations such as: air cavities or 
patient exteriors. As the electron exits from a higher-density material and enters into a 
lower-density material, the electron will curve back into the high-density material and 
deposit dose (Figure 6). In Monte Carlo studies, dose deposited in complex 
heterogeneous systems generally showed that the dose decreased in low-density to high-
density interfaces but increased in high-density to low-density interfaces33. Further 
investigation also showed that, at first order, opposing photon beams could 
counterbalance the ERE effect in heterogeneous materials33.  
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Figure 6: A single electron trajectory propagating through high to low density medium in 
absence (left) and presence (right) of a magnetic field34. 
 
High magnetic field can also affect general radiation beam characteristic, namely, 
percent depth dose (PDD) curves and beam profiles.  In general, the secondary electron’s 
helical-shape trajectories reduce the overall path, causing the PDD to shift. Specifically 
in a 7 MV photon beam perpendicular to a 1.5T magnetic field configuration, the PDD 
is modified causing a shorter build-up region, a 4-5 mm shift in the depth of maximum 
dose (dmax) towards the surface, and an approximately 0.5% reduction in dose beyond 
build up region (Figure 8)35; 36.  In the presence of a 1.5T magnetic field, the output at 
dmax is enhanced by 1.9%36. For a 7 MV beam the dmax was measured at 1.3 cm and 
1.7 cm for 1.5T and 0T configurations, respectively36. 
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Figure 7:  Geant4 Monte Carlo measurements comparing PDD curves under the presence of 
0T and 1.5T magnetic field strengths for a 7 MV photon beam with a 10x10 cm2 field size35.  
 
Magnetic fields also affect beam profiles by creating asymmetric dose deposition 
in the lateral direction. The entire field, towards the Lorentz force direction, shifts 
approximately 1 mm for all field sizes at the 50% level35; 37. A more dramatic shift was 
seen in the shoulder region of the profiles due to the magnetic field influence. As shown 
in Figure 8, the general shape of beam profiles measured in a 1.5T magnetic field are 
asymmetric and more pronounced in smaller field sizes. From the central axis, the 
disproportional penumbras are less pronounced on the right side and vice versa, more 
pronounced on the left side due to the effects of the magnetic field. In general, smaller 
fields (1x1cm2) are affected more by a magnetic field than larger field sizes (i.e., 10 x 
10cm2)32.  
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Figure 8: GEANT4 Monte Carlo generated beam profiles for a 6 MV radiation beam 
incident perpendicular to 1.5T and 0T magnetic field strengths for 1.0 cm x 1.0 cm2 and 5.0 x 
5.0 cm2 field size34. 
  
 
1.1.4 Conventional IROC Phantoms  
IROC-Houston, formally known as Radiological Physics Center or RPC, has 
been funded by the National Cancer Institute (NCI) since 1968 to help credential and 
audit institutions participating in NCI sponsored clinical trials. IROC monitors NCI 
participating institutions’ performances through either on-site dosimetry visits or off-site 
auditing methods.  
Among various off-site quality assurance (QA) programs, IROC-Houston 
implemented an anthropomorphic program designed to evaluate multi-institutions’ 
performances through an end-to-end examination. The main purpose of this off-site QA 
program was to ensure that all institutions participating in NCI clinic trials could deliver 
comparable and consistent radiation treatments. During the examination, the 
anthropomorphic phantom will experience the same clinical workflow (i.e., CT imaging, 
treatment planning, treatment setup, and dose delivery) as a patient, thus analyzing the 
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institution’s capability of delivering radiation based on their expected treatment plan. 
IROC-Houston’s current site-specific phantoms used in photon beams include: SRS 
Head, IMRT Head and Neck (H&N), IMRT Thorax, 3D CRT Thorax, IMRT Spine, liver 
and pelvis/prostate. Most of IROC-Houston’s phantoms are similarly designed consisting 
of a water-fillable shell and a removable insert which contains: dosimeters, tumor targets 
and organ(s) at risk (OAR) structures. 
IROC-Houston’s most widely used phantoms are the H&N and thorax 
anthropomorphic phantoms and are, respectively, visualized in Figure 10 & Figure 9. 
The materials used to manufacture these phantoms are described in Table 2. In short, the 
H&N phantom insert consists of an acrylic spinal cord representing an OAR, surrounding 
tissue constructed of high impact polystyrene (HIPS), and two (primary and secondary) 
planning target volumes (PTV) constructed from solid water. The thorax phantom utilizes 
a programmable stepper motor to reflect normal inhale/exhale physiology and consists 
of an acrylic spinal cord, nylon heart, two lungs constructed from compressed cork, and 
HIPS representing a PTV centrally located inside the left lung. Substituted materials used 
in the H&N and thorax phantoms are tissue equivalent and have similar density as 
corresponding human tissues (Table 3). 
 
Structure H&N Materials Thorax Materials 
Tumor Solid Water HIPS 
Surrounding Tissue HIPS Compressed Cork 
OAR: Spinal Cord Acrylic Acrylic 
OAR: Heart n/a Nylon 
Table 2: Material assigned to IROC-Houston’s conventional thorax and H&N phantom.  
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Figure 9: IROC-Houston’s water-fillable anthropomorphic lung phantom contains a nylon 
heart, an acrylic spinal cord, two compressed cork lungs and a centrally located HIPS tumor 
inside the left-side lung. The left-sided lung is created from an external insert that is 
mounted to a motion table to simulate breathing. 
 
 
Figure 10: IROC-Houston’s conventional H&N phantom is constructed using solid HIPS 
and is equipped with a centrally located single insert. The insert has two parts that combine 
to create an acrylic spinal cord, a semi-circle primary PTV and  a circular secondary PTV 
constructed of solid water.  
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Material 
Density 
[g/cm3] 
Acrylic 1.17 
Compressed Cork 0.33 
HIPS 1.20 
Nylon 1.08 
Solid Water 1.04 
Table 3: Density of substituted materials used in IROC-Houston’s conventional H&N and 
thorax phantoms. 
 
1.1.5 Detectors used in IROC Phantoms 
IROC-Houston’s anthropomorphic phantoms use thermoluminescent detectors 
(TLD) and radiochromic film. The measured doses on these detectors are compared with 
the expected treatment planning data. In total, eight double-loaded TLDs and three planar 
films were inserted into the H&N phantom. Similarly, the thorax phantom was equipped 
with four double-loaded TLDs and three planar films. TLDs are used as an absolute point 
dose measurement at a specific location and radiochromic films are used to describe 
planar relative dose distributions across a specific region within the insert.  
 
1.1.5.1 Thermoluminescent Detectors 
Thermoluminescent (TL) is a phenomenon in which inorganic crystals absorb 
radiation energy and proportionally emit energy in the form of light when heated. The 
generally accepted TL model theorizes that the impurities from the inorganic crystal 
causes electron traps in the forbidden energy bands38. These energy traps are located in 
between the “allowable” conduction (excited state) and valence (ground state) energy 
bands. When an inorganic material is irradiated, electrons in the ground state can absorb 
enough energy to rise to the excited state; thereby creating a vacancy (knowns as a 
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positive hole) in the ground state (Figure 11). Both excited electrons and positive holes 
move around in the conduction and valence bands until they recombine, respectively. 
Recombination can occur in two ways: 1) the excited electron can recombine with the 
positive hole in the ground state or 2) the excited electron and positive hole can get 
“trapped” respectively in an electron trap and hole trap38; 39. When the inorganic crystal 
is heated, electrons and positive holes receive enough energy to excite out of their traps, 
recombining and emitting one light photon per recombination39. The light photon is 
converted into an electrical current through a photomultiplier tube, and then read out. 
The intensity of light photons emitted is a function of temperature and is displayed on a 
glow curve. Figure 12 shows a typical example of a glow curve for TLD-100s. The area 
under the glow curve represents the signal which is the total number of light photons 
emitted39.
  
 
Figure 11: The physics behind TL phenomena. Impurities in lithium fluoride doped with 
magnesium and titanium (LiF: M, Ti) structures create positive hole and electron traps (a). 
When radiation passes through a TL structure, the electrons will be excited to a higher energy 
state and will leave holes in the valence band. Both holes and electrons will move around the 
valence and conduction bands, respectively, until they are either recombined or trapped (b). The 
electrons and holes are trapped until a source of heat simulates the structure. Heat energy is 
transferred to the electrons and holes thereby releasing them from their traps and allowing for 
them to recombine (c). Energy is conserved in the recombination process. The excess energy is 
released in the form of a visible light photon.  
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Figure 12: Typical Glow Curve for a TLD-100. The intensity represents the total light 
emitted as the material is heated40. 
 
Dose measurements from TLDs can be converted into absorbed dose by applying 
several correction factors to the average TL response from photomultiplier readout. Some 
of these correction factors include: system sensitivity, dose-response linearity, fading and 
energy response. System sensitivity correction factor accounts for the readout system. 
Since TLDs are linear up to 4 Gy, a linearity correction factor is used to account for 
superlinearity corrections at higher doses. At shallow traps, electrons and holes may 
recombine at room temperature and can “fade” the signal. Fading corrections are a factor 
of time and are implemented to account for reductions in the signal from irradiation time 
to read-out time.  
The most extensive TLDs used in radiation therapy are TLD-100s and are 
composed of lithium fluoride (LiF) and doped with titanium (Ti) and magnesium (M). 
TLD-100s are popular clinical dosimeters since they are nearly tissue equivalent 
(effective atomic number of: 6.06) and have deep traps which prevent extreme fading39; 
41. Impurities, caused from doping with Ti and M, allow for trap structures. TLDs can 
  22 
come in various forms (i.e., powder, rod, chip, and disk). IROC-Houston purchases 
powder-form TLDs (ThermoFisher Scientific, Waltham, Massachusetts, USA) which 
come in cylindrical capsules that have a 4 mm diameter and 15 mm length. Double-
loaded TLDs are filled with approximately 22 mg of LiF: M, Ti and is produced with no 
air gaps inside the TLD capsule. These TLDs have a linear range of 10 µGy to 1 Gy and 
provide two absolute point dose measurements. Previous studies, concluded by Kirby et 
al. 1992, showed TLDs to have a 3% precision and a dosimetrically accuracy of 5% (at 
93% confidence interval) compared to measured ion chambers readings42. 
 
1.1.5.2 Radiochromic EBT3 Film 
In addition to TLDs, IROC-Houston inserts radiochromic film into 
anthropomorphic phantoms to analyze the relative 2D radiation dose distributions. 
Currently, IROC-Houston uses GafChromic EBT3 (International Specialty Products 
Ashland Inc., Covington, Kentucky, USA) film for all anthropomorphic phantom studies.  
As shown in Figure 13, EBT3 film is manufactured with three main layers. A thin active 
layer (28µm) is located in between two transparent, matte polyester base sheets each 
having 125µm thickness. The two identical polyester base sheets that are directly 
attached to the active layer prevents the user from keeping track of what side the film 
was placed on the light source of a densitometer. According to the manufacturer, the 
active layer is comprised of marker dye, stabilizers, active component and aluminum 
oxide to minimize low-energy dependence43; 44.  EBT3 is nearly tissue equivalent with 
an effective atomic number of 6.71 and is generally used to measure radiation dose from 
0.01Gy to 10Gy43. EBT3 film is extremely useful for IROC-Houston since it can easily 
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be modified to fit inside an insert, does not require wet-post-processing methods, and is 
nearly insensitive to light.  
 
 
 
 
 
 
 
 
  
1.1.6 Dosimetric End-to-End Evaluations 
Gamma Analysis, first developed by Low et al. 1998, is a quantitative method 
which compares two distributions (calculated treatment planning dose distribution vs. 
measured dose distribution) using a point-by-point methodology. Specifically, this 
technique uses 3D spatial coordinates to align the two dose distributions and phantom 
dimensions to perform the comparison. The gamma comparison is a measure of the 
agreement in dose distributions (DD) considering dose delivered (percent difference 
criterion) and position of the dose [distance to agreement (DTA) criterion]. The percent 
criterion dominates in regions of shallow to no dose gradient, whereas the DTA criterion 
applies to dose distribution areas where there are steep dose gradients. IROC-Houston’s 
common evaluation criterion for H&N is 7% dose delivery and 4mm DTA (also written 
as 7%/4mm) and for the thorax phantom is 7%/5mm. During evaluation the normalized 
gamma-index (γ) will measure the smallest length between the reference point and the 
evaluation distributions. If the smallest length in the voxel is >1 (i.e., γ<1), then it said to 
be outside the assigned normalized criterion. Vice versa, if the smallest length is <1 (i.e., 
γ>1), then it is within the criteria tolerance.  The distributions of all γ values are 
Matte Polyester Base Sheet: 125µm 
Matte Polyester Base Sheet: 125µm 
 
Active Layer: 28µm  
Figure 13: Cross-section describing Gafchromic EBT3 film component layers. Two 125µm 
polyester base sheets protecting a 28µm active layer.  
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collectively used as a composite to determine whether the measured dose passes or fails 
the gamma analysis. This means that for each point in the measured volume, the 
measured dose must closely agree with the expected dose to within 7% or it must be 
nominally within 4mm of a point dose. For IROC-Houston’s H&N phantom, film is said 
to have a gamma passing rate when at least 85% of pixels have γ>1 for sagittal and axial 
film dose distribution.  Similarly, IROC-Houston’s thorax phantom was said to pass if 
the individual axial and sagittal films had at least 80% of pixel passing and if the 
combined films had greater than 85% of pixels passing.  
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1.2 STATEMENT OF PROBLEM 
The NCI requires participating institutions that intend to use IMRT techniques to 
first become credentialed by demonstrating their ability to accurately deliver radiation45; 
46.  IROC-Houston has developed various site-specific anthropomorphic phantoms that 
are used to credential participating institutions. These phantoms were designed as end-
to-end QA tests used in a traditional radiotherapy workflow. To complete an end-to-end 
test, the institution was required to capture a CT image, create an individual treatment 
plan based on IROC-Houston’s dose criteria, and irradiate the phantom using a 
conventional linear accelerator. IROC-Houston’s conventional phantoms are insufficient 
end-to-end QA tools for MRgRT systems. 
Unlike conventional linear accelerators, MRgRT systems use MR images to verify 
treatment setup, treatment guidance and online adapted radiotherapy. Using one phantom 
to perform an end-to-end test means the phantom must be used and visualized in both CT 
and MR imagers. IROC-Houston’s current phantoms are constructed of rigid materials 
that lack MR signal. Consequently, the lack of signal causes the tumor and surrounding 
tissue to be indistinguishable (Figure 14).  With future developments of MR-only 
workflows, IROC-Houston’s phantoms must be visible in MR to be used for end-to-end 
tests. Therefore, new MRgRT phantoms must be constructed with tissue equivalent 
materials that are visible in both CT and MR imagers.   
The goal of this project was to create two anthropomorphic phantoms, one being 
a homogenous H&N phantom and the other being a motion enabled heterogeneous 
thoracic phantom. These phantoms were designed for MRgRT systems that have a 
magnetic field ranging from 0.35T to 1.50T. The two phantoms will be used as remote 
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end-to-end auditing tools to credential institutions wishing to use MRgRT systems in 
NCI-sponsored clinical trials. 
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1.3 HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis: A homogeneous head and neck (H&N) and dynamic heterogeneous 
thoracic anthropomorphic phantom can be designed to evaluate MRgRT which will 
assure agreements between the measured and calculated doses within ±7%/4mm and 
±7%/5mm, respectively. 
 
Specific Aim 1:  
Identify synthetic tissue substitutes that are visible in MR, share common tissue 
equivalent properties in CT and are accurately modeled in a treatment planning system.  
Specific Aim 2:   
Characterize radiochromic EBT3 film, and thermoluminescence detectors (TLD) 
in the presence of a magnetic field and validate the detector characterizations using a 
Monte Carlo model.  
Specific Aim 3:  
Design and construct a homogeneous H&N and a dynamic heterogeneous thoracic 
anthropomorphic QA phantom; which will be used to verify the dose delivery with the 
characterized dosimeters while under the presence of a magnetic field ranging from 
0.35T to 1.50T. 
Specific Aim 4: 
Conduct a feasibility study for the homogeneous head and dynamic heterogeneous 
thoracic anthropomorphic phantoms while under the presence of 0.35T and 1.50 T 
magnetic field strengths. 
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1.4 BENEFITS TO SCIENCE 
End-to-end tests are performed with IROC-Houston’s phantoms to ensure all NCI 
participating institutions are delivering radiation accurately and in a comparable manner. 
Implementing MR into the clinical workflow will require new CT/MR visible 
anthropomorphic H&N and thorax phantoms. These specially designed MRgRT QA 
phantoms will be used as tools to credential institutions wishing to use MRgRT systems 
in NCI-sponsored clinical trials. MR/CT visible phantoms will be used to benefit the 
advancement of radiotherapy in two ways: 1) ensuring safe radiation delivery using 
MRgRT systems and 2) contributing to the general understanding of the 
advantages/disadvantages of MRgRT systems.  
A single QA device must be used to evaluate the overall treatment workflow in 
MRgRT systems. MRgRT systems have altered the conventional radiotherapy workflow. 
On-board MR imagers in MRgRT systems will be used to verify treatment setup, 
treatment guidance and online adapted radiotherapy. Some MRgRT systems are not 
equipped with lasers in the treatment room and solely depend on MR guidance to 
correctly setup a patient. Some systems will require reoptimizing the plan based on MR 
images acquired the day of treatment. The overall workflow uncertainty will be evaluated 
comprehensively by using IROC-Houston’s MRgRT phantoms as end-to-end test.  
MRgRT H&N and thorax phantoms will be essential tools used to credential 
institutions participating in NCI sponsored clinical trials. Ultimately, the NCI-sponsored 
clinical trials will be used to quantify the benefits of MRgRT systems. The MRgRT 
phantoms will contribute to the overall understanding of using on-board MR imagers in 
the clinic.  
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Chapter 2:  Developing and Characterizing MR/CT 
visible materials used in QA phantoms for MRgRT systems  
 
A substantial portion of this chapter is written or based on the following publication: 
 
A.Steinmann, R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller, D. Followill, 
“Developing and characterizing MR/CT visible materials used in QA phantoms for 
MRgRT systems,” Medical Physics. Doi: 10.1002/mp.12700. (2018). © John Wiley and 
Sons. 
 
The permission for reuse of this material was obtained from John Wiley and Sons. 
 
2.1 ABSTRACT 
Purpose: Synthetic tissue equivalent (STE) materials currently used to simulate 
tumor and surrounding tissues for IROC-Houston’s anthropomorphic head and thorax 
QA phantoms cannot be visualized using magnetic resonance (MR) imaging. The 
purpose of this study was to characterize dual MR/CT visible STE materials that can be 
used in an end-to-end QA phantom for MR guided radiotherapy (MRgRT) modalities. 
Methods: Over 80 materials’ MR, CT, and dosimetric STE properties were 
investigated for use in MRgRT QA phantoms. The materials tested included 
homogeneous and heterogeneous materials to simulate soft-tissue/tumor and lung tissues. 
Materials were scanned on a Siemens’ Magnetom Espree 1.5T using four sequences, 
which showed the materials visual contrast between T1 and T2 weighted images. Each 
material’s Hounsfield number and electron density data was collected using a GE’s CT 
Lightspeed Simulator. Dosimetric properties were examined by constructing a 10 x 10 x 
20 cm3 phantom of the selected STE materials that was divided into three sections: 
anterior, middle, and posterior. Anterior and posterior pieces were composed of 
polystyrene, whereas the middle section was substituted with the selected STE materials. 
EBT3 film was inserted into the phantom’s midline and was irradiated using an Elekta’s 
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Versa 6 MV beam with a prescription of 6 Gy at 1.5 cm and varying field size of: 10 x 
10 cm2, 6 x 6 cm2, and 3 x 3 cm2. Measured film PDD curves were compared to planning 
system calculations and conventional STE materials’ percent depth dose (PDD) curves. 
Results: The majority of the tested materials showed comparable CT attenuation 
properties to their respective organ site; however, most of the tested materials were not 
visible on either T1 or T2 weighted MR images. Silicone, hydrocarbon, synthetic gelatin 
and liquid PVC plastic-based materials showed good MR image contrast. In-house lung 
equivalent materials made with either silicone or hydrocarbon-based materials had HUs 
ranging from: -978 to -117 and -667 to -593, respectively. Synthetic gelatin and PVC 
plastic-based materials resembled soft tissue/tumor equivalent materials and had HUs of: 
-175 to -170 and -29 to 32, respectively.  
PDD curves of the selected MR/CT visible materials were comparable to IROC-
Houston’s conventional phantom STE materials. The smallest field size showed the 
largest disagreements, where the average discrepancies between calculated and measured 
PDD curves were 1.8% and 5.9% for homogeneous and heterogeneous testing materials, 
respectively. 
Conclusions: Gelatin, liquid plastic, and hydrocarbon-based materials were 
determined as alternative STE substitutes for MRgRT QA phantoms.   
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2.2 INTRODUCTION 
Advances in radiation oncology have drastically evolved over the past decade. 
Among the many changes, one of the most prominent additions is the use of on board 
imaging in conjunction with a radiation therapy treatment modality (i.e., cone-beam CT 
guided linear accelerator). While the integration of cone-beam CT (CBCT) with a 
modern linear accelerator enables patient set-up verification and target localization; this 
imaging modality is often limited to interfraction setup verifications 47-49. Several 
research collaborations were initiated several years ago to integrate a magnetic resonance 
imager (MR) with either a 60Co unit or a linear accelerator as a new form of image guided 
radiation therapy 13; 48. In comparison with CBCT, the integrated MR can provide images 
with superior soft tissue contrast, permit real-time imaging, and not cause any additional 
radiation dose. The incorporation of a magnetic resonance guided radiation therapy 
(MRgRT) modality into the clinic can provide visualization for both intrafractional and 
interfractional target motion. 
In the United States, there are two MRgRT systems: the Unity developed by 
Elekta/Philips (Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands) 
which is not yet in clinical use and the ViewRay MRIdian (ViewRay, Oakwood Village, 
Ohio) which is in clinical use. The Unity system is equipped with an Elekta 7 MV linear 
accelerator that is located in between a Philips’ 1.5 T MR scanner. Due to the active 
shielding on the superconducting magnets, a low magnetic field toroid is created, which 
enables a linear accelerator to be positioned and operate in between the two magnets with 
only a minimal magnetic effect10; 12.  In contrast, the MRIdian is a radiation therapy (RT) 
treatment machine with three independent 60Co sources located in between a split 0.35T 
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superconducting MR imager15. Each of the three 60Co treatment heads are equipped with 
a double focused multileaf collimator; thus, permitting the MRIdian unit to have a 
comparable penumbra and dose rate as a conventional 6 MV linear accelerator15.  
Additionally, ViewRay has developed a linac-based version of the MRIdian system. The 
MRIdian Linac, which was FDA approved in February 2017, is an upgraded system that 
incorporates a 0.35T superconducting magnetics with a 6 MV linear accelerator.  
Both MRgRT systems have the ability to provide real-time imaging and deliver 
adaptive RT. Despite the innovation and potential benefits of using a MR unit for 
MRgRT treatments, there are challenges that limit a MR-only RT workflow. Two of 
these include: 1) the inability to easily determine the patient’s electron density for 
treatment planning dose calculations and 2) geometric distortions produced on MR 
images 50-54. Conventionally, the patient’s electron density is indirectly determined 
through a bi-linear relationship between the linear attenuation data collected from a CT 
and the material’s respectively density. Unlike CT, where images are created from back 
projections of photons penetrating the body, MR does not use radiation to produce an 
image and solely relies on small fluctuations of the materials’ net magnetic moment. Due 
to the inherent differences in the acquisition process of MR and CT, the linear attenuation 
data is not collected in MR. Therefore, current MR scanners are unable to indirectly 
measure electron density from one scan. Additionally, it is critical to know the exact size 
and location of a patient’s anatomy in radiotherapy (RT). MR images commonly 
misrepresent actual patient anatomy in space (geometric distortion) due to the inherent 
configuration and design of a MR unit55.  Nonlinear gradients and heterogeneities in the 
static magnetic field primarily contribute to geometric distortions in the image52; 54; 55. 
Since geometric distortions and electron densities are limited to the inherent differences 
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in the acquisition process between MR and CT, it is critical that current MRgRT 
modalities rely on both CT and MR for treatment planning and treatment 
verification/treatment adaptation, respectively.  
End-to-end QA verifications performed for conventional radiation treatments 
have routinely focused on using a CT imager in a radiotherapy modality. However, with 
the incorporation of MR in radiotherapy, it is important that end-to-end QA tests expand 
to also include MR imagers. Current end-to-end QA phantoms used at the Imaging and 
Radiation Oncology Core at Houston (IROC-Houston) QA Center for credentialing 
purposes in National Cancer Institute (NCI) funded clinical trials are not MR visible. As 
shown in Figure 14, tumor and surrounding tissue in IROC-Houston’s anthropomorphic 
thorax phantom are distinguishable in CT images but are not in T1 and T2 weighted MR 
images. Dosimetrically the phantoms are accurate, but the plastics used to represent 
tumor and surround tissue in IROC-Houston’s phantoms do not yield any MR signal, 
which makes these phantoms deficient as end-to-end QA phantoms for MRgRT. Other 
researchers have attempted to create dual MR/CT phantoms, but the phantoms are limited 
by either: shelf-life storage, require refrigeration or additives to prevent microorganism 
growth and therefore were not suitable for shipping to other RT institutions56-58. 
The aim of this study was to identify and characterize STE materials that could 
be used to develop an anthropomorphic dual MR/CT QA phantom which would require 
minimal maintenance and be used to credential RT institutions wishing to use MRgRT 
modalities in NCI funded clinical trials.   
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Figure 14: Images a-c are used to illustrate the need for a dual CT/MR visible phantom for 
MRgRT modalities. This figure displays IROC-Houston’s Anthropomorphic Thorax 
phantom imaged in a GE Lightspeed CT simulator (a.) and Siemen’s Magnetom Espree 1.5T 
MR scanner (b-c). The phantom’s tumor and lung were constructed out of polystyrene and 
compressed cork, respectively. The tumor is located in the phantom’s left lung and is 
completely visible on a CT (a.) however, the tumor and surrounding lung tissue are not 
visually distinguishable in either a T1-weighted (b.) or T2-weighted (c.) MR image. 
 
2.3 MATERIAL AND METHODS 
2.3.1 IROC-Houston’s Traditional QA Phantoms 
IROC-Houston’s two anthropomorphic phantoms used most often are the 
heterogeneous thorax and homogeneous head and neck (H&N) phantoms. The thorax 
and H&N phantoms were previously described in detail by Followill and Molineu, 
respectively59; 60. Briefly, the current thorax phantom is a water fillable shell and contains 
two lungs made of compressed cork (one with a centrally located target made of nylon). 
Other organs at risk represented in IROC-Houston’s thorax phantom include a heart and 
spinal cord composed of polystyrene and acrylic, respectively. In IROC-Houston’s H&N 
phantom, the primary and secondary targets are constructed out of solid water and are 
surrounded by polystyrene. The polystyrene/solid water insert is enclosed into a water 
fillable plastic shell, which is shaped as a human head. For both phantoms, the materials 
used to simulate the targets and surrounding normal tissues are synthetic, rigid, and 
hydrogen deficient. These materials are ideal for traditional QA phantoms since they do 
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not require special storage conditions, require minimal maintenance, can easily hold 
radiation dosimeters, maintain their shape, are distinguishable using CT, and are 
dosimetrically similar to human tissue. 
 
2.3.2 Required Material Properties Used in MRgRT QA Phantoms 
To develop an appropriate MRgRT QA phantom, it is vital that the materials used for 
this dual modality phantom are:  1) visible on both T1 and T2 weighted MR images, 2) 
visible on CT images, and 3) have comparable HUs and dosimetrically simulate tumor 
and surrounding tissue. Since IROC-Houston ships their end-to-end QA phantoms to 
other institutions, these materials must also satisfy non-dosimetric characteristics. IROC-
Houston’s MR/CT visible materials must also endure rough shipping conditions, show 
longevity without adding preservatives, maintain their physical structure (i.e., high 
melting point) and show a relative ease in manipulating the material to form a realistic 
tissue shape and hold dosimeters.  A wide variety of materials (listed in Table 4) were 
tested for their dosimetric, MR and CT compatibility. The materials were first imaged 
using a MR and CT scanner. Based on the material’s MR and CT assessment, a decision 
was made on what materials to continue with dosimetric testing. Potential materials 
examined for a MR/CT QA phantom included: nylon-based, silicon-based, acrylic-based, 
and gel-based materials. In addition to commercially purchased materials, some tested 
materials were manufactured in-house.  The in-house mixtures incorporated mini 
Styrofoam balls with ranging diameters of 2-4mm with either a petroleum or silicone-
based material. Combining a based material with Styrofoam balls created a 
heterogeneous material that could potentially be used to represent a synthetic lung 
equivalent tissue.   
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Testing Material Material Type HU 
T1-
Visible 
T2- 
Visible 
Tissue 
Equivalent 
Superflab a Plastic 59.9 Y Y Y 
SuperStuff a Plastic 65.2 Y Y - 
100% Liquid PVC Plastic b Plastic -10.4 Y Y Y 
100% Super Soft PVC Plastic b Plastic 3.70 Y Y - 
90% Liquid PVC Plastic & 10% 
Plastic Softener Mix b 
Plastic 15.7 Y Y - 
100% Plastic Hardener b Plastic 32.0 Y N - 
75% Plastic Hardener & 25% Plastic 
Softener Mix b 
Plastic 21.9 Y Y - 
75% Super Soft Plastic & 25% 
Softener Mix b 
Plastic -29.7 Y Y - 
75% Liquid PVC Plastic & 25% 
Plastic Softener Mix b 
Plastic -6.5 Y Y - 
Gel #10 c Synthetic Gelatin -170 Y Y - 
Gel #20 c Synthetic Gelatin -164 Y Y Y 
Gel #1 c Synthetic Gelatin -169 Y Y - 
Gel #2 c Synthetic Gelatin -172 Y Y - 
Gel #3 c Synthetic Gelatin -171 Y Y Y 
Gel #4 c Synthetic Gelatin -175 Y Y - 
Multiwax h Hydrocarbon -156 N N - 
Petroleum Jelly h Hydrocarbon -154 Y Y - 
91.7% Petroleum Jelly & 8.3% 
Styrofoam ball Mix i,‡ 
In-House Hydrocarbon 
Mix 
-593 Y Y Y 
95% Petroleum Jelly & 5% Styrofoam 
ball Mix i,‡ 
In-House Hydrocarbon 
Mix 
-667 Y Y - 
Dragon Skin 10 g Silicone 262 Y Y - 
Dragon Skin 30 g Silicone 294 Y Y N 
Dragon Skin FX-Pro g Silicone 231 Y Y - 
Eco Flex 00-10 g Silicone 202 Y Y - 
EcoFlex 00-30 g Silicone 185 Y Y - 
EcoFlex 00-50 g Silicone 203 Y Y N 
PlatSil® Gel 00 d Silicone 275 Y Y - 
PlatSil® Gel 10 d Silicone 319 Y Y - 
PlatSil® Gel 25 d Silicone 290 Y N - 
PlatSil® Gel 00 +H (10:10:10) d,◊ In-House Silicone Mix -978 Y Y - 
PlatSil® Gel 10 +H (10:10:10) d,◊ In-House Silicone Mix -970 Y Y - 
PlatSil® Gel 25 +H (10:10:10) d,◊ In-House Silicone Mix -972 Y N - 
PlatSil® Gel 25 (20:20:0.5) d,‡ In-House Silicone Mix -117 Y N - 
PlatSil® Gel-00/Styrofoam ball Mix 
(20g:20g:1g) d,‡ 
In-House Silicone Mix -510 Y Y - 
PlatSil® Gel 25 (20:20:1) d,‡ In-House Silicone Mix -358 Y N - 
PlatSil® Gel-00/Styrofoam ball Mix 
(20g:20g:1.5g) d,‡ 
In-House Silicone Mix -406 Y Y N 
PlatSil® Gel 25 (20:20:1.5) d,‡ In-House Silicone Mix -470 Y N - 
PlatSil® Gel 25 (20:20:2) d,‡ In-House Silicone Mix -494 Y N - 
PlatSil® Gel-00/Styrofoam ball Mix 
(10g:10g:1g) d,‡ 
In-House Silicone Mix -655 Y Y - 
PlatSil® Gel-00/Styrofoam ball Mix 
(40g:40g:1g) d,‡ 
In-House Silicone Mix -350 Y Y N 
Nycast ® 6PA- Blue e Nylon 161 N N - 
Nycast ® 6PA- MoS2 Filled e Nylon 94.2 N N - 
Nycast ® 6PA-Orange e Nylon 99.2 N N - 
Nycast CP e Nylon 82.7 N N - 
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Nycast Rx e Nylon 90.9 N N - 
Nylon Nyloil e Nylon 94.2 N N - 
EP 30 f Epoxy 72.9 N N - 
EP424T f Epoxy 63.0 N N - 
PMC ® 121/30 g Urethane -10.5 Y N - 
PMC ® 744 g Urethane -2.90 N N - 
PMC ® 746 g Urethane -11.0 N N - 
PMC ® 770 g Urethane 78.0 N N - 
PMC ® 790 g Urethane 66.1 N N - 
ReoFlex ® 20 g Urethane -19.5 Y N - 
ReoFlex ® 30 g Urethane -45.0 Y N - 
Simpact®  85 A g Urethane 66.0 N N - 
Simpact® 60 A g Urethane 71.6 N N - 
VytalFlex® 10 g Urethane -9.0 N N - 
VytalFlex® 20 g Urethane -18.3 Y N - 
VytalFlex® 30 g Urethane -27.0 Y N - 
 
 
a: Radiation Products Design Incorporation, Albertville, Minnesota b: M-F Manufacturing Company, Fort 
Worth, Texas c: Clear Ballistics, Fort Smith, Arkansas d: Polytek® Development Corporation, Easton, 
Pennsylvania e: Cast Nylons Limited, Willoughby, Ohio f: MasterBond, Hackensack, New Jersey g: Smooth-
On Inc., Macungie, Pennsylvania h: Sonneborn, Parsippany, New Jersey ‡:In-house mixture that used % 
weight of Styrofoam balls from Steve Spangler Science Styrofoam Beads, Englewood, Colorado.  
 
Table 4: Above is a list of materials tested for a MR/CT visible STE phantom. As displayed in 
the second column, testing materials were grouped as: plastic, synthetic gelatin, 
hydrocarbon, urethane, epoxy, silicone, and nylon based materials. These material’s HU 
were measured from a GE LightSpeed CT Simulator and are displayed in the third column.  
The materials were also imaged on a Siemen’s Magnetom Espree 1.5 MR scanner using T1 
and T2 weighted sequences. The fourth and fifth columns display whether the materials 
could visually be distinguished in T1 and T2 weighted images, respectively. Materials were 
visualized on a both T1 and T2 weighted sequences, and also shared reasonable HUs for 
either tumor, soft tissue, and lung materials were then dosimetrically tested. The last column 
displays whether or not a material was tested dosimetrically. If the material was tested 
dosimetrically the final column displays if it was considered STE. 
 
 
2.3.2.1 MR Imaging 
All materials listed in Table 4 were submerged in water and were scanned using 
four MR scanning protocols on a Siemen’s Magnetom Espree 1.5T MR scanner (Siemens 
Healthcare, Erlangen Germany). Common T1 and T2 MR sequences were chosen based 
on an assumption that similar sequences would be equipped in all of MRgRT treatment’s 
imaging software. MR scans represented four different MR sequences that were either: 
1) currently used in an MRgRT modality (TRUFI) or 2) shared similar sequences (T1-
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weighted and T2-weighted) that were expected to be equipped in all new MRgRT 
modalities. All materials were specifically scanned under a TRUFI sequence since 
ViewRay exclusively uses this sequence. 
Four MR sequences, summarized in Table 5, were used to image the testing 
material’s MR properties. The water bath was used as a baseline to assess the material’s 
contrast in various MR sequences.  A T1-weighted image was obtained from a 3D 
gradient echo sequence and used the following parameters: FA= 25°, TR= 9.5 ms, TE= 
4.68 ms, ETL= 1, NEX=1. A true fast imaging with steady-state free precession 
sequence, commonly referred as a TRUFI sequence, was acquired with the following 
parameters: FA= 70°, TR= 4 ms, TE= 2 ms, ETL= 1, NEX=1. Two additional T2-
weighted images were also obtained for each material. The first T2 weighted image was 
a gradient sequence and had parameters of: FA= 120°, TR= 3200 ms, TE= 245 ms, ETL= 
109, NEX=2. The second T2-weighted image used a fluid-attenuated inversion recovery 
sequence, commonly referred as a FLAIR sequence, and had scanning parameters of: 
FA= 120°, TR= 5000 ms, TE= 336 ms, ETL= 109, NEX=2.  
 
Scanning 
Sequence 
T1-Weighted 
Gradient 
TRUFI T2-Weighted 
Gradient 
FLAIR 
FA 25° 70° 120° 120° 
TR (ms) 9.5 4 3200 5000 
TE (ms) 4.68 2 245 336 
ETL 1 1 109 109 
NEX 1 1 2 2 
Table 5: Four MR scanning parameters were used to visually compare the selected material's 
contrast between water. Among the parameters, a T1 weighted and T2 weighted sequence 
were scanned based off of the assumption that other MRgRT systems would have the 
capability to image basic T1 weighted and T2 weighted protocols. A TRUFI sequence was 
scanned to ensure that the materials could be visualized on ViewRay systems.  Since FLAIR 
sequences are commonly used to enhanced lesions in the clinic, a FLAIR sequence was also 
used to compare the selected material’s contrast. 
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2.3.2.2 CT Imaging 
All of the materials listed in Table 4 were submerged in a water bath and were 
scanned using a brain protocol on a GE Lightspeed CT simulator (General Electric 
Company, New York, New York). The scanning parameters were: DFOV= 500.0 mm, 
120 kVp, 275 mA, and slice thickness= 3mm. The materials’ HU were obtained after 
exporting the CT images into Philips IntelliSpace PACS Enterprise (Philips, Amsterdam, 
Netherlands) system. 
2.3.2.3 Dosimetric properties 
A dual MR/CT visible end-to-end QA anthropomorphic phantom used in 
radiotherapy must also dosimetrically represent human tissue. Percent depth dose (PDD) 
curves were obtained to determine the material’s dosimetric properties on materials that 
were MR/CT visible. As shown in Figure 15, a 10 cm x 10 cm x 20 cm rectangular 
phantom was constructed to determine the PDD for selected MR/CT visible materials. 
The 20 cm long PDD phantom was divided into three sections: anterior, middle, and 
posterior, which had lengths of 5.0 cm, 10.0 cm, and 5.0 cm, respectively. The anterior 
and posterior sections were composed of polystyrene, whereas the middle section was 
substituted with materials that were visible on both CT and MR. Additionally, two 
materials commonly used in IROC-Houston’s QA phantoms (compressed cork and 
polystyrene) were included in this study to provide controlled PDD curves.  
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Figure 15: PDD phantom was used to determine the testing material’s dosimetric properties. 
The PDD phantom was divided into three subsections where the anterior and posterior 
sections were composed of polystyrene and the middle section was interchanged with testing 
materials. Film was placed in the sagittal plane to measure the material’s PDD curve. 
 
 
The 6 MV beam from an Elekta Versa HD (Elekta, Stockholm, Sweden) was used 
to irradiate the PDD phantoms with three different field sizes of: 10 x 10 cm2, 6 x 6 cm2, 
3 x 3 cm2. During each irradiation, EBT-3 radiochromic film was inserted into the 
midline of the PDD phantom. Additional 5 cm of polystyrene was placed around the PDD 
phantom which ensured proper scatter conditions.  Within each field size, the PDD 
phantom was irradiated three times with a prescribed dose of 600 cGy to dmax (d=1.5 cm).  
It was also important to assess how accurate the experimental PDD curves 
compared to the treatment planning system (TPS).  A treatment plan was created among 
the testing materials for each of the three field sizes. Using Pinnacle’s treatment planning 
(Philips, Amsterdam, Netherlands), the dose from 0.5 to 17.0 cm was calculated and 
normalized to a depth of 1.5 cm using the collapsed cone dose algorithm. After the films 
were irradiated, a photoelectron CCD microdensitometer (Photoelectron Corporation, 
North Billerica, Massachusetts) was used to capture the optical density of the film at the 
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different depths of interest. The intensity of the film was then converted into dose and 
the dose at the varying depths were normalized to the dose at 1.5 cm.  
 
2.4 RESULTS 
2.4.1 Tested Material’s Properties 
2.4.1.1 MR properties 
Most plastic, silicone, and gelatin-based materials tested were visible in both T1 
and T2 weighted images.  In-house mixtures were mostly visible on all four MR 
sequences. Specifically, testing materials that used either Polytek Development 
Corporation’s Gel 25 or M-F Manufacturing Company’s 100% Plastic Hardener were 
visible on T1-weighted images but were not visible on T2-weighted images. With few 
exceptions most nylon, urethane, and epoxy-based materials were not visible on either 
T1 or T2 weighed MR sequences. Specifically, Smooth-On’s Reoflex 20, Reoflex 30, 
VytalFlex 20, VytalFlex 30, and PMC 121/30 materials were all urethane-based materials 
and were only visible on T1-weighted images.   
Materials that were heterogeneous and showed a random absence of signal were 
more favorable lung materials compared to the homogeneous substitutes since these 
materials were better representations of lung tissue. Heterogeneous tested materials were 
constructed in-house and were combined with a base material (either Sonneborn’s 
petroleum jelly or Polytek Development Corporation’s silicon gels) and different 
concentrations of 2-4mm miniature Styrofoam balls. Within the heterogeneous lung 
materials, miniature Styrofoam balls represented air pockets with no MR signal while the 
surrounding base materials generated MR signal. MR visibility of potential lung-
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equivalent materials greatly depended on the Styrofoam ball concentration. As the 
concentration of Styrofoam balls increased, the MR visibility greatly decreased since 
there was less signal from the surrounding materials. Among the in-house mixtures, the 
most visible lung substitute was a combination of 8.3% weight of Styrofoam balls and 
91.7% of petroleum jelly (Figure 16). 
Contrary to potential lung candidates, homogeneous materials better represented 
soft tissue and tumor substitutes.  Potential soft tissue and tumor substitutes were not 
required to have the same grey-scale contrast as their human flesh counterparts, but these 
materials were required to have visible contrast between water and each other. Taking 
into account all four MR sequences, three materials (Clear Ballistics’ Gel #20, M-F 
Manufacturing Company’s 100% Liquid PVC Plastic, and Radiation Products Design 
Incorporation’s Superflab) were shown to have the most visible contrast between water, 
each other and other testing materials. Therefore, Gel #20, 100% Liquid PVC Plastic and 
Superflab were chosen to be tested further as suitable soft tissue or tumor substitutes 
(Figure 16).  
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Figure 16: From top to bottom the materials shown are: 1.) compressed cork, 2.) in-house 
petroleum/styrofoam mixture (8.3% weight composed of mini Styrofoam balls and 91.7% 
weight composed of Sonneborn’s Petroleum jelly), 3.) polystyrene, 4.) Clear Ballistic Gel #20, 
5.) M-F Manufacturing 100% liquid PVC plastic, and 6.) Superflab. Four different MR 
sequences (a-d) and a CT scan (e) were performed on these materials to visually determine 
their contrast between water and IROC-Houston’s conventional materials. The MR 
sequences shown in this figure were a (a.) T1-weighted, (b.), TRUFI, (c.) T2-weighted, and 
(d.) fluid-attenuated T2-weighted scans. The HU measured from the CT image for 
compressed cork, in-house petroleum/styrofoam mixture, polystyrene, Clear Ballistic Gel 
#20, Liquid plastic, and Superflab were, respectively, -800, -685, -33, -160, 20 and 51. 
 
2.4.1.2 CT properties 
The testing materials’ (listed in Table 4) HU was measured from images acquired 
on GE’s Lightspeed CT simulator.  In general, homogeneous plastic, nylon, epoxy-based 
materials most resembled soft tissue and their HU’s, ranging from, -29 to 65, 82 to 161, 
63 to 72, respectively. Urethane based materials showed a larger HU range of -45 to 78. 
Gelatin based materials resembled more fatty-like tissues with HU’s ranging from -164 
to -175 whereas homogenous silicone materials resembled more contrast-enhanced soft 
tissue with HU’s ranging from 185 to 319. In-house mixtures, that incorporated either 
silicone or hydrocarbon-based materials, visually and numerically simulated lung-like 
materials with HU’s that ranged from, -978 to -117 and -667 to -593, respectively. 
Similar to MR, the concentration of the Styrofoam balls directly affect their attenuation 
coefficient. Mixtures with greater Styrofoam ball concentrations had more air pockets 
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which, enable the synthetic materials to better visually resembled lung tissue and had 
lower HU values.  
The four selected MR-visible materials were collectively imaged on GE’s 
Lightspeed CT simulator and are displayed in Figure 16e. Among the four selected MR-
visible materials 100% Liquid PVC Plastic, and Superflab numerically represented soft 
tissue with HU of -10.4, and 59.9, respectively. Visually, the 100% Liquid PVC Plastic 
and Superflab materials had similar contrast as water, whereas Gel #20, showed a greater 
contrast relative to water and had a lower HU value of -170. Clear Ballistics’ Gel #20 
could potentially be used as either a fat or a tumor equivalent material since it did have 
lower HU value than water.  Small fluctuations between mini Styrofoam balls and 
surrounding based materials in the heterogeneous mixtures created random signals that 
resemble high and low contrast areas.  These random signals seen among in-house 
heterogeneous mixtures on a MR image were also comparable to random signal seen in 
lung tissue on a CT image. The in-house mixture with compositions of 8.3% of 
Styrofoam balls and 91.7% of petroleum jelly (which was previously selected as a 
potential synthetic lung substitute in MR) numerically resembled synthetic lung tissue 
with a HU of -685.   
 
2.4.1.3 Dosimetric properties 
The selected MR/CT visible materials (in-house 91.7%/8.3% petroleum 
jelly/styrofoam mixture, Clear Ballistic Gel #20, and Liquid PVC Plastic) were further 
dosimetrically investigated. Since Superflab is currently used in the clinic as a tissue 
equivalent material, it was excluded from dosimetric measurement. Each selected 
material was irradiated under three different field sizes, then corresponding PDD curves 
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were generated using the data from the TPS and radiochromic film.  From a depth of 1.5 
cm to 17 cm, the deviations between the film PDD and TPS PDD curves were determined 
for 10 x 10 cm2, 6 x 6 cm2, and 3 x 3 cm2 field sizes. The greatest deviation between film 
and TPS PDD curves was found for the smallest field size for all materials.  At a field 
size of 3 x 3 cm2 the maximum deviation was: 12.2% at 17.0 cm for compressed cork, 
10.8% at 16.5 cm for the in-house petroleum jelly styrofoam mixture, 7.1% at 16.5 cm 
for polystyrene, 4.1% at 12.5 cm for Gel #20, and 4.6% at 17.0 cm for 100% Liquid PVC 
Plastic (Table 6). While the greatest deviation between film and TPS PDD were shown 
for the 3 x 3 cm2 field size, the average deviation for the 3 x 3 cm2 field size for all of the 
materials, was less than 6%. The mean deviation between film PDD and TPS PDD for 
the selected materials for the 10 x 10 cm2 and 6 x 6 cm2 field sizes were all less than 
1.9%, and 2.8%, respectively.  Quantitatively, the mean deviation for a 3 x 3 cm2 field 
size the mean deviation for compressed cork, the in-house petroleum jelly styrofoam 
mixture, polystyrene, Gel #20, and Liquid PVC Plastics were: 3.8 ± 3.60 cm, 5.9 ± 2.75 
cm, 1.9 ± 2.02 cm, 1.5 ± 1.15 cm and 2.0 ± 1.13 cm, respectively. At a field size of 3 x 3 
cm2 the maximum deviation was: 12.2% at 17.0 cm for compressed cork, 10.8% at 16.5 
cm for, 7.1% at 16.5 cm for polystyrene, 4.1% at 12.5 cm for Gel #20, and 4.6% at 17.0 
cm for 100% Liquid PVC Plastic (Table 6). 
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Materials 
10 x 10 cm2 6 x 6 cm2 3 x 3 cm2 
Max 
Deviation 
[%] 
Depth 
[cm] 
Mean 
Deviation 
[%] 
Max 
Deviation 
[%] 
Depth 
[cm] 
Mean 
Deviation 
[%] 
Max 
Deviation 
[%] 
Depth 
[cm] 
Mean 
Deviation 
[%] 
Compress 
Cork 
4.3 8.5 
1.9 
(± 1.12) 
5.1 15.5 
2.0 
(± 1.24) 
12.2 17.0 
3.8 
(± 3.60) 
Petroleum 
Styrofoam 
Mix 
7.7 15.0 
1.9 
(± 2.04) 
7.2 13.5 
2.8 
(± 2.26) 
10.8 16.5 
5.9 
(± 2.75) 
Polystyrene 5.7 17.0 
1.8 
(± 1.67) 
2.5 16.0 
1.1 
(± 0.59) 
7.1 16.5 
1.9 
(± 2.02) 
Clear 
Ballistic 
Gel #20 
1.9 15.0 
0.6 
(± 0.46) 
3.3 14.5 
1.2 
(± 0.81) 
4.1 12.5 
1.5 
(± 1.15) 
M-F 
Manufacture 
Liquid PVC 
Plastic 
3.7 16.5 
1.2 
(± 1.03) 
4.5 11.0 
1.7 
(± 1.21) 
4.6 17.0 
2.0 
(± 1.13) 
Table 6: A measured film PDD curve and a TPS PDD curve were generated for both current 
IROC-Houston’s phantom materials and testing materials for a large (10 x 10 cm2), medium 
(6 x 6 cm2), and small (3 x 3 cm2) field size. For each material (compressed cork, 
petroleum/Styrofoam mixture, polystyrene, Clear Ballistic Gel #20, and M-F manufacture’s 
liquid PVC plastic) the maximum deviation between the material’s measured PDD and TPS 
PDD and the overall mean deviation between 0.5 cm to 17 cm were recorded. 
 
 
In addition to quantifying the maximum deviation between the film PDD and TPS 
PDD for each of the selected materials, the general shape of the tested material’s PDD 
curves were compared with PDD curves of current IROC-Houston’s lung and soft tissue 
equivalent materials. The in-house petroleum jelly/styrofoam mixture was compared to 
compressed cork, which is commonly used as IROC-Houston’s lung equivalent 
materials. Similarly, Gel #20, 100% Liquid PVC Plastic were compared to polystyrene, 
which is also commonly used as IROC-Houston’s soft tissue equivalent materials. 
Collective PDD data for soft tissue and lung equivalent materials for the smallest (3 x 3 
cm2) and largest (10 x 10 cm2) field sizes are shown in Figure 17. Overall, the general 
PDD curve for Gel #20, and 100% Liquid PVC Plastic agreed with the polystyrene curve 
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and the in-house petroleum/styrofoam mixture was in agreement with the compressed 
cork curve.  While modest discrepancies between general curve shapes between 
compressed cork and the in-house heterogeneous mixture were seen in all three field 
sizes, the 3 x 3 cm2 PDD curve showed a slightly higher deviation around 16 cm, where 
the lung-to-tissue interface was located. The PDD phantom’s CT, which was used in the 
TPS, was not imaged with film sandwich between the two halves. Therefore, it is 
believed that the higher deviation between the film and TPS measure in the smallest field 
size was primarily due to the dose build up from the film. Additionally, the 
petroleum/styrofoam mixture had a slightly higher physical density than compressed 
cork, which translated to having a smaller charge particle disequilibrium than compressed 
cork. 
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Figure 17: The four graphs are a summary of the PDD curve comparisons between IROC-
Houston’s current soft tissue and lung equivalent materials and testing materials for a large 
(10 x 10 cm2) and small (3 x 3 cm2) field size. The interfaces between the testing materials 
and polystyrene of the PDD phantom occur between 5 cm and 15 cm. All graphs show the 
current tissue substitute’s film (red) and treatment planning (blue) PDD curves. The testing 
materials were then compared to current tissue’s film and TPS PDD curves.  The greatest 
curve deviation occurs for the lung equivalent material for the small field size. 
 
2.5 DISCUSSION 
The materials selected for MRgRT end-to-end QA phantoms for IROC-Houston 
were based off of three major criteria: practicality, reliability, and accuracy. Since IROC-
Houston credentials radiotherapy modalities by regularly shipping end-to-end QA 
phantoms to institutions, materials selected for a MR/CT visible phantom needed to share 
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practical characteristics that would ensure the phantom’s shape and size remain constant 
over time. Materials that do not require specific shipping or storage conditions (i.e., could 
be left in room temperature, and insensitive to light) and show relative ease in 
constructing abnormal shapes were considered as practical materials.  Prior to testing a 
material’s imaging and dosimetric properties, the material’s melting point was first 
investigated. The material’s melting point was used to determine whether a material 
could withstand extreme temperatures during shipment. The highest temperatures a 
package may experience for domestic and international shipments are, respectively, 37.1 
°C and 45.5 °C61. Therefore, it was important that potential candidates had melting points 
greater than 45.5 °C. Specifically, the melting points for: Superflab, in-house petroleum 
jelly styrofoam mixture, Gel #20, and Liquid PVC Plastics were: 93.3 °C, 58.0 °C, 92.2 
°C, and 121.1 °C, respectively. The material’s selection process was also judged based 
off of the material’s reliability. Since IROC-Houston’s QA phantoms are used for many 
years, the material’s shape and consistency must remain constant over time (i.e., the 
materials must not deteriorate or dehydrate over time). The materials listed in Table 4 
were tested for their reliability by sitting in room temperature for 3 months. All materials 
except for Gel #4 and SuperStuff showed no forms of degradation. In addition to the 
practicality and reliability requirements, the materials selected for a MRgRT phantom 
had to be visible in common MR sequences, show comparable HU, and dosimetrically 
mimic their respective organ site.   
Previously reported MR/CT visible materials in the literature did not meet IROC-
Houston’s criteria since most of these materials shared short shelf lives and required 
refrigeration storage56-58. We tested over 80 materials, which could potentially be used to 
manufacture IROC-Houston’s MRgRT anthropomorphic phantoms. Most of the test 
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materials shared comparable HU values as human tissue but were not visible on both T1 
and T2 weighted MR images. Materials that were classified as either epoxy, urethane, or 
nylon based sometimes showed contrast in T1-weighted images, but were consistently 
not visible in T2-weighted images. Either Polytek’s silicone-based gels or Sonneborn’s 
petroleum jelly were mixed with miniature Styrofoam balls in attempts to create various 
lung equivalent materials. Styrofoam balls were used to more realistically resemble a 
lung’s heterogeneous appearance as viewed in MR and CT, and to lower the HU value. 
As we increased the concentration of Styrofoam balls it created a more realistic lung 
attenuation coefficient, but consequently, became less visible in MR images. The in-
house mixture of 8.3% Styrofoam balls and 91.7% petroleum jelly was selected as the 
most optimal material for a dual modality since it was a good compromised between MR 
image visibility and typical lung attenuation data. 
Other promising MR/CT visible materials were Smooth-On’s Dragon Skin 30, 
Smooth-On’s EcoFlex 50, and in-house mixtures composed of different concentration of 
Polytek’s Gel 00 and miniature styrofoam balls. These materials were further 
investigated for their dosimetric properties but are not displayed in Figure 16 since these 
materials: 1) had higher physical density than their respective organ sites, and 2) did not 
have good dosimetric properties. 
The selected testing materials visually showed different contrast among the four 
MR scans. However, amongst the scans, TRUFI showed the smallest contrast between 
the selected MR visible materials. All materials were imaged using a magnetic field of 
1.5T. Using a smaller magnetic field (i.e., 0.35T) would generate a smaller net magnetic 
moment, which would consequently lower SNR. Lowering the magnetic field strength 
could change the material’s T1 and T2 relaxation times which would consequently 
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affecting the MR contrast. In order to predict the contrast in a lower magnetic field, the 
material’s T1 and T2 relaxations times would need to be calculated. 
The measured PDD curves for the selected materials were comparable with their 
predicted PDD curves. The general PDD shape of IROC-Houston’s typical soft tissue 
substitute, polystyrene, was most comparable to measured PDD curves of Gel #20, and 
100% Liquid PVC Plastic. Similarly, the general PDD curve shape of IROC-Houston’s 
conventional lung equivalent material, compress cork, was comparable to the in-house 
styrofoam/petroleum jelly mixture’s measured PDD curve. Soft tissue equivalent 
materials showed a closer PDD curve agreement than lung equivalent materials. While 
all PDDs showed expected curve shapes, small differences were only noted for the 
smallest field size (3 x 3 cm2) between the testing materials’ measured and predicted 
PDD curves. 
 
2.6 CONCLUSION 
It was determined that four testing materials were visible and distinguishable in 
both MR and CT and dosimetrically represent human tissue. The in-house 91.7% 
petroleum jelly/ 8.3% styrofoam ball mixture resembled lung tissue since its HU was         
-685, dosimetrically showed expect lung-equivalent PDD curves, and visually showed 
random signal in both modalities. Superflab is currently used in the clinics as a tissue 
equivalent bolus, so it was only visually examined. It was determined as a potential 
material to use in a MR/CT visible phantom, since Superflab was visible in both imaging 
modalities. Lastly, Gel #20, and 100% Liquid PVC Plastic were determined to 
dosimetrically represent soft tissue and were easily view in both MR and CT modalities 
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and was therefore determined that both Gel #20 and 100% Liquid PVC Plastic are 
possible tumor equivalent substitutes for MRgRT end to end QA phantoms. 
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Chapter 3:  Characterize and validate radiation detectors 
under the presence of a magnetic field 
 
A substantial portion of this chapter is written or based on the following publication: 
 
A. Steinmann, D. O’Brien,  R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller, D. Followill, 
“Characterization and validation of TLD and Radiochromic EBT3 film under the presence of 
1.5T, 0.35T and 0T magnetic field strengths in MR/CT visible materials,” Medical Physics. [In 
review] (2018). © John Wiley and Sons. 
 
The permission for reuse of this material was obtained from John Wiley and Sons. 
 
 
 
3.1 ABSTRACT 
Purpose: The aim of this study was to characterize and validate 
thermoluminescent dosimeters (TLD) and radiochromic EBT3 film inside MR/CT 
visible geometric head and lung phantoms in the presence of: 0T, 0.35T and 1.5T 
magnetic fields. 
Methods: TLD reproducibility studies were examined by irradiating IROC-
Houston’s TLD acrylic block five times under 0T and 1.5T configurations of Elekta’s 
Unity system and three times under 0T and 0.35T configurations of ViewRay’s MRIdian 
Cobalt-60 (60Co) system. Both systems were irradiated with an equivalent 10 x 10 cm2 
field size, and a prescribed dose of 3 Gy to the maximum depth deposition (dmax). 
EBT3 film and TLDs were characterized using two geometrical Magnetic 
Resonance (MR) guided Radiation Therapy (MRgRT) head and lung phantoms. Each 
geometrical phantom had eight quadrants that combined to create a centrally located 
rectangular tumor (3x3x5cm3) surrounded by tissue to form a 15x15x15cm3 cubic 
phantom. Liquid PVC plastic and Superflab were used to simulate the tumor and 
surrounding tissue in the head phantom, respectively. Synthetic ballistic gel and a 
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heterogeneous in-house mixture were used to construct the tumor and surrounding tissue 
in the lung phantom, respectively. EBT3 and double-loaded TLDs were used in the 
phantoms to compare beam profiles and point dose measurements with and without 
magnetic fields. GEANT4 Monte Carlo simulations were performed to validate the 
detectors for both Unity 0T/1.5T and MRIdian 0T/0.35T configurations. 
Results: Average TLD block measurements which, compared the magnetic field 
effects (magnetic field vs. 0T) on the Unity and MRIdian systems, were 0.5% and 0.6%, 
respectively. The average ratios between magnetic field effects for the geometric lung 
and head phantoms under the Unity system were -0.2% and 1.6% and for the MRIdian 
system were 0.2% and -0.3%, respectively. Beam profiles generated with both systems 
agreed with Monte Carlo measurements and previous literature findings.  
Conclusions: TLDs and EBT3 film dosimeters can be used in MR/CT visible 
tissue equivalent phantoms that will experience a magnetic field environment. 
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3.2 INTRODUCTION 
While magnetic fields from both MRIdian (ViewRay, Oakwood Village, Ohio) 
and Unity (Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands) 
systems do not directly affect their primary photon beam, their secondary electrons are 
influenced by the magnetic field via the Lorentz force62. A magnetic field will influence 
the electron’s trajectory and will consequently affect the dose deposited in a medium. In 
general, the magnetic field will cause an increase in penumbra, a reduction of buildup 
and an asymmetric dose profile shift laterally32; 62. Previous studies from Raaymakers et 
al. 2004 used GEANT4 to simulate a homogenous water phantom irradiated with a 6 MV 
beam perpendicular to a 0T and a 1.5T magnetic field62. In this study, beam profiles 
generated under a 1.5T magnetic field shifted 0.7 mm from the 50% isodose line whereas 
beam profiles generated without a magnetic field did not shift62. 
Magnetic fields can cause irregular dose deposition in heterogeneous materials 
due to the secondary electron’s helical trajectories. At tissue-air interfaces, the electrons 
traveling out of the tissue medium into air will curve back into the medium and deposit 
additional dose laterally33.  This phenomenon, known as the electron return effect (ERE), 
is dependent on the magnetic field strength and electron energy32. The ERE in tissue-air 
interfaces previously has been shown to increase dose up to 40% along the central axis63. 
Irregular electron dose deposition, induced from the presence of a magnetic field, could 
potentially compromise the accuracy of radiation detectors typically used in 
radiotherapy32; 37. Therefore, typical radiation dosimeters must be analyzed and 
characterized in the presence of a magnetic field prior to being used to measure dose in 
the clinic.  
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TLD-100s (ThermoFisher Scientific, Waltham, MA, USA) frequently are used 
by the Imaging and Radiation Oncology Core Quality Assurance (QA) Center in Houston 
(IROC-Houston) to measure the delivered dose in anthropomorphic QA phantoms. 
Previous studies have started to characterize TLDs in the presence of a magnetic field64-
66. Mathis et al. 2014 studied the effects of powder-form TLDs and radiochromic EBT3 
film under the presence and absence of a 1.5T magnetic field when exposed to a range 
(200cGy to 600cGy) of radiation dose65. In this study, the TLDs and film irradiated with 
and without magnetic fields agreed within a 5% criterion65.  However, the Mathis et al. 
study irradiated TLDs and film using two different machines (a conventional linear 
accelerator and an MR-Linac prototype at UMC-Utrecht). Comparing radiation 
measurements on two different systems introduced additional uncertainties such as 
fluctuations in machine output. Wen et al. 2015 studied the directional dependence of 
single-loaded TLD capsules using IROC-Houston’s output verification acrylic TLD 
block66. It was noted that the TLD capsules irradiated parallel to a 1.5T magnetic field 
experienced a 2.3% higher output compared to TLD capsules irradiated perpendicular to 
a 1.5T magnetic field66. This small difference was most likely due to the air gap within 
the single-loaded TLD capsule itself. To the authors’ knowledge, no studies have 
characterized double-loaded TLDs (no air gap) perpendicular to a radiation beam. 
Double-loaded TLDs have twice the amount of LiF:M,Ti than in single-loaded TLDs, 
thus, removing the air spacing that are normally found in single-loaded TLDs.  
IROC-Houston’s end-to-end phantoms also use radiochromic EBT3 film 
(Ashland Inc., Wayne, NJ, USA) to measure the planar dose distribution near the tumor 
and organs at risk. Studies have shown that different radiochromic film prototypes (EBT3 
and EBT2) respond differently when irradiated in the presence of a magnetic field67-70. 
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The protective polyester layers in EBT2 film change after a magnetic field exposure 
causing an under response that varies with dose67; 68. Preliminary studies showed that the 
EBT3 film’s dose distribution did not change in a magnetic field likely due to EBT3 
having a different protective layer than EBT269-71. EBT3 films preliminarily were studied 
in 0.35T and 1.5T magnetic field environments. However, there was not a single 
comprehensive study used the same experiment methodology to compare the film’s 
response to a magnetic field in both MRIdian and Unity systems. Additionally, these 
previous studies only compared the film’s relative signal and were not validated with 
Monte Carlo measurements62. To the authors’ knowledge, no complete comprehensive 
study has characterized and validated TLDs and EBT3 film under the presence of 0.35T 
and 1.5T magnetic fields for MRIdian and Unity systems, respectively. 
To develop appropriate MRgRT tissue equivalent end-to-end QA phantoms, 
radiation detectors used in these phantoms must be characterized and validated under the 
presence of a magnetic field first. Since heterogeneous interferences and density can 
contribute to the ERE, dosimeters must be characterized under the same material 
conditions for which they were designed. The purpose of this study was to characterize 
and validate double-loaded TLDs and radiochromic EBT3 film, used in IROC-Houston’s 
phantoms, under the presence and absence of a 0.35T and 1.5T magnetic fields for the 
MRgRT systems.  
 
3.3 MATERIAL AND METHODS 
TLD’s dose response and reproducibility were characterized first using a simple 
homogenous acrylic block. Finally, both detectors were characterized in MRgRT 
phantom slabs and validated using Monte Carlo calculations. Both TLD acrylic block 
  58 
reproducibility studies and geometrical slab phantom studies were conducted on a 
Elekta’s Unity system (Elekta, Crawley, United Kingdom and Philips, Amsterdam, 
Netherlands) and a ViewRay’s MRIdian 60Co system (ViewRay, Oakwood Village, 
Ohio). 
 
3.3.1 TLD Acrylic Block Reproducibility Studies  
IROC-Houston’s TLD acrylic blocks are used to verify the output for 
megavoltage beams and are designed with three small cylindrical holes that perfectly fit 
TLD capsules. Once a TLD is inserted into the acrylic block, each TLD capsule’s end 
will be surrounded by an air channel. The dose deposition of small tissue-air interfaces 
will be affected by a magnetic field due to the secondary electron’s curving back into the 
tissue-air interface32; 62. This ERE phenomenon also would occur in the acrylic-air 
channels in the acrylic block, consequently, affecting the TLD dose measurement. To 
minimize any extra dose being deposited in the acrylic-air interfaces, six tight-fitting 
acrylic plugs were inserted into all air passages and double-loaded TLDs were used 
instead of single-loaded TLDs. A single acrylic TLD block was reloaded and irradiated 
five separate times for two magnetic field configurations (0T and 1.5T) on the Unity 
system and three separate times for a 0T and a 0.35T magnetic field configuration on the 
MRIdian 60Co system. The setup configurations for both MRgRT systems are shown in 
Figure 18. During the Unity system irradiations, the acrylic TLD block was placed above 
14.5 cm of solid water (Sun Nuclear, Melbourne, FL) to achieve the 143.5 cm SAD 
isocenter and a gantry angle of 0°. Additionally, these blocks were irradiated using a 10 
x 10 cm2 field size and were prescribed 300cGy at dmax (1.3cm at 0T and 1.7cm at 1.5T). 
During the MRIdian system irradiations, the TLD blocks were placed at 80 SSD, and 
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were irradiated using an equivalent 10x10 cm2 field size with a prescription of 300cGy 
delivered at dmax (0.5cm).   
 
 
Figure 18: TLD blocks were irradiated at isocenter on Elekta’s Unity system at 0T and 1.5T 
magnetic field strengths (a) and on ViewRay’s MRIdian system at 0T and 0.35T (b). 
 
3.3.2 Geometrical Phantom Studies 
Radiochromic EBT3 film and TLDs were characterized using two geometrical 
head and lung phantoms slabs. These phantoms were developed using tissue equivalent 
and MR/CT visible materials which were described in the Steinmann et al. 2018 study72. 
Geometrical phantom slabs were constructed from eight 7.5 x 7.5 x 7.5 cm3 quadrants 
that had a rectangular (3.0 x 3.0 x 5.0 cm3) tumor centrally located around surrounded 
tissue to form two 15 x 15 x 15 cm3 cubic phantoms (Figure 19). A 3.0 cm thick acrylic 
sleeve was placed around the entire cubic phantom to ensure that all eight segments were 
secured tightly. Having a tight fit was important since it minimized any air gaps between 
the quadrants. The geometrical phantoms were constructed using four different MR/CT 
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visible tissue equivalent materials. Clear Ballistic Gel #20 (Clear Ballistic, Fort Smith, 
AR, USA) and SuperFlab Bolus (Radiation Products Design Incorporation, Albertville, 
MN, USA) were used as tumor and surrounding soft tissue materials for the geometrical 
head phantom, respectively. The geometrical lung phantom was constructed using 100% 
liquid PVC plastic (M-F Manufacturing Company, Fort Worth, TX, USA) for the tumor 
material and an in-house mixture containing 8.3% wt. of Styrofoam balls with diameters 
ranging from 2-4 mm (Steve Spangler Science, Englewood, CO, USA) and 91.7% wt. of 
petroleum jelly (Sonneborn, Parsippany, NJ, USA) for the surrounding lung tissue. As 
shown in Figure 19, EBT3 film was inserted in all three planes and two double-loaded 
TLD powder capsules were inserted near the synthetic tumor’s center. The geometrical 
phantoms were positioned on the treatment couch so that the TLDs were perpendicular 
to the magnetic field.  
 
 
Figure 19: The geometrical lung and head phantoms were constructed out of tissue 
equivalent and MR/CT visible materials (figure 19a shows the lung phantom). As shown in 
figure 19c, radiochromic films were placed in all three fields and two TLDs were placed 
inside the tumor. 
 
Solid water was positioned posteriorly and anteriorly to the geometrical phantom. 
Solid water positioned anteriorly was fixed for both MRgRT setups and was used to 
a. b. c. 
TLD 
FILM 
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secure the segments together. Solid water positioned posteriorly to the geometrical 
phantom allowed the tumor’s center to align with the isocenter. Since the radiation 
isocenters were different in the Unity and MRIdian systems, the amount of solid water 
varied posteriorly to the phantom. The geometrical phantoms setups for MRIdian and 
Unity systems are shown in Figure 20. Under 0T and 1.5T conditions, the geometrical 
head and lung phantoms were irradiated five times on the Unity system. The irradiation 
parameters on the Unity system were: 10 x 10 cm2 field size, 131 SAD and prescription 
dose of 600cGy delivered at dmax. Under 0T and 0.35T conditions, the two phantoms 
were irradiated three times on the MRIdian 60Co system with a prescribed dose of 600cGy 
at 0.5 cm depth, an 80 SSD and an equivalent 10x10 cm2 field size. Repeating the 
irradiations five times on the Unity system and three times on the MRIdian 60Co system 
allowed a total of 20 and 12 TLD readings, respectively. A total of ten axial films were 
captured on the Unity system; five axial films were irradiated with 0T and the remaining 
five films were irradiated under 1.5T configuration. A total of six axial films were 
captured on the MRIdian 60Co system; three were irradiated with 0T and the remaining 
three were irradiated with 0.35T. Individual films from each setup were used to create an 
average beam profile. 
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Figure 20: Head and Lung geometrical slab phantom setups for irradiation using Elekta's 
Unity (figure 20a) and ViewRay's MRIdian (figure 20b) systems 
 
 
  TLDs and radiochromic EBT3 film were read and analyzed using the same 
standard analysis procedures as IROC-Houston42; 60. TLDs were read by weighing the 
amount of lithium fluoride (LiF) powder on a Mettler AT261 DeltaRange (Mettler 
Toledo, Greifensee, Switzerland) scale and measuring the light output using a Harshaw 
3500 TLD reader (ThermoFisher Scientific, Waltham, MA, USA). TLD readings in the 
lung and head configurations were collectively averaged and were compared with and 
without a magnetic field for both MRgRT systems. Film was processed by converting 
the optical density into dose using IROC-Houston’s photoelectron CCD 
microdensitometer (Photoelectron Corporation, North Billerica, MA, USA). IROC-
Houston’s in-house MATLAB software generated dose distributions and profiles.  
Measured beam profiles on MRIdian and Unity systems were validated with 
Monte Carlo calculations using GEANT4 (v9.6.p04). GEANT4 was chosen to perform 
validation measurements since it was a freely available software and previous studies 
used GEANT4 to simulate a radiation beam exposed to a magnetic field35; 37; 62; 73-76. The 
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GEANT4 application used for this study was developed at MD Anderson Cancer Center 
and was described in detail by O’Brien et al. 201635. In short, this application simulated 
either a 7 MV or 60Co beam incident to a virtual phantom. The 7 MV beam model was 
provided by Elekta and was developed specifically for the Unity system as a point-source 
model defined at isocenter (143.5 cm from the target) with a field size of 10x10 cm2 35; 
37. A 60Co spectrum was used from the International Atomic Energy Agency (IAEA) 
phase-space database to simulate a ViewRay configuration. This phase-space data was 
based on of Mora et al.’s 1999 60Co beam model with a 2cm source capsule77.  
A virtual head and lung phantom was created in GEANT4. The materials in these 
virtual phantoms could be defined several ways in GEANT4. Some generic materials 
(i.e., water, air) were predefined in GEANT4’s material database while others could be 
defined manually if the chemical composition and density were known. The tissue 
equivalent MR/CT visible materials used to construct the geometrical slab phantoms 
were not available in GEANT4’s material database; so, the chemical composition and 
density were reported. The four materials used in the geometrical phantoms were sent to 
Intertek Pharmaceutical Services (Whitehouse, NJ, USA) to determine the materials’ 
carbon, hydrogen, nitrogen, oxygen and chloride content.  The Intertek Pharmaceutical 
Services used a Perkin-Elmer 2400 elemental analyzer to determine the elemental 
composition of carbon, hydrogen, nitrogen and oxygen and a Calorimetric Titration to 
determine the chloride content. The results provided from the Intertek Pharmaceutical 
Services are shown in Table 7.  
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Tested Material 
Material 
Application 
Elemental Composition 
Carbon Hydrogen Nitrogen Oxygen Chloride 
Synthetic Gel #20 H&N 
Tumor 
84.7 % 15.3% <0.05% <0.05% - 
Superflab Surrounding 
H&N Soft 
Tissue 
68.8% 11.0% <0.05% 12.4% 7.8% 
Liquid PVC Plastic Lung Tumor 66.2% 11.9% <0.05% 12.6% 9.3% 
In-house 
Petroleum/styrofoam 
mixture 
Surrounding 
Lung Tissue 
87.2% 12.8% 0.38% - - 
Table 7: The percent elemental composition of the four MR/CT visible tissue equivalent 
materials used in the head and lung geometrical slab phantoms.  
 
The virtual phantoms had the same geometry as the physical phantoms. The 
virtual phantoms were designed with a centrally located rectangular 5.0 x 3.0 x 3.0 cm3 
tumor inside a 15 x 15 x 15 cm3 cubic phantom and 5.0 cm of solid water anteriorly above 
the phantom. Both head and lung geometrical slab phantoms were simulated with 0T and 
1.5T magnetic fields for a 7 MV beam, and 0T and 0.35T magnetic fields for a 60Co 
beam. Four beam profiles were generated in each lung and head phantom for both virtual 
and physical environments. For each phantom configuration, two beam profiles were 
created from a 60Co beam under 0T and 0.35T magnetic field strengths and the other two 
beam profiles were created from a 7 MV beam under 0T and 1.5T magnetic field 
strengths.  
 
3.4 RESULTS & DUSCUSSION 
3.4.1 TLD Block Reproducibility Studies  
Each block had three double-loaded TLD capsules aligned perpendicular to the 
magnetic field. Three double-loaded TLDs, in a single acrylic block, created six TLD 
readings per irradiation. The average measured TLD doses in the presence or absence of 
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a magnetic field are listed in Table 8 for Elekta’s Unity and ViewRay’s MRIdian MRgRT 
systems. The Unity system’s average TLD doses for 0T and 1.5T magnetic field strengths 
were 334.9 cGy (±0.5%) and 333.1 cGy (±1.4%), respectively, whereas the MRIdian 
system’s average doses for 0T and 0.35T magnetic field strengths were 273.4 cGy 
(±0.9%) and 275.1 cGy (±1.0%), respectively. The average ratio between measurements 
with and without magnetic fields of the Unity and MRIdian systems were 0.995 and 
1.006, respectively. The standard deviations of the average TLD doses for all conditions 
were small (<1.4%) and showed excellent reproducibility in the TLD readings.   
A two-sided, unpaired T-test was used to determine whether there was a statistical 
significance between TLDs exposed with and without magnetic fields. With a 95% 
confidence interval, both ViewRay (p>0.08) and Unity (p> 0.06) p-values were greater 
than 0.05, thus suggesting with a 95% confidence, that there was not a statistical 
significance between TLDs irradiated with and without magnetic field. Since the p-values 
were close to 0.05, a followed up was done with a two one-sided equivalence test (TOST) 
to determine whether TLDs irradiated with a magnetic field were statistically equivalent 
to TLDs irradiated without a magnetic field. The delta used for the TOST allowed the 
differences in means to be within 1%. The TOST test showed p-values <0.05 (Unity: 
p<0.04 and MRIdian: p<0.02) on both MRgRT configurations. Therefore, with 95% 
confidence, the TOST test indicated that TLDs irradiated with and without magnetic 
fields on the same treatment system were statistically equivalent.  
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Acrylic 
TLD 
Blocks 
Unity MRIdian 
0.0T 1.5T Ratio 
[1.5T/0T] 
0.0T 0.35T Ratio 
[0.35T/0T]  
[cGy] [cGy] [cGy] [cGy] 
334.9 333.1 
0.995 
273.1 275.1 
1.006 ( ± 0.5% ) (± 1.4%) (± 0.9%) (± 1.0%) 
n=5 n=5 n=3 n=3 
Table 8: The acrylic block TLD irradiations for both MRgRT Unity and MRIdian systems in 
the presence and absence of the magnetic field. All standard error of means were less than 
1.4%. (Note: n corresponds to the number of times the acrylic block was irradiated under a 
specific condition.) 
 
With MRgRT systems recently installed in the radiation oncology centers and 
recently used in NCI supported clinical trials, future large multi-institutional clinical 
studies will be conducted on these systems. IROC-Houston has the responsibility to 
ensure that these systems can treat patients in a comparable and accurate manner, which 
is accomplished through IROC-Houston’s end-to-end anthropomorphic QA phantoms by 
credentialing institutions wishing to participate in NCI sponsored clinical trials. 
Institutions’ performances are analyzed by comparing measured TLD and radiochromic 
film to expected treatment plans. Double-loaded TLDs are equipped with 22 mg of 
powder LiF compared to 11 mg of LiF found in single-loaded TLDs. The extra powder 
effectively eliminates any air gaps within the capsules and allows for two reading 
measurements. Double-loaded TLDs were used to mitigate any potential ERE effects due 
to the absence of any air gaps. Dose measurements with double-loaded TLDs in the 
acrylic blocks and geometrical slab phantoms were shown not to be affected by ERE in 
both MRgRT systems when comparing doses with and without magnetic fields. 
Our results agreed with previous studies, showing that there is not a statistical 
difference between TLDs irradiated with and without magnetic fields for both ViewRay 
and Unity systems. Furthermore, our studies showed smaller differences in the ratios 
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between TLDs irradiated in 0T and 1.5T environments than shown in previous studies.  
Specifically, we found TLDs to be within 0.6% compared to a previous study that found 
TLDs to be within 5%65. One reason our results had greater agreement was attributed to 
the TLD readout process. IROC-Houston has an established TLD readout process that 
allows TLDs to be measured within 2.3% certainty (at 1 standard deviation)42. This study 
used standardized double-loaded TLD capsules, whereas the previous study self-
packaged LiF and self-measured the TLD dose. If a user had less experience, TLD 
uncertainties could be as great as 4.6% (at 1 standard deviation)78. Additionally, the 
previous study examined the magnetic effect on TLDs by comparing the TLD response 
on two different systems: a conventional 6 MV linear accelerator (B=0 T) and a 6 MV 
MR-Linac (B= 1.5T)65. Directly comparing TLDs irradiated with and without magnetic 
fields on two different systems will introduce greater uncertainties. This work had the 
unique opportunity to irradiate the TLD acrylic blocks and geometrical phantoms with 
and without magnetic field using the same machine for both MRIdian and Unity 
treatments. 
While this work was performed on the same unit, the window of opportunity to 
irradiate the phantoms with and with a magnetic field was extremely limited. The magnet 
on an MRgRT unit was ramped down rarely and were usually ramped down to perform 
upgrades on the system. Due to the time constraints, the phantoms and TLD blocks were 
only irradiated three and five times on the MRIdian and Unity MRgRT systems, 
respectively, yet the phantoms were irradiated on a single system and had direct 
comparisons between irradiations with and without a magnetic field. The output of the 
machines, when irradiated with and without magnetic fields, were assumed to have 
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negligible fluctuations. The Unity system, based on a series of output measurements, had 
less than a 0.7% fluctuation in the output over time35.  
 
3.4.2 Geometrical Slab Phantom Studies 
Radiochromic EBT3 film and double-loaded TLDs were irradiated in both the 
head and lung geometrical phantoms. TLDs were read in-house using IROC-Houston’s 
standard reading procedure. The measured TLD doses for each phantom type, i.e. head 
and lung, were averaged and are shown in Table 9 for the two MRgRT systems. The 
average Unity system TLD doses for 0T and 1.5T magnetic fields were 491.9 cGy 
(±1.5%) and 492.9 cGy (±1.3%) for the geometrical lung phantom and 453.1 cGy 
(±0.7%) and 441.6 cGy (±1.6%) for the geometrical head phantom. The average 
measured TLDs ratios between without/with magnetic fields in the Unity system 
configuration for lung and head phantoms were, respectively 1.002 and 0.984. The ratio 
of 0.984 comparing 1.5T dose measurements to those without any magnetic field was 
corrected due reconstructing the geometrical head phantom’s quadrants between the 0T 
measurements and the 1.5T measurements. After 0T measurements, it was discovered 
that the Superflab had interacted with the high-impact polystyrene (HIPS) barrier used to 
encapsulate the gel materials it, so, the HIPS was replaced with solid water. After the 
1.5T measurements it was realized that the geometrical head phantom’s modified solid 
water exterior thickness was thicker than the original HIPS and resulted in a 1.008 
correction to the original values. For the MRIdian 60Co system, the average TLD doses 
for 0T and 0.35T magnetic field strengths were 296.4 cGy (±1.1%) and 295.7 cGy 
(±1.1%) for the geometrical lung phantom and 271.7 cGy (±1.1%) and 272.4 cGy 
(±1.2%) for the geometrical head phantom, respectively. The average ratios of measured 
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TLD average doses for the MRIdian system comparing with to without magnetic fields 
for the lung and head phantoms were 0.998 and 1.003, respectively. 
The ratios between TLD irradiated with and without magnetic fields on a single 
MRgRT system were all within 1.6%, which is well within IROC-Houston’s 2.3% TLD 
uncertainty. The TLD results agreed with previous studies using a thimble ion chamber 
(Exradin A1SL) that showed a 1.26% higher dose output in the 1.5T than in a 0T 
magnetic field environment79. TLDs agreeing within 1.6% would suggested that the ERE 
effect is not affecting double-loaded TLDs dosimetry in either homogenous or 
heterogeneous configurations. If the magnetic field influenced the TLD dose, it was 
within the TLD’s inherent dose measurement 2.3% uncertainty and could not be 
delineated physically from the TLD reading uncertainty42. Therefore, these results would 
conclude that double-loaded TLDs were sufficient dosimeters to measure dose in 0.35T 
to 1.5T environments.  
  
Miniature 
Phantom 
Unity MRIdian 
0.0T  
[cGy] 
1.5T  
[cGy] 
Ratio 
[1.5T/0T] 
0.0T  
[cGy] 
0.35T  
[cGy] 
Ratio 
[0.35T/0T] 
Lung 491.9 
(± 1.5%) 
492.9 
(± 1.3%) 1.002 
296.4 
(± 1.1%) 
295.7 
(±1.1%) 0.998 
Head 453.1 
(±0.7%) 
446.1 
(± 1.6%) 0.984* 
271.7 
(± 1.1%) 
272.4 
(± 1.2%) 1.003 
Table 9: Geometrical lung and head phantoms measured doses with and without magnetic 
field from a total of five and three times irradiations on the Unity and MRIdian systems, 
respectively. All standard errors of the means were less than 1.6%. *Corrected by 1.008 for 
the increased barrier thickness. 
 
Radiochromic EBT3 films were used to measure beam profiles centrally located 
inside the geometrical phantoms. The right/left axial beam profiles were analyzed due to 
the ERE affecting the lateral planes in both ViewRay and Elekta systems. The measured 
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and simulated beam profiles for the head and lung geometrical phantoms in the presence 
and absence of a magnetic field were compared and are shown in Figure 21 and Figure 
22 for the Unity and MRIdian systems, respectively. Figure 21b shows a disagreement 
in the shoulder region between the two profiles due to an accumulation of petroleum gel 
without styrofoam beads that was not simulated in the GEANT4 Monte Carlo. Monaco 
treatment planning software was used as a different dose calculation method to validate 
the geometrical lung’s 1.5T film measurement. Under all conditions the two curves 
(simulated vs. measured) fall within the measurement uncertainty as evidenced by the 
error bars. The absolute differences between measured and calculated beam profiles were 
compared at the 80%, 50% and 20% dose levels along the edge of each set of profiles. 
The differences are shown in Table 10 for the Unity MRgRT system with the exception 
of the shoulder region (80% dose level) of the Unity lung phantom comparisons as 
explained above. The maximum average difference between the measured and calculated 
profiles was less than 2.2 mm. 
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Figure 21: Beam profiles comparing GEANT4 Monte Carlo measurements and EBT3 film 
for the geometrical lung (a-b) and head (c-d) phantoms that were irradiated on Unity’s 7 MV 
beam under 0T(a and c)  and 1.5T (b and d) magnetic field strengths. The error bars were 
calculated using the standard error of mean. 
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Lung   Head   
Unity B= 0T 
DTA [mm] 
Unity B= 1.5T 
DTA [mm] 
Unity B= 0T 
DTA [mm] 
Unity B= 1.5T 
DTA [mm] 
80% 1.1 ± 0.7 - 1.2 ± 0.8 0.9 ± 0.7 
50% 0.5 ± 0.3 1.3 ± 0.7 0.3 ± 0.3 0.5 ± 0.4 
20% 2.2 ± 1.0 1.2 ± 0.3 1.4 ± 0.5 0.3 ± 0.3 
Table 10: Measure distance at 80% and 50% on both left and right side of the beam profiles 
were used to calculate absolute differences between measured and simulated beam profiles 
on the Unity’s 0T and 1.5T for both head and lung phantoms.  Average absolute differences 
between both left and right sides of the curves were recorded 
 
Virtual beam profiles were generated by modifying the Monte Carlo code used in 
the O’Brien et al. 2016 study35. These modifications included: 1) adding a virtual 
geometrical phantom and 2) defining the chemical compositions of the MR/CT visible 
tissue equivalent materials used in the geometrical phantoms. The most accessible and 
a
. 
b
. 
c
. 
a. c. 
b. d. 
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practical way to define the materials in GEANT4 was to describe their chemical 
composition and density. The material safety data sheets and patents of each material 
used in the geometrical phantoms gave a general idea of the elements used in each 
material. Tests performed by Intertek Pharmaceutical Services measured the percentage 
of specific elements thought to be used in each material. It should be noted that there are 
uncertainties in estimating the elements in the materials. It was thought that the materials 
only had oxygen, nitrogen, hydrogen, carbon and chloride elements, and thus only those 
elements were examined. Each elemental composition test added an uncertainty of up to 
0.4%. Since only five elements were assessed, there were additional uncertainties as to 
other possible elements present in the materials which were not defined in the Monte 
Carlo.  
 
Figure 22: Beam profiles comparing 0T and 0.35T for the geometrical lung (a-b) and head 
(c-d) phantoms that were irradiated on MRIdian’s 60Co beam (a and c) and Monte Carlo 
generated beam profiles using Geant4 (b and d). The error bars were calculated using the 
standard error of mean. 
a
. 
c
. 
b
. 
d
. 
a. 
b. 
c. 
d. 
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Lung   Head   
Geant4: 
B= 0T VS 
B=0.35T 
DTA [mm] 
Film: 
B=0T VS B=0.35T 
DTA [mm] 
Geant4: 
B= 0T VS 
B=0.35T DTA 
[mm] 
Film: 
B=0T VS 
B=0.35T 
DTA [mm] 
80% 0.4 ± 0.3 0.6 ± 0.3 0.1 ± 0.1 0.5 ± 0.5 
50% 0.4 ± 0.2 0.4 ± 0.3 0.2 ± 0.1 0.4 ± 0.2 
20% - 0.6 ± 0.3 - 0.4 ± 0.2 
Table 11: Measured distance at 80% ,50% and 20% on both left and right sides of the beam 
profiles were used to calculate absolute differences between MRIdian’s  0T and  0.35T 
configurations for Monte Carlo (Geant4) and measured films. The average differences 
between the beam profiles were measured for both lung and head phantoms.  
 
Figure 22 displays measured and generated beam profiles for lung and head 
configurations using the MRIdian system. The absolute differences between 0T and 
0.35T beam profiles generated on Monte Carlo were compared to the absolute differences 
between 0T and 0.35T beam profiles measured on film. The absolute differences were 
compared at 80%, 50% and 20% for each profile set. Table 11 displays the average 
differences using the MRIdian configuration. The maximum average difference between 
0T and 0.35T was 0.6 mm for film and 0.4 mm for Monte Carlo. Under all conditions, 
the two curves fall within the measurement uncertainty as evidenced by the shown 
standard deviation. Despite the disagreement seen in the penumbra between measured 
and Monte Carlo generated beam profiles, both curves showed that low magnetic fields 
(i.e., 0.35T) did not shift the beam profiles and showed the same beam profile shape as 
0T configurations. This result would suggest, at first order, the 0.35T magnetic field 
environment does not influence the dose deposition on the EBT3 film. 
The MRIdian system was simulated using an open-source head model, provided 
from the International Atomic Energy Agency. This phase-space data simulated a 60Co 
capsule with a finite width of 2 cm77. GEANT4 did not accurately simulate a true 
MRIdian 60Co system since the phase space file only accounted for a single multi leaf 
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collimator (MLC) and a common finite source width. The treatment head of an MRIdian 
60Co system has two sets of MLCs that were used to focus the radiation beam to create a 
steep penumbra. Having two sets of MLCs allowed a 60Co system to better resemble a 
penumbra traditionally seen on a 6 MV linear accelerator. However, the MRIdian 60Co 
system did not have the same penumbra slope as a 6 MV beam. The phase-space file used 
to simulate a 60Co beam had a typical 60Co treatment head configuration including a 
single MCL set. The head configuration could not be altered to better resemble an 
MRIdian head configuration due to using a phase-space data with fixed parameters. This 
factor created additional uncertainties to the penumbra on the simulated beam profiles of 
the MRIdian system since only a single MLC set was simulated. Film validation was 
performed by computing the distance to agreement (DTA) between 0T and 0.35 T beam 
profiles on film and the DTA between 0T and 0.35T on Monte Carlo simulated beam 
profiles.  
Two geometrical phantoms were irradiated using EBT3 film on a Unity and 
MRIdian system. Monte Carlo generated beam profiles were used to validate EBT3 film 
irradiated with and without magnetic fields for Unity and MRIdian MRgRT systems. 
Using a 1.5T magnetic field parameter, Monte Carlo accurately resembled film 
measurements in a 1.5T environment, thus suggesting that a high field does not affect 
EBT3 readings. Higher magnetic fields (i.e., 1.5T) are more likely to have a greater effect 
on radiation dosimeters than on low magnetic field environments (i.e., 0.35T), thus 
suggesting that EBT3 film also would not affect a lower (i.e. 0.35T) magnetic field 
environment. This assumption was proven to be true when comparing the average DTA 
between 0T and 0.35T setups for both film and Monte Carlo measurements.  
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3.5 CONCLUSION 
TLDs irradiated with and without magnetic fields showed high reproducibility in 
both MRgRT systems. Both Unity and MRIdian systems showed less than 0.6% 
difference in the acrylic block study. Under a homogenous acrylic block setting, the TLD 
dose indicates a negligible effect from the presence of a magnetic field in MRgRT 
systems with 0.35T and 1.5T magnetic fields. Furthermore, TLD’s and radiochromic 
film’s responses are reproducible in MRIdian and Unity systems when using more 
complex conditions (i.e., lung and head geometrical slab phantom configurations). The 
ratio between TLD doses with and without a magnetic field agreed within 1.6% for 
geometrical phantoms irradiated in both MRgRT system. Beam profiles generated from 
radiochromic film irradiated in the lung and head geometrical phantoms on the Unity 
system agreed very well with the general shape of beam profiles generated from a Monte 
Carlo simulation. Beam profiles generated on the MRIdian configurations did not match 
beam profiles generated on Monte Carlo due to the limitations of using a phase-space 
with fixed parameters that simulated a single MLC set. The beam profiles generated on 
Monte Carlo with and without magnetic fields showed similar shifts as beam profiles 
measured in the MRIdian system.  This study showed that, double-loaded TLDs and 
radiochromic EBT3 films can be used in phantoms that will experience a 0.35T to 1.5T 
magnetic field. 
 
 
  
  76 
Chapter 4: MRgRT Head and Neck QA Phantom:  
Design, Construction and Feasibility Study  
 
A substantial portion of this chapter is written or based on the following publication: 
 
A.Steinmann, P Alvarez, H Lee, R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller, 
D. Followill, “MRgRT Head and Neck Anthropomorphic QA Phantom: Design, 
Development, Commissioning and Feasibility Study,” Medical Physics. [In review] 
(2018). © John Wiley and Sons. 
 
The permission for reuse of this material was obtained from John Wiley and Sons.  
 
 
4.1 ABSTRACT 
Purpose:  The purpose of this paper was to design, manufacture, and evaluate a tissue 
equivalent, dual MR/CT visible anthropomorphic Head and Neck (H&N) phantom. This 
phantom was specially designed as an end-to-end quality assurance (QA) tool for 
magnetic resonance (MR) guided radiotherapy (MRgRT) systems participating in NCI-
sponsored clinical trials. 
 
Method: The MRgRT H&N phantom was constructed using a water-fillable acrylic shell 
and a custom insert that mimics an organ at risk (OAR) and target structures. The insert 
consists of a primary and secondary PTV manufactured of a synthetic clear ballistic gel, 
an acrylic OAR and surrounding tissue fabricated using melted Superflab. Radiochromic 
EBT3 film and TLDs were used to measure the dose distribution and absolute dose, 
respectively.  
The phantom was commissioned by conducting an end-to-end test that included: 
imaging on a GE Lightspeed CT simulator, planning on Monaco treatment planning 
software (TPS), verifying treatment setup with MR and irradiating on Elekta’s 1.5T Unity 
  77 
MR linac system. The phantom was irradiated three times using the same plan to 
determine reproducibility. Three institutions, equipped with either ViewRay MRIdian 
60Co or ViewRay MRIdian Linac, were used to conduct a feasibility study by performing 
independent end-to-end studies. TLDs were evaluated in both commissioning and 
feasibility studies by comparing ratios of measured TLD to reported TPS calculated 
values. Radiochromic film was used to compare measured planar dose distributions to 
expected TPS distribution. Film was evaluated by using an in-house gamma analysis 
software to measure the discrepancies between film and treatment planning software 
(TPS). 
Results:  Commissioning of the MRgRT H&N phantom on the Unity system resulted in 
reproducible TLD doses (SD < 1.5%). The measured TLD to calculated dose ratios for 
the Unity system ranged from 0.94 to 0.98. The Viewray dose result comparisons had a 
larger range (1.03-0.94) but these depended on the TPS dose calculations from each site. 
Using a 7%/4mm (85% pixels passing) gamma analysis, Viewray institutions had 
average axial and sagittal passing rates of 97.3% and 96.2% and the unity system had 
average passing rates of 97.8% and 89.7%, respectively. All of the results were within 
IROC’s 7%/4mm criterion.  
Conclusions: An MRgRT H&N tissue equivalent and visible on both CT and MR was 
developed. There was no difference in the results noted between Unity, MRIdian Linac 
and MRIdian 60Co systems. The MRgRT HN phantom can be used as a credentialing tool 
for NCI-clinical trials using MRgRT systems. 
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4.2 INTRODUCTION 
New radiotherapy devices, referred to as MRgRT systems, integrate an MR 
imager with either a linear accelerator or radioactive 60Co source.  Globally, there are 
presently four different MRgRT prototypes used in the clinic. These include: the MRgRT 
suite (Varian, Palo Alto, California, USA and Siemens, Erlangen, Germany), the Unity 
(Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands), the MRIdian 
60Co (ViewRay, Oakwood Village, Ohio), and the MRIdian Linac (ViewRay, Oakwood 
Village, Ohio) 10-13.  In short, the MRgRT suite is a 1.5T MR-on-rails system that moves 
an MR unit into a linear accelerator vault to acquire images.  The Unity system is 
equipped with a 7 MV beam mounted to a slip-ring gantry located above a modified 1.5T 
magnet. The MRIdian and MRIdian Linac systems are equipped with three 60Co sources 
and a single 6 MV linear accelerator, respectively, that are centrally located within a split 
0.35T magnet.  Clinics within the United States either have the MRIdian 60Co, the 
MRIdian Linac, or the Unity system. 
Technologies used in an MRgRT system, compared to current image guided 
systems, have the potential to revolutionize radiotherapy. Unlike conventional KV or MV 
image guided systems, MRgRT systems offer superior soft tissue delineation while not 
subjecting the patient to a dose of radiation. The ability to visualize the gross tumor 
volume (GTV) could further reduce margins, thereby, reducing normal tissue toxicity 
and increasing local control. Acquiring MR images can be done more frequently since 
they would not contribute to additional dose.  MRgRT systems can monitor treatment 
effectiveness since their near diagnostic-quality MR images could delineate between soft 
tissue and would be captured before every treatment. Advance radiotherapy techniques 
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can be enhanced with an MRgRT system by permitting real-time gating, target tracking 
and online adapted radiotherapy80; 81. These techniques would revolutionize radiation 
therapy since treatment would be based on the actual disease location at the given time 
radiation was delivered.  
The safety and usefulness of MRgRT systems are still being investigated.  The 
National Institutes of Health (NIH) has sponsored several short-term clinical trials that 
preliminarily address safety issues in acquiring daily MR images (NCT02973828) and 
delivering radiation using MRgRT systems (NCT03284619). Additionally, NIH-
sponsored clinical trials (NCT03048760, NCT01999062) have begun to investigate how 
new MRgRT workflows (i.e., online adapted radiotherapy) and advanced treatment 
techniques (i.e., auto-contouring, MR gating) would affect the clinic. NIH has also 
sponsored several short-term pilot studies (NCT02264886, NCT02683200, 
NCT02701712, NCT02264886) to investigate the effectiveness of using an MRgRT 
system for various anatomical locations. While these pilot studies can preliminarily 
determine regions that would likely benefit from MRgRT, more extensive multi-
institutional clinical trials will be needed in the future to thoroughly evaluate clinical 
outcomes (i.e., local control, survival rates) for a given disease site. A proposed clinical 
trial could examine the correlation between local control rates and MR image guidance 
on an MRgRT system82. Head and neck (H&N) region tumors would be ideal for this 
proposed clinical trial since CT images lack soft tissue delineation83.  
In order for radiotherapy centers to participate in large multi-institutional studies, 
the National Cancer Institute (NCI) requires each participating institution to be a part of 
the Imaging and Radiation Oncology Core (IROC) QA program which includes 
credentialing for advanced technologies. The Imaging and Radiation Oncology Core 
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quality assurance (QA) center in Houston (IROC-Houston) has been funded by the NCI 
since 1968 to ensure all institutions participating in National Clinical Trial Networks 
(NCTN) can accurately and consistently deliver radiation doses to trial patients such as 
from intensity modulated radiotherapy (IMRT) treatments. IROC-Houston has 
developed various on-site and off-site auditing tools to assure quality is maintained 
throughout participating institutions. Among such QA tools, IROC-Houston ships off-
site anthropomorphic phantoms to credential NCTN trial participants using advanced 
technology treatment modalities84. During the credentialing process, the phantom will 
undergo the same treatment workflow as a patient would and an end-to-end QA 
examination is performed to assess the institution’s ability to deliver the treatment plan. 
IROC-Houston has a collection of site-specific anthropomorphic phantoms. 
These anatomical regions include:  H&N, pelvis, brain, thorax, spine and liver. The H&N 
phantom is IROC-Houston’s oldest and most common phantom used in the credentialing 
process.  This custom phantom is constructed using a solid high impact polystyrene 
(HIPS) slab that is fitted into an anthropomorphic shaped human head. The custom insert 
contains an acrylic spinal cord, and two (primary and secondary) PTVs manufactured 
using solid water which are dosimetrically monitored with radiochromic film and 
thermoluminescent detectors (TLD)60. The spinal cord is adjacent to the primary PTV 
which requires each institution to create an IMRT plan with a steep dose gradient. 
Integrating an MR imager within a radiotherapy system will inherently transform 
how treatment plans and deliveries are performed. In order to account for an MRgRT 
workflow, comprehensive end-to-end phantoms must be CT and MR compatible. 
Conventional IROC-Houston phantoms, designed for CT-only workflows, are not suited 
for MR workflow72. The aim of this study was to design, manufacture, and evaluate a 
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tissue equivalent MR/CT visible anthropomorphic H&N phantom, that met IROC-
Houston’s phantom requirements and could be used as a QA tool to credential MRgRT 
systems participating in NCI-sponsored NCTN clinical trials.  
4.3 MATERIAL AND METHODS 
The MRgRT H&N phantom was designed to meet IROC-Houston’s 
radiotherapy, diagnostic and practicality criteria. Materials used in the MRgRT H&N 
phantom were carefully selected based on findings in the Steinmann et al. 2018 study72. 
To meet radiotherapy and diagnostic requirements, the entire phantom was designed to 
dosimetrically represent human tissues (i.e., spinal cord, soft tissue) by using materials 
that were dosimetrically tissue equivalent and visible on MR and CT imagers. To meet 
practicality criteria, materials were carefully selected so that they required minimal 
maintenance, did not morph over time, did not require preservatives, and had high 
melting points to withstand any harsh shipping conditions. Once the H&N insert was 
constructed, the phantom was reproduced on a 1.5T Unity system and then sent out to 
three institutions to conduct a miniature end-to-end feasibility study. 
 
4.3.1 Phantom Design 
The MRgRT H&N phantom consisted of a water-fillable acrylic shell (The 
Phantom Laboratory, Salem, New York, USA) and a custom designed H&N insert. 
Externally the hollow acrylic shell was morphed to resemble a human head, but internally 
consisted of a rectangular concavity that tightly held a MR/CT compatible insert. The 
hollow anthropomorphic MRgRT H&N phantom next to its 7.5 cm x 10.5 cm x 13 cm 
custom insert is seen in Figure 23. The custom H&N insert was designed based on a 
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Radiation Therapy Oncology Group (RTOG) oropharyngeal protocol (H-0022) which 
consisted of two PTVs (primary and secondary) and an OAR60. 
 
Figure 23: The MRgRT H&N Phantom. The phantom consists of a water-fillable 
anthropomorphic shell and a MR/CT compatible insert.  
 
Figure 24 displays a CT axial view of the H&N insert. Internally, the insert 
consists of: 1) a moon-shaped cylindrical primary PTV, 2) a cylindrical secondary PTV 
and 3) a cylindrical spinal cord that simulated an OAR. The primary PTV is adjacent to 
the OAR and the secondary PTV is located at a distance. Inferior and superior pieces of 
the two-part insert were secured together from two high impacted polystyrene (HIPS) 
plastic screws. The MRgRT H&N insert used radiochromic EBT3 film and double-
loaded TLDs as portable dosimeters. A total of three radiochromic films were placed into 
the insert to capture axial and sagittal planes. A sagittal film was placed in between the 
primary PTV and OAR for each superior and inferior piece and an axial film was inserted 
in between the two pieces. Radiochromic films were pinpricked on the outer parameters 
to allow for film registration. At the insert’s center, eight double-loaded TLD capsules 
were placed into the insert. Half of the TLDs were inserted into the inferior portion and, 
the other half were inserted in the same position on the superior piece.   
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Figure 24: A CT image of the MRgRT H&N insert. 
 
Clear Ballistic Gel #20 (Clear Ballistics, Fort Smith, Arkansas, USA) was used 
to create the PTV structures. The primary and secondary PTV had dimensions of 5.0 cm 
in length and had diameters of 4.0 cm and 2.0 cm, respectively. The primary and 
secondary PTV held a total of four and two TLDs, respectively. The primary PTV had 
TLDs located anteriorly and posteriorly from the center whereas TLDs were held in the 
center of the secondary PTV. The OAR was constructed using acrylic (Professional 
Plastics, Fullerton, California, USA) which extended 13 cm in length and was 1 cm in 
diameter. The OAR held a total of two TLDs. Each TLD was located in the center of the 
spinal cord structure in each insert piece. Table 12 summarizes the materials used in each 
structure as well as the dimension and total TLDs used. All structures were surrounded 
by melted Superflab which was encapsulated in solid water to create a rigid rectangular 
structure. Both Superflab and Clear Ballistic Gel #20 were melted at, respectively, 
121.1°C and 148.9°C then poured into a solid water mold. The molds were moved to a 
vacuum chamber until the melted materials had solidified at room temperature.  
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Structure Material 
Diameter 
(cm) 
Length 
(cm) 
Total 
TLDs 
Used* 
Primary PTV Clear Ballistic Gel #20a 4 5 4 
Secondary 
PTV 
Clear Ballistic Gel #20a 2 5 2 
OAR Acrylicb 1 13 2 
a: Clear Ballistics, Fort Smith, Arkansas, USA, b: Professional Plastics, Fullerton, California, USA,  
 
Table 12: The materials used to manufacture a MRgRT H&N insert, dimensions of each and 
total number of TLD used in each structure (*half of the TLDs were inserted into the inferior 
part and the other half inserted into the superior part of the MRgRT H&N insert).  
 
 
4.3.2 Phantom Imaging 
The MRgRT H&N phantom was imaged on a CT simulator, MRIdian 60Co, and 
Unity system. The phantom was first scanned using a brain protocol on a GE Lightspeed 
CT simulator (General Electric Company, New York, New York, USA) with scanning 
parameters of: DFOV= 500.0 mm, 120 kVp, 275 mA, and slice thickness=3mm. 
ViewRay’s 0.35T MRIdian 60Co system captured a single MR image of the MRgRT 
H&N phantom using a TrueFISP (true fast imaging with steady-state free precession) 
sequence with scanning parameters of: FA=60°, TR=3.33 ms, TE=1.43 ms, NEX=1.  A 
T1-weighted image was produced from Elekta’s 1.5T Unity system and had scanning 
parameters of: FA=8°, TR=8.0 ms, TE=3.6 ms, ETL=136, NEX=1. Table 13 summarizes 
the MR scanning parameters on both the MRIdian and Unity systems.  
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Parameters MRIdian Unity 
MR Scanning 
Sequence 
True Fast Imaging with 
Steady-state free 
Precession (TrueFISP)* 
T1-Weighted 
Gradient 
FA 60° 8° 
TR (ms) 3.33 8.0 
TE (ms) 1.43 3.6 
ETL - 136 
NEX 1 1 
Table 13: MR images were captured on both MRIdian and Unity systems. The ViewRay 
system acquired a TRUFI image and the Unity system acquired both T1- weighted and T2-
weighted image. * TRUFI and TrueFISP are the same sequence, but under different 
manufactures have different names. 
 
 
4.3.3 Dose Prescription 
The prescription dose was based on the dosimetric requirements set for IROC-
Houston’s conventional H&N phantom. The dosimetric criteria is illustrated in Table 14. 
The primary and secondary PTV prescriptions required at least 95% coverage of 6.6 Gy 
and 5.4 Gy, respectively. Less than 93% of the prescribed dose, for both PTV sites, 
received less than 1% of the PTV. The OAR was restricted to receive a maximum dose 
of 4.5 Gy and the normal tissue structure was restricted to receive less than 110% (i.e., 
7.3 Gy) of the prescribed dose.  
MRgRT H&N 
Structure 
Dose Prescription 
Primary PTV D95 ≥ 6.6 Gy 
D99 ≥ 6.1 Gy 
Secondary PTV D95 ≥ 5.4 Gy 
D99 ≥ 5.0 Gy 
OAR DMax < 4.5 Gy 
Normal Tissue DMax ≤ 7.3 Gy 
 
Table 14: During both reproducibility and feasibility studies, treatment plans were based on 
the same dose constraints.  
 
  86 
4.3.4 Treatment Delivery 
Reproducibility and feasibility studies were conducted on the MRgRT H&N 
phantom. During the reproducibility study, the MRgRT H&N phantom was irradiated 
three times on a single Unity system and then sent out to three other MRgRT sites to 
conduct a multi-institutional feasibility study. During this miniature feasibility study the 
phantom was irradiated using two different MRIdian 60Co systems and irradiated once 
on an MRIdian Linac system. The MRgRT H&N phantom was evaluated based on an 
end-to-end test for both reproducibility and feasibility studies using the TLD and EBT3 
radiation dosimeters.   
TLDs were read in-house using the same method as IROC-Houston’s off-site 
auditing program42. Double-loaded TLDs (ThermoFisher Scientific, Waltham, 
Massachusetts, USA) were used as an absolute dosimeter and were read two weeks from 
irradiation date to account for fading. The exact amount of lithium fluoride power inside 
a double-loaded TLD capsule was weighed using a Mettler AT261 DeltaRange (Mettler 
Toledo, Greifensee, Switzerland) scale and light output was measured using the Harshaw 
M3500 TLD reader (ThermoFisher Scientific, Waltham, Massachusetts, USA). The 
optical density from the irradiated film was read using a photoelectron CCD 
microdensitometer (Photoelectron Corporation, North Billerica, Massachusetts, USA). 
The measured intensity read on the CCD microdensitometer was converted to dose and 
was post processed using an in-house MATLAB software (The MathWorks, Inc., Natick, 
Massachusetts, USA).  
Treatment delivery was compared to the expected TPS and was analyzed by two 
methods.  These methods included: 1) comparing the reported to measured dose for each 
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TLD location, 2) performing gamma analysis on axial and sagittal films and generating 
dose profiles for each orientation.  
 
4.3.4.1 Reproducibility Study 
The phantom was filled with water and imaged on a GE Lightspeed CT simulator 
using a brain protocol with parameters of: DFOV=500.0 mm, 120 kVp, 275 mA, and 
slice thickness=3mm. The CT image was transferred to Monaco TPS (Elekta, Crawley, 
United Kingdom) where TLDs, OAR, and PTVs were contoured and an IMRT plan 
created. The IMRT treatment plan used nine gantry angles and used IMRT constraints 
similar to Tonigan’s thesis using a median complexity treatment plan85. 
The MRgRT H&N phantom was positioned on the Unity system’s couch and a 
uniform foam coil was placed above the phantom. Figure 25 displays the treatment setup 
used for the reproducibility study. Once the phantom was positioned on the couch, the 
phantom was moved into the gantry. During each irradiation the phantom captured a T1-
weighted MR image (with scanning parameters of: FA=8°, TR=8.0 ms, TE=3.6 ms, 
ETL=136, NEX=1). The MR image was fused to the CT image using Monaco’s 
automatic image fusion tool. The fused image data set was used to re-optimize the dose 
distribution based on the phantom’s current position. The adjusted plan was accepted and 
was used to treat the MRgRT H&N phantom. The maximum, minimum and mean dose 
were recorded on all TLD locations. For each irradiation, the treatment took around 35 
minutes and reloading the phantom with new detectors took around 15 minutes. The 
MRgRT H&N treatment plan used to compare the treatment plan to the measured dose 
was exported from a universal memory thumb drive.   
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Figure 25: The MRgRT H&N setup at MD Anderson’s Unity System. The MRgRT H&N 
phantom was secured in place with blue tape and a white foam coil was fastened above the 
phantom. The coil was used to capture an MR image and remained on during the 
irradiation. It should be noted that the coil was lowered close to the phantom’s surface but 
did not directly contact the phantom.   
 
4.3.4.2 Feasibility Study 
The MRgRT H&N phantom was used to conduct a multi-institutional 
feasibility study. During this feasibility study, the phantom was irradiated on 
either an MRIdian 60Co or an MRIdian Linac system. Each institution received 
detailed instructions which helped to create uniformity between the participating 
institutions. These instructions required the institutions to: 1) prepare the phantom 
for imaging and treatment (i.e., fill the hollow phantom with tap water and place 
the insert into the phantom), 2) capture a CT simulated image, 3) design an IMRT 
treatment plan, 4) verify treatment setup by capturing an on-board MR image and 
5) deliver the expected IMRT treatment plan. Each institution was also instructed 
to contour the TLD capsules and record the TLD’s expected minimum, maximum 
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and mean doses.  The digital treatment plan data was sent to IROC-Houston, where the 
institution’s treatment delivery was evaluated. 
4.4 RESULTS  
4.4.1 Phantom Imaging 
As shown in Figure 26, the MRgRT H&N phantom was imaged using a GE CT 
simulator, Unity and MRIdian MRgRT system. All three images in Figure 26 clearly 
display distinguishable internal structures. This ability to see contrast between the disease 
site and surrounding tissue allows institutions to real-time visualize the phantom during 
treatment. The insert’s rigid exterior and OAR are made of solid water and acrylic, 
respectively. These materials lack hydrogen content and appear black on the MR image. 
The OAR is visualized through the contrast between the absences of signal surrounded 
by MR-visible surrounding tissue. In comparison to the MRIdian 60Co system, the Unity 
system captures a higher spatial resolution image. MRgRT systems show different 
contrasts within the insert. These variations in contrast and spatial resolution are 
attributed to the different MR scanning sequences and magnetic fields, respectively. A 
T1-weighted imaging sequence was applied to the 1.5T Unity system whereas a 
TrueFISP sequence was applied to the 0.35T MRIdian system.  The MR image from the 
Unity system captures greater susceptibility artifacts compared to the MRIdian image.   
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Figure 26: The MRgRT H&N phantom was filled with water and scanned on: (a) GE CT 
simulator, (b) Unity system’s 1.5T MRI with a T1 sequence and (c) ViewRay’s MRIdian Co-
60 0.35T system with a TRUFI sequence. All images clearly show the OAR, primary and 
secondary PTV. 
 
 
4.4.2 Treatment Delivery 
Measured TLD readings were compared to the TPS. Ratios between measured 
TLD dose to reported dose are shown in  
Table 15 and  
Table 16 for the commissioning and feasibility study, respectively. TLDs that fall 
within 7% (i.e. 0.93 to 1.07) of the reported dose were considered to be within IROC’s 
acceptance criteria. For the commissioning study, the average ratio between measured 
and reported values for the primary PTV’s superior anterior, inferior anterior, superior 
posterior, and inferior posterior TLD locations were: 0.98, 0.96, 0.94, 0.96 and for the 
secondary PTV’s superior and inferior were: 0.96 and 0.96, respectively. The first row 
in Table 15 and Table 16 displays the average results in the reproducibility study. The 
average ratios between measured TLD and reported doses in the feasibility study were: 
1.00, 0.99, 0.98, and 0.99 for the primary PTV’s superior anterior, inferior anterior, 
superior posterior and inferior posterior locations, respectively. For both studies, the 
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ratios between measured TLD readings to treatment planning readings were all within 
IROC’s acceptable criteria region. 
 
 
Table 15: Reproducibility results of four TLD positions in the Primary PTV. The left column 
represents TLD locations for the doses calculated from Monaco’s treatment planning 
software. The middle three columns represent the average TLD measured for each location. 
The average ratios between measured and calculated dose and the coefficient of variance are 
displayed in the right column. The TLD measurements were all within 6% of the reported 
TLD dose.  
 
 
 
Institution Energy 
Superior 
Anterior 
Inferior 
Anterior 
Superior 
Posterior 
Inferior 
Posterior 
Unity 1  7 MV 0.98 0.96 0.94 0.95 
ViewRay 2 6 MV 1.01 1.01 1.02 1 
ViewRay 3 Co-60 1.03 1.03 1.02 1.01 
ViewRay 4 Co-60 0.98 0.97 0.95 0.99 
Average -- 1.00 0.99 0.98 0.99 
 
Table 16: Feasibility study results for four TLD positions in the primary PTV. Results are the 
ratio between measured TLD dose and reported dose from the treatment planning software.   
 
 
Axial and sagittal films were evaluated using a gamma analysis86. Films were 
said to pass if more than 85% of the pixels passed a 7%/4mm criterion. Table 17 and 
Table 18 display the percentage of pixels passing the gamma criterion for axial and 
sagittal film planes in the reproducibility and feasibility study, respectively. The 
commissioning study’s three irradiations had individual passing rates of 96.4%, 98.1%, 
and 99.1% for axial films and 89.9%, 89.9% and 89.2% for sagittal films. The average 
TLD Location 
Reproducibility Test  
Average 
 
Unity 1-a Unity 1-b  Unity 1-c 
Coefficient 
of variance 
PTV Sup. Anterior 0.97 0.98 0.98 0.98 0.7% 
PTV Inf. Anterior 0.97 0.95 0.96 0.96 1.5% 
PTV Sup. Posterior 0.94 0.94 0.94 0.94 0.4% 
PTV Inf. Posterior 0.94 0.95 0.94 0.95 0.9% 
Secondary PTV: Sup. 0.97 0.95 0.96 0.96 1.1% 
Secondary PTV:  Inf. 0.96 0.95 0.96 0.96 0.4% 
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percent of pixels passing in the reproducibility study were 97.8% and 89.7% for axial 
and sagittal film planes, respectively. For the three feasibility study irradiations on the 
MRIdian units, the axial film had individual passing rates of: 97.8%, 97.6%, and 96.7%, 
and for the sagittal films had respectively passing rates of: 89.7%, 95.7%, and 95.6%. On 
the feasibility study, all axial and sagittal films passed IROC’s gamma criteria with an 
average pixel passing of 97.6% and 92.3%, respectively. During the gamma analysis 
three dose profiles were generated in anterior-posterior, left-right, and superior-inferior 
orientation.  The typical dose profiles generated from these studies are shown in Figure 
27.  From a qualitative perspective, film dose profiles and calculated dose profiles were 
in excellent agreement with all studies.   
 
Institution 
% Pixel Passing 
[±7%/4mm] 
Axial Sagittal 
Unity 1-a 96.4% 89.9% 
Unity 1-b 98.1% 89.9% 
Unity 1-c 99.1% 89.2% 
Average 97.8% 89.7% 
 
Table 17:  The MRgRT H&N phantom was irradiated three times on a 1.5T Unity MR Linac 
system. Axial and sagittal planes were evaluated based on 7%/4mm gamma criteria.  
 
Institution Energy 
% Pixel Passing 
[±7%/4mm] 
Axial Sagittal 
Unity 1 7 MV 97.8% 89.7% 
ViewRay 2 6 MV 97.9% 95.7% 
ViewRay 3 Co-60 96.7% 96.6% 
ViewRay 4* Co-60 - - 
Average - 97.6% 96.2% 
 
Table 18: Five different MRgRT systems treatments were evaluated based on the 7% dose 
and 4mm distance to agreement gamma criteria for both axial and sagittal planes. This table 
displays the percentage of pixels passing the gamma criteria. *Data unavailable from 
institution for analysis.   
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Figure 27: Dose profiles generated in the (a) anterior-posterior, (b) left-right, and (c) 
superior-inferior direction.  These graphs compare dose profiles generated on film to those 
generated from the treatment planning. These graphs were generated from institution 3, but 
resemble the typical dose profiles generated from both feasibility and commissioning studies.  
a. 
b. 
c. 
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4.5 DISCUSSION 
The MRgRT H&N phantom was designed as a tool to credential institutions 
wishing to use an MRgRT system to participate in NCI-sponsored clinical trials. IROC-
Houston’s conventional phantoms were originally designed for CT-only workflow and 
constructed of solid materials that were tissue equivalent and visible on CT but were not 
visible on MR72. The lack of MR signal in IROC-Houston’s traditional H&N phantom 
created a solid black MR image and caused internal structures to be indistinguishable. In 
order to use an H&N phantom in all aspects of the MRgRT treatment workflow, it was 
critical that the phantom be tissue equivalent and visible in both CT and MR. Having a 
multi-modality phantom would truly simulate an MRgRT end-to-end workflow. 
Therefore, IROC-Houston’s conventional H&N phantom was an insufficient end-to-end 
tool for MRgRT systems since it was not MR visible.  
Several studies have attempted to manufacture phantoms that are MR and CT 
compatible, but these do not fit IROC-Houston’s requirements. These requirements 
include: 1) materials must be dosimetric equivalent to tissue, 2) materials must be MR/CT 
visible, 3) portable radiation dosimeters are easy to install into the insert, 4) phantom 
insert must be durable, and 5) the phantom requires minimal maintenance (i.e., can be 
stored at room temperature). Some studies have created H&N phantoms using materials 
that either had short shelf-lives, required additional additives to prevent micro-organism 
infestation or required special storage conditions (i.e., refrigerators)57; 87. Some studies 
attempted to construct a dual MR/CT H&N phantom by adding MR visible markers to 
phantoms that are traditionally used in CT-only workflow88; 89.  Other MR/CT compatible 
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H&N phantoms are simplistic and were designed to address different challenges in MR-
only workflows90. These phantoms were not designed to perform end-to-end tests, but 
instead they were designed to quantify MR distortion and study the ability to create 
synthetic electron density from a MR image. Therefore, there is not an end-to-end 
MRgRT H&N phantom which supports portable dosimeters and have complex multi-
contrast internal structures. 
The MRgRT H&N insert was constructed from gel-based materials. Gel-based 
materials, compared to solid materials, were more difficult to manufacture and required 
extra construction time since these materials could not precisely be sculpted into a 
complex internal structure. The construction process to create precise structures using 
gel-based materials included: 1) melting Superflab (121.1 °C) and Clear Ballistic Gel #20 
(148.9 °C), 2) pouring melted materials into custom made molds and 3) storing materials 
in an air-tight vacuum until solidified. The vacuum chamber was used to eliminate air 
bubbles created during the pouring process and the molds were used to create precise and 
reproducible structures. To increase rigidity and to sustain shape during rough shipping 
conditions, solid water was used to encapsulate internal structures and to create an 
exterior insert shell.  
IROC-Houston’s conventional phantoms are also equipped with several film pin 
prick registration locations. The purpose of these small pinpricked areas is to identify the 
film’s location relative to the phantom’s location. Film pin pricks are created in IROC-
Houston’s conventional H&N phantom by inserting a fine needle into a small drilled hole 
near the internal structures. This method was not feasible in the MRgRT H&N insert 
since a fine needle could pierce through any direction inside the gel material; thus, 
creating greater film registration uncertainties. Additionally, piercing a needle through 
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gel material could damage the internal parts of the insert. To prevent additional 
uncertainties and increase the insert’s longevity, small holes were not created in the gel 
material. Rather, the insert was designed with wider exterior walls and small holes were 
drilled into the solid water exterior shell.   
IROC-Houston is responsible for ensuring multi-institutions are delivering 
consistent treatments. One method by which IROC-Houston evaluates this consistency 
is by sending anthropomorphic phantoms with detail dose prescription instructions to 
institutions. With the goal of using the MRgRT H&N phantom to examine an institution’s 
ability to deliver radiation consistently among other institutions, it was important that 
this phantom also use the same instructions and evaluation metrics as IROC-Houston’s 
conventional H&N phantom. During both commissioning and feasibility studies, 
institutions were required to use a specific dose prescription and to use on-board MR 
imagers to verify treatment setup. Additionally, IROC-Houston allowed institutions to 
use other MR workflow components as needed. Thus, institutions were free to 
incorporate MR-based treatment planning and real-time MR image guidance. While most 
institutions used CT-only to create an IMRT plan, one institution (ViewRay 4) chose to 
use the electron density captured on a CT image and then plan based on the MR image.   
Unlike MRIdian systems, the Unity system was not equipped with lasers inside 
the vault. In fact, the Unity system solely relied on capturing an MR image to account 
for any setup discrepancies between each irradiation. Part of the Unity system’s 
workflow required a re-optimization based on the current setup position. The 
commissioning test encompassed all parts of the workflow including MR setup 
verification methods. During each irradiation the treatment couch was moved outside the 
bore and the insert was removed from the phantom to load new unirradiated detectors 
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into the insert. Once unirradiated TLDs and film sheets were reloaded into the phantom, 
the H&N insert was screwed into the phantom and the treatment couch was moved back 
inside the bore.  During this process, the phantom could have been moved in a slightly 
different position due to the couch movement and the insert’s re-installation into the 
phantom. There were no lasers to verify whether the phantom was in the same position 
as the previous irradiation. To account for any movement, MR images were acquired 
before each irradiation and the treatment plan was re-optimized accordingly.  
Each step in the radiation treatment process will have associated uncertainties. 
Since MRgRT systems have different workflows than conventional linear accelerators, 
they will also have different associated uncertainties.  Some of the various sources of 
uncertainties could arise from: 1) MR/CT image fusion, 2) potential minor dosimetric 
effects on TLDs from an MR environment, 3) linear accelerator output consistency 4) 
MR geometrical accuracy and 5) re-optimization differences. While the major purpose 
of these studies was not to quantify the source of uncertainties, these studies were used 
to evaluate an institution’s performance based on the entire treatment process. If an 
institution failed IROC-Houston’s passing criterion then it was that institution’s 
responsibility to further investigate the source of errors and implement new protocols to 
mitigate uncertainties from those components.  Even with various uncertainties, the 
gamma results from them MRgRT H&N phantom demonstrated that those uncertainties 
played a minimal role in the overall dose delivery. These studies also demonstrated that 
the Unity, MRIdian 60Co, and MRIdian Linac systems have the ability to consistently 
deliver IMRT treatments.  
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4.6 CONCLUSION 
NCI sponsored clinical trials will further investigate the impact of using MRgRT 
systems for various disease sites including cancers in the H&N region. The MRgRT 
H&N phantom was designed to credential institutions wishing to use IMRT techniques 
with MRgRT systems. This phantom was designed to be used in all aspects of MRgRT 
treatment workflows in that it was constructed using tissue equivalent materials which 
could be visualized in 0.35T-1.5T MR imagers, and CT imagers. Commissioning and 
feasibility studies showed high reproducibility and agreement between all MRgRT 
systems, thus, indicating that the MRgRT H&N phantom would be a useful metric in 
credentialing institutions participating in NCI clinical trials. Additionally, the end-to-end 
test demonstrated that the Unity, MRIdian 60Co, and MRIdian Linac systems workflows 
could deliver comparable advanced IMRT treatments in the H&N region. 
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Chapter 5: MRgRT Thorax QA Phantom:  Design, 
Construction and Feasibility Study  
 
A substantial portion of this chapter is written or based on the following publication: 
 
A.Steinmann, P Alvarez, H Lee, R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller, 
D. Followill, “MRgRT Thorax Anthropomorphic QA Phantom: Design, Development, 
Commissioning and Feasibility Study,” Medical Physics. [In review] (2018). © John 
Wiley and Sons. 
 
The permission for reuse of this material was obtained from John Wiley and Sons. 
 
5.1 ABSTRACT 
 
Purpose: To design, manufacture and evaluate a dynamic MRI/CT compatible 
anthropomorphic thorax phantom used to credential MR guided radiotherapy (MRgRT) 
systems participating in NCI-sponsored clinical trials. 
Method: The anthropomorphic thorax phantom was constructed from a water-fillable 
acrylic shell that contained several internal structures representing radiation sensitive 
organs within the thoracic region. A custom MR/CT visible cylindrical insert was 
designed to simulate the left lung with a centrally located tumor target. The surrounding 
lung tissue was constructed from a heterogeneous in-house mixture using petroleum jelly 
and miniature (2-4mm diameter) styrofoam balls and the tumor structure was 
manufactured from liquid PVC plastic. An MR conditional pneumatic system was 
developed to allow the MRgRT insert to move in similar inhale/exhale motions. TLDs 
and radiochromic EBT3 film were inserted into the phantom to measure absolute point 
doses and dose distributions, respectively.  
The MRgRT thorax phantom was evaluated through a commissioning study and 
a feasibility study. Comprehensive end-to-end examinations were done where the 
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phantom was imaged on a CT, an IMRT treatment plan was created and an MR image 
was captured to verify treatment setup.  Then, the phantom was treated on an MRgRT 
system. The commissioning study evaluated the phantom’s reproducibility ease by 
irradiating three times on an Elekta’s 1.5T Unity system.  The phantom was shipped to 
three independent institutions and was irradiated on either an MRIdian cobalt-60 (60Co) 
or an MRIdian linear accelerator system. Treatment evaluations used TLDs and 
radiochromic film to compare the planned treatment reported on the treatment planning 
software against the measured dose on the dosimeters.   
Results: The commissioning of the phantom on the Unity system resulted in reproducible 
TLD doses (SD < 1.5%). The measured TLD to calculated dose ratios from the 
commissioning and feasibility studies ranged from 0.93 to 1.01 and 0.96 to 1.03, 
respectively. Using a 7%/5mm gamma analysis criteria, the commissioning and 
feasibility studies resulted in an average passing rate of 93.3% and 96.8%, respectively. 
No difference was noted in the results between the MRIdian 60Co and 6 MV delivery to 
the phantom and all treatment evaluations were within IROC-Houston’s acceptable 
criterion. 
Conclusions: The motion enabled anthropomorphic MRgRT thorax phantom, CT/MR 
visible and tissue equivalent, was constructed to simulate a lung cancer patient and was 
evaluated as an appropriate NIH credentialing tool used for MRgRT systems. 
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5.2 INTRODUCTION 
Magnetic resonance (MR) guided radiotherapy (MRgRT) systems integrate MR 
imagers with either a radioactive 60Co source or a linear accelerator. Within the United 
States there are three different MRgRT clinical models, which include the MRIdian 60Co 
(ViewRay, Oakwood Village, Ohio), the MRIdian Linac (ViewRay, Oakwood Village, 
Ohio), and the Unity (Elekta, Crawley, United Kingdom and Philips, Amsterdam, 
Netherlands) 10-13. All of these MRgRT systems are equipped with an on-board MR 
imager which has a magnetic field ranging from 0.35T to 1.5T. The MRIdian 60Co system 
was the first system to treat patients in the United States and is equipped with three 60Co 
head sources that are centrally located between a split 0.35T superconducting magnet. 
The MRIdian Linac is an upgraded prototype of the MRIdian 60Co system and is 
equipped with a single 6 MV linear accelerator in between a 0.35T split magnet. The 
Unity system is equipped with a single 7 MV linear accelerator mounted above a 
modified 1.5T magnet.  
MRgRT systems utilizing on-board MR imagers during treatment could 
potentially revolutionize radiation therapy. Some of the most promising advancements 
are: gating, target tracking and online adapted radiotherapy (ART) techniques80; 81; 91.  
Inherently, MR imagers do not contribute to patient dose. This means a patient’s tumor 
could be tracked during the entire treatment through a series of cine MR images without 
increasing the patient’s absorbed dose. If a target structure moves outside a desired 
treatment boundary, the MRgRT system can theoretically recognize this variation and 
momentarily stop delivering radiation until the target moved backed into the desire 
location91. MR gating techniques would most benefit tumor sites located on anatomical 
structures that regularly move (i.e., lungs, pancreases, GI track). In addition to tumor 
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tracking, these MRgRT systems could potentially perform online ART by capturing an 
MR image prior to every treatment and recalculating a new treatment plan based on the 
disease site’s response to radiation, location, and size. Online ART and MR-based 
tracking could help create even more patient-specific radiation treatments by modifying 
tumor margins before every treatment. As a result, these techniques can potentially 
improve local tumor control and reduce normal tissue toxicity. 
Clinical outcomes and applications are still being explored since the first MRgRT 
system to treat a patient in the United States was in 201492. To preliminarily address 
MRgRT safety concerns, the National Institutes of Health (NIH) has sponsored two 
clinical trials that focused on the safety aspects of capturing MR images (NCT02973828) 
and delivering radiation (NCT03284619). With on-board MR imagers having the 
potential to use MR cine images to track tumors, NIH has also sponsored several short-
term single institutional studies that permit MRgRT systems to track and treat moving 
disease sites located on either a liver (NCT02683200) or a lung (NCT02264886) 
structure. NIH has also sponsored several limited clinical trials that used online ART 
techniques. Much of these clinical trials focused on disease sites located on either lung 
(NCT02264886/ NCT02950792) or breast (NCT01999062) anatomical structures. Many 
of NIH sponsored clinical trials have used tumors located in the thorax region to 
understand the potential applications of MRgRT systems. Larger multi-institutional 
National Clinical Trial Networks (NCTN) will be sponsored by the NIH to further 
investigate the clinical uses and outcomes of treating lung tumors on an MRgRT system.  
Institutions participating in multi-institutional clinical trials must cohesively 
deliver the same treatment protocol as other participating institutions on the trial. NIH 
requires each institution to first participate in a credentialing process to demonstrate its 
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ability to consistently deliver intensity modulated radiation therapy (IMRT) using a strict 
treatment protocol. NIH has funded the Imaging and Radiation Oncology Core Quality 
Assurance (QA) center in Houston (IROC-Houston) to credential all institutions wishing 
to participate in NCTN clinical trials. During the credentialing process, IROC-Houston 
ships out a standardized anthropomorphic phantom and requires the institution to follow 
a standard treatment protocol that is provided by IROC-Houston. These instructions 
require the institution to capture a CT simulation, create an individual treatment plan and 
deliver radiation to the phantom.  IROC-Houston will then evaluate the institution’s end-
to-end performance by comparing the treatment plan to the dose delivered on the 
phantom.  
IROC-Houston has an assortment of site-specific anthropomorphic phantoms. 
Depending on the clinical trial, IROC-Houston will ship either a head and neck (H&N), 
thorax, spine, liver, or prostate anthropomorphic phantom to an institution for an off-site 
credentialing test. IROC-Houston’s conventional thorax phantom is the second most 
common phantom used to credential institutions and is described in detail by Followill et 
al. 200759. In short, the conventional thorax phantom is a water-fillable shell that contains 
several internal structures. Inside the thorax-shape external shell, the phantom is 
equipped with two lungs manufactured of compressed cork, an acrylic spinal cord and a 
nylon heart. The left ipsilateral lung was designed as an attachable insert that can connect 
to a motion table. The insert movement simulates patient breathing by regularly moving 
every three seconds. The conventional lung insert was designed with a single tumor 
manufactured from high impact polystyrene (HIPS) and was centrally located around 
surrounding lung mimicking tissue that was manufactured from compressed cork.  
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Integrating an MR imager with a radiotherapy system will inherently change the 
overall workflow. As described in the Steinmann et al. study, IROC-Houston’s 
conventional thorax phantom was constructed with hydrogen deficient materials72. The 
lack of hydrogen creates a lack of MR signal between the tumor and surrounding tissue 
materials, thus, causing the two structures to be indistinguishable in a MR image. 
Additionally, the motion table used to simulate patient breathing is MR unsafe since it 
contains ferromagnetic materials. If the motion table is placed too close to the MR 
system, the ferromagnetic materials would become magnetized and would dangerously 
project into the MR system. If the motion table’s rotary motor was positioned far away 
from the magnetic field (i.e., past the 5 G line) and was turned on, it would still affect the 
MR components since the induced magnet field would interfere with the acquired signal 
and distort the MR image. Therefore, IROC-Houston’s conventional thorax phantom and 
motion table are completely inadequate for use in MR environments and a new MRgRT 
thorax phantom and motion system must be developed for MRgRT workflows so that 
they are safe to use in an MR system and all of their internal structures are 
distinguishable. 
Current studies have attempted to manufacture MR/CT compatible thorax 
phantoms, but they do not fit IROC-Houston’s off site anthropomorphic phantom 
requirements. IROC-Houston’s phantoms must contain multiple internal structures (i.e., 
tumor, heart, contralateral lung, spinal cord) and use passive dosimeters. Specifically, for 
MRgRT workflows, the phantom materials also must be MR/CT visible, tissue 
equivalent, durable, and they must require minimal maintenance and storage conditions57; 
87. To the author’s knowledge, there are only three MR/CT compatible thorax phantom 
designs that use synthetic materials. The MRI-LINAC Dynamic thorax phantom (CIRS, 
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Norfolk, Virginia, USA) contains two sections: the superior part is a grid used to quantify 
MR geometrical distortions and the inferior part attempts to create a very simplistic 
phantom with a moving target. The inferior portion of the phantom has a single 
cylindrical-shape air cavity which is not a realistic simulation of a lung with a moving 
MR target. This phantom does not anatomically represent the thorax since it does not 
contain critical organs (i.e., spinal cord, heart, and contralateral lung). The target is 
attached to a rigid extended shaft that is connected to a stepper motor. The stepper motor 
itself contains ferromagnetic materials and is considered MR unsafe. If this stepper motor 
is placed too close to the bore, it could become magnetized and dangerously project into 
the MRgRT system. Therefore, this phantom is not ideal for IROC-Houston since it does 
not contain multiple internal structures and the motor is MR unsafe.   
The other two MR/CT compatible thorax phantoms, which used synthetic 
materials, are similarly designed and contain a water-fillable acrylic shell with limited 
internal structures.  The PET/MRI/CT Compatible Respiratory Tumour Motion Phantom 
(CRTMP) (Shelley Medical Imaging Technologies, London, Ontario, Canada) consist of 
two equally spaced cylindrical air cavities representing lungs and a fillable cylinder 
representing a spinal cord. Inside one of the air cavities is a fillable spherical tumor that 
connects to an MR safe motor. The QUASAR™ MRI4D motion phantom consists of two 
asymmetric cylindrical inserts and was not designed with other important critical 
structures (i.e., heart or spinal cord). Additionally, the QUASAR™ MRI4D phantom does 
not anatomically represent two lungs since the created air cavities are adjacent to each 
other with little separation. The center air cavity is equipped with a fillable spherical 
tumor that connects to an MR safe motor. Both CRTMP and QUASAR™ MRI4D 
phantoms are similarly designed with a customizable insert that mimics tumor motion 
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with an MR safe ceramic piezoelectric motor. These phantoms only show a single 
contrast (i.e., absent signal vs. water signal) in an MR image. While MR contrast agents 
(i.e., gadolinium) could be used to add additional contrast, the contrast has a high atomic 
number and would not dosimetrically resemble tissue. These phantoms did not meet 
IROC-Houston’s requirements since they lack organ at risk (OAR) structures and are not 
equipped with portable dosimeters.   
The aim of this study was to design, manufacture, and evaluate an MR/CT 
compatible, dynamic anthropomorphic thorax phantom used as an end-to-end test for 
MRgRT systems.  
5.3 MATERIAL AND METHODS 
The MRgRT thorax phantom and motion system were designed to meet IROC-
Houston’s radiotherapy, diagnostic imaging and practicality criteria. To meet 
radiotherapy and diagnostic criterion, materials used in the phantom were selected based 
on their ability to structurally represent human anatomy, be visible in both MR and CT 
images and be tissue equivalent. Practicality criteria were met in the phantom by selecting 
materials that maintained constant shape, required minimal maintenance, and were made 
with synthetic materials that did not require additives. For the practicality criteria of the 
motion systems, the motion parts used in the treatment vault needed to be MR safe and 
easily connect to the thorax phantom. Once designed and manufactured, the MRgRT 
thorax system was reproduced on a single Unity system and sent out to three institutions 
for a miniature multi-institutional feasibility study.  
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5.3.1 Phantom Design 
All internal structures in the conventional thorax phantom, except the ipsilateral 
lung and tumor, were distinguishable in an MR image since the MR signal from water 
outlined their shapes. IROC-Houston’s conventional thorax phantom was modified so 
that the entire thorax phantom could be used in an MRgRT workflow. These 
modifications included: 1) a new MRgRT lung insert and 2) an MR safe motion system.  
The MRgRT thorax phantom was designed to resemble closely human anatomy 
by constructing several shapes to represent internal structures and to mimic IROC-
Houston’s current photon thorax phantom. The thorax phantom was manufactured with 
an external water-fillable PVC shell (The Phantom Laboratory, Salem, New York, USA) 
and contained four internal structures which geometrically represented a spinal cord, a 
heart and two lungs.  The right contralateral lung, spinal cord and heart were immobile 
structures whereas the left ipsilateral lung was designed to connect to a motion system 
so that it could simulate patient breathing. A platform with a 15 degree inclination was 
connected to the exterior shell to create anterior-posterior and superior-inferior motion. 
Figure 28 displays the MRgRT thorax phantom compartments which include: the exterior 
phantom, the 15-degree platform, the attachable ipsilateral lung insert’s shell and the four 
individual lung pieces.  
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Figure 28: The MRgRT Thorax Phantom. The phantom consists of a water-fillable 
anthropomorphic thoracic shell, an inclining 15-degree platform and an external insert shell 
that holds four individual MR/CT compatible insert pieces. 
 
 
Figure 29: A CT image of the center of an MRgRT thorax phantom. Inside the acrylic shell 
are a contralateral lung, an ipsilateral lung, a heart, and a spinal cord structure. The PTV is 
located at the center of the ipsilateral lung.  Sagittal and axial radiochromic films are 
inserted into the ipsilateral lung. Each heart and spinal cord structure holds a single TLD 
and the PTV holds two (superior and inferior) TLDs.  
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The OAR structures were manufactured using acrylic, nylon, and compressed 
cork for the spinal cord, heart and contralateral lung structures, respectively. The heart 
and spinal cord were each designed to hold a double-loaded TLD.  The materials used in 
the MRgRT lung insert were selected from the Steinmann et al. 2018 study72.  The 
ipsilateral lung had an outer diameter of 12.5 cm and a length of 19 cm and was 
constructed with an in-house heterogeneous mixture of 8.3% wt. of 2-4 mm styrofoam 
balls and 91.7% wt. of petroleum jelly. The in-house heterogeneous mixture was 
encapsulated in high impact polystyrene (HIPS). Centrally located in the lung insert was 
a prolate spheroid which represented the tumor and had a major and minor diameter of 
10 cm and 5 cm, respectively. The tumor was constructed with 100% liquid PVC plastic 
that was encapsulated with solid water and held two double-loaded TLDs.  
Table 19 summarizes the internal structures’ materials, dimensions, and total TLD used 
and Figure 29 displays an axial CT image of the internal structures.   
The MRgRT lung insert was composed of four individual pieces which combined 
into a single unit when a HIPS shell was used to secure the pieces in place. Alignment 
notches were built into the individual lung pieces and the HIPS lid to create a unique 
reproducible orientation. The HIPS lid was also constructed with an aluminum rod which 
was designed to connect to part of the pneumatic system and not interfere with the target’s 
dose delivery. The MRgRT lung insert allowed radiochromic films and TLDs to be 
inserted centrally to the tumor. A total of three radiochromic films were installed into the 
MRgRT lung insert. Two radiochromic films captured the sagittal plane by placing each 
film at the superior and inferior parts of the insert. A single film was placed in between 
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the sagittal planes to capture an axial plane. Double-loaded TLDs were installed at the 
centers of the superior and inferior pieces.  
  
Structure Material 
Diameter 
(cm) 
Length 
(cm) 
Total 
TLDs 
Used 
Primary PTV 100% Liquid PVC Plastica 4 5 2* 
Ipsilateral 
Lung  
In-house Petroleum Jellyb 
Styrofoam ballc mixture‡ 
12.5 18 - 
Contralateral 
Lung 
Compressed Corkd 12.5 18 - 
OAR: Spinal 
Cord  
Acrylice 1 13 1 
OAR: Heart  Nylond 8 - 1 
a: M-F Manufacturing Company, Fort Worth, Texas, b: Sonneborn, Parsippany, New Jersey, USA c: Steve Spangler 
Science Styrofoam Beads, Englewood, Colorado, USA, d: McMaster-Carr, Elmhurst, Illinois, USA, e: Professional Plastics, 
Fullerton, California, USA 
‡:In-house mixture that used 8.3% weight of Styrofoam balls and 91.7% weight of petroleum jelly.  
*: One TLD was inserted in the superior piece and the other TLD was inserted into the inferior piece.  
 
Table 19: The materials used to manufacture the MRgRT thorax phantom.    
 
5.3.2 Pneumatic Motion System Design 
IROC-Houston’s conventional photon lung phantom is moved physically to 
mimic breathing patterns by attaching a programmable stepper motor/bi-slider system to 
a motion platform on which the phantom rests. The stepper motor system components 
are classified as MR unsafe materials since they contain ferromagnetic materials. A 
pneumatic system was designed as an alternative way to represent breathing motion 
inside an MR environment. The schematic of the pneumatic system used for the MRgRT 
thorax phantom is shown in Figure 30. A compacted 1.5 L air compressor (Model#: 
D55140, DeWalt, Baltimore, Maryland, USA) was used to constantly supply air to a 3-
way valve (Part#: S20U30-SS-11-2, Bimba, University Park, Illinois, USA) which was 
manually controlled through a physical on/off electric switch (Model#: R62-02653-02W, 
Leviton, Melville, New York, USA). When the electric switch was positioned off, the 3-
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way valve would naturally release air to the exhaust pipe. If the electric switch was 
flipped on, the 3-way valve would electrically close the exhaust pipe port and open the 
4-way valve port (Part#: N2-SCD-120-VAC, Bimba, University Park, Illinois, USA). 
When the port was open, the 4-way valve supplied air to the cylinder which physically 
moved the MRgRT lung insert. Additionally, the red and blue plastic nylon tubing (Part# 
4HHC8, Granger, Lake Forest, Illinois, USA) attached to the 4-way valve were used to 
control the air flow supply on the cylinder. The blue tubing represented expiration 
whereas the red tubing represented inspiration. An electrical time delay counter (Model# 
IO23B01, Ebay Item# 232013288409, Ebay, San Jose, California, USA) was used to 
regulate the 4-way valve air flow direction. This 110V timer was programmed to 
fluctuate the air supply between the inhale (red) and exhale (blue) tubing every three 
seconds. Both exhale and inhale tubing were connected to a flow control knob (Part#: 
RAFK-2x2, Bimba, University Park, Illinois, USA). The knobs were used to manually 
control the speed at which the lung insert would move by adjusting the air flow pressure. 
The inhale (red) and exhale (blue) plastic tubing were connected to an MR safe cylinder 
(Part#: FOD-040.8-ABBMT, Bimba, University Park, Illinois, USA). The cylinder was 
modified with a custom brass piston to make it MR safe and was specially designed to 
connect to the HIPS lid. The piston physically moved the lung insert according to the air 
flow direction. When the red tubing supplied pressurized air, the piston would extend 
and cause the lung insert to move inferiorly. Vice versa, the piston would contract and 
move the lung insert superiorly when the blue tubing supplied pressurized air. 
As illustrated in Figure 30, the equipment used in the pneumatic system was 
divided into two broad sections: MR safe and MR unsafe parts. The MR safe parts could 
be used inside the MRgRT treatment vault and included: the cylinder, the piston, the lung 
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insert and the plastic tubing.  MR unsafe materials were required to stay outside the vault 
and these parts were: the compressor, the 3-way valve, and the 4-way valve. The red and 
blue plastic tubing were placed through the MR waveguide; thereby creating a physical 
wall barrier between MR safe and MR unsafe parts of the pneumatic system. The cylinder 
was screwed directly into the MRgRT thorax phantom and during treatment was placed 
at the center of the bore.  
 
 
Figure 30: Schematic of the pneumatic system used to mimic lung motion in a MR 
environment. The pneumatic system was broadly divided into two sections: MR safe and MR 
unsafe parts. MR safe parts were allowed inside the treatment vault whereas MR unsafe 
parts were stored outside the treatment room. The MR unsafe parts consisted of the air 
compressor and parts used to regulate the air flow. The MR safe parts included the plastic air 
tubing and a custom cylinder. The two tubes were colored red and blue to distinguish the air 
flow used to move the cylinder’s brass piston. The red tubing represented inspiration and 
blue tubing represented expiration.  
 
5.3.3 Phantom Imaging 
The MRgRT thorax phantom was imaged on a CT simulator and two MRgRT 
systems using 1.5T and 0.35T magnetic field strengths. Under a GE Lightspeed CT 
simulator (General Electric Company, New York, New York, USA), the phantom was 
  113 
imaged using a breast protocol with scanning parameters of: DFOV= 500.0 mm, 120 
kVp, 275 mA, and slice thickness=3mm. The MRgRT thorax phantom was imaged on a 
1.5T Unity system using a T1-weighted sequence and had scanning parameters of: FA= 
8°, TR= 8.0 ms, TE= 3.6 ms, ETL= 136, NEX=1. Using a 0.35T MRIdian 60Co, the 
MRgRT thorax phantom was scanned with a TrueFISP (true fast imaging with steady-
state free precession) sequence and had scanning parameters of: FA= 60°, TR= 3.33 ms, 
TE= 1.43 ms, NEX=1. The MR scanning parameters from the Unity and MRIdian 
systems are summarized in Table 20. 
 
 
Parameters ViewRay Unity 
MR Scanning 
Sequence 
True Fast Imaging 
with Steady-state free 
Precession (TrueFISP) 
T1-Weighted 
Gradient 
FA 60° 8° 
TR (ms) 3.33 8.0 
TE (ms) 1.43 3.6 
ETL - 136 
NEX 1 1 
Table 20: MR images were captured on both the ViewRay and Unity systems. The ViewRay 
system acquired a true fast imaging with steady-state free precession image and the Unity 
system acquired a T1- weighted image.  *TRUFI and TrueFISP are the same sequences but 
are under different names for different manufactures. 
 
5.3.4 Dose Prescription 
The dose prescriptions set for the MRgRT thorax phantom were the same 
prescriptions used for IROC-Houston’s conventional thorax phantom. In short, 95% and 
99% of the primary tumor volume (PTV) were required to receive at least 6.0 Gy and 5.4 
Gy, respectively. Excluding the PTV, 37% of the whole lung (i.e., both left and right 
lung) was restricted to receive a maximum of 2.0 Gy. The spinal cord and heart had 
maximum received dose limits of 5.0 Gy and 4.0 Gy, respectively. Additional dose 
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constraints limited 6.0 Gy and 4.5 Gy to 33% and 66% of the heart volume, respectively.  
IROC-Houston’s dose prescriptions for the MRgRT thorax phantom are summarized in 
Table 21. 
MRgRT Thorax 
Structure 
Dose Prescription 
PTV 
D95% ≥ 6.0 Gy 
D99% ≥ 5.4 Gy 
Whole Lung 
(Contralateral & 
Ipsilateral) 
D37% < 2.0 Gy 
 
OAR: Spinal Cord D0% ≤ 5.0 Gy 
OAR: Heart 
D33% ≤ 6.0 Gy 
D66% ≤ 4.5 Gy 
D100% ≤ 4.0 Gy 
Table 21: The dose prescription for the MRgRT thorax phantom. Both commissioning and 
feasibility studies used the same dose constraints.  
 
5.3.5 Treatment Delivery 
The MRgRT thorax phantom was reproduced using a 1.5T Unity system and then 
sent out to three institutions for an independent feasibility study. During the multi-
institutional feasibility study, the MRgRT thorax phantom was irradiated using either an 
MRIdian Linac or an MRIdian 60Co and Unity MRgRT system.  The performance of both 
reproducibility and feasibility studies were evaluated based on an end-to-end test.  
 Double-loaded TLDs (ThermoFisher Scientific, Waltham, Massachusetts, USA) 
were read two weeks from the irradiation date to account for fading. These absolute 
dosimeters were read with the same method as IROC-Houston uses for its phantom 
studies. The amount of lithium fluoride powder was read using a Mettler AT261 
DeltaRange (Mettler Toledo, Greifensee, Switzerland) scale and a Harshaw M3500 TLD 
reader (ThermoFisher Scientific, Waltham, Massachusetts, USA) was used to measure 
the light output. Additionally, the MRgRT thorax phantom used EBT3 film as relative 
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dosimeters. The intensity from the irradiated films was read on a photoelectron CCD 
microdensitometer (Photoelectron Corporation, North Billerica, Massachusetts, USA) 
and converted into dose using an in-house MATLAB program (The MathWorks, Inc., 
Natick, Massachusetts, USA).  
The end-to-end tests for reproducibility and feasibility studies were analyzed by 
using the same two evaluation methods. These analytical methods included: 1) 
comparing measured TLD dose to expected plan and 2) performing a gamma analysis 
using a 7%/5mm criterion. 
 
5.3.5.1 Reproducibility Study 
During the reproducibility study, the MRgRT thorax phantom was irradiated 
three times on a 1.5T Unity system. The exterior thorax shell was filled with tap water 
and imaged on a GE Lightspeed CT simulator using a breast protocol. The parameters of 
this protocol were: DFOV= 500.0 mm, 120 kVp, 275 mA, and slice thickness= 3mm. 
The electron density data collected from the CT simulator was transferred to Monaco’s 
Treatment Planning Software (TPS) (Elekta, Crawley, United Kingdom) and an IMRT 
plan was designed using 7 beams angles.  All anatomical structures and TLD capsules 
were contoured and labelled accordingly. 
The MRgRT thorax phantom was placed above a 15-degree inclining platform 
and was positioned in the center of the Unity’s treatment couch. The surface coil did not 
properly fit over the phantom and platform; so, the Unity’s body coil was used to capture 
a MR image. The treatment setup used in the reproducibility study for the thorax phantom 
is shown in Figure 31. New dosimeters were replaced in the thorax phantom after each 
irradiation. To reload new radiation detectors the treatment couch was moved out of the 
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bore, the pneumatic system was momentarily switched off to release pressurized air and 
the lung insert was removed from the phantom. Once the portable dosimeters were 
replaced, the insert and the pneumatic system were screwed back to the phantom, the 
pneumatic system was turned on, and the phantom was moved back into the center of the 
bore. A T1-weighted MR image was captured using scanning parameters of: FA= 8°, 
TR= 8.0 ms, TE= 3.6 ms, ETL= 136, NEX=1 after every irradiation. The treatment plan 
was re-optimized based on the MRgRT thorax’s current position and then irradiated. 
Each irradiation took approximately 30 minutes to deliver all 7 beams. TLD capsules’ 
maximum, minimum and mean doses were recorded, and the treatment plan was exported 
to further analyze the treatment performance.  
 
 
Figure 31: The MRgRT Thorax Phantom setup up for the reproducibility study. The 
MRgRT body coil was used to capture an MR image.  
 
5.3.5.2 Feasibility Study 
The MRgRT thorax phantom was shipped to three institutions within the 
United States that either had an MRIdian 60Co or an MRIdian Linac MRgRT 
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system. In addition to receiving the thorax phantom and the pneumatic system, each 
institution received from IROC-Houston detailed instructions describing how to use the 
motion system and the dose prescriptions requirement. Upon receiving the phantom, the 
institutions were required to perform an end-to-end test. This test required each 
institution to image the thorax phantom on a CT, create a treatment plan based on IROC-
Houston’s dose prescriptions, capture an MR image to verify treatment setup and, finally, 
irradiate the phantom. Since this end-to-end test was to demonstrate the ability to treat a 
moving target, IROC-Houston required each institution to use the pneumatic system 
during imaging and treatment stages. Institutions were allowed to emulate their typical 
MR workflow by choosing gantry angles, type of motion management, and any 
additional MR workflow components. Each institution was required to submit a digital 
copy of the treatment plan and record the expected TLDs’ maximum, minimum, and 
mean dose. End to end tests were analyzed by evaluating the treatment plan to measured 
dose.  
 
5.4 RESULTS  
5.4.1 Phantom Imaging 
As shown in Figure 32, the MRgRT thorax phantom was imaged on a GE CT 
simulator, and Unity and MRIdian MRgRT system. Internal structures and the disease 
site are clearly visible in all three images. The contralateral lung, heart, and spinal cord 
were constructed of non-MR visible materials. The absence of MR signal in these internal 
structures could be seen due to the contrast between the lack of signal surrounded by the 
MR signal from water. The ipsilateral lung and disease site were constructed of MR 
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visible materials and the contrast between these structures was visible on all three images. 
On the Unity system, the disease site appears brighter and has a higher spatial resolution 
which is attributed to the magnetic field strength and MR sequence, respectively. The 
Unity system used a T1-weighted sequence whereas the MRIdian system used a true fast 
imaging with a steady-state free precession (TrueFisp) sequence.  
 
 
Figure 32: The MRgRT thorax phantom was filled with water and scanned on: (a) GE CT 
simulator, (b) Unity system’s 1.5T MRI with a T1 sequence and (c) ViewRay’s MRIdian 60Co 
0.35T system with a TrueFISP sequence. In all images, the OAR, primary and secondary 
PTV are clearly visible. 
 
 
5.4.2 Treatment Delivery 
In both the commissioning and the feasibility study, measured TLD dose was 
compared to predicted dose from the TPS. Table 22 and Table 23 display the ratios 
between measured and predicted dose under the commissioning and feasibility study, 
respectively. TLDs within the superior portion of the PTV had ratios of: 1.00, 1.01, and 
1.00 and in the inferior portion had ratios of: 0.93, 0.98, and 0.96 for the commissioning 
study. Overall, the average ratios between measured and reported doses for superior and 
inferior PTVs locations were 1.00 and 0.96, respectively. The feasibility study showed 
greater agreement between measured and expected dose at the inferior PTV than did the 
commissioning study. The superior portion of the PTV had ratios of: 0.98, 1.03, 1.00, 
whereas the inferior portion had ratios of: 1.00, 1.00, and 0.98. TLDs that fall within 0.92 
a. b. c. 
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and 1.05 to reported dose were considered to pass IROC-Houston’s TLD dose criterion. 
In both studies, TLD readings were within IROC-Houston’s acceptable criteria. 
 
 
TLD Location 
Reproducibility Test 
Average 
Coefficient of 
Variance Unity 1-a Unity 1-b Unity 1-c 
PTV Superior 1.004 1.006 1.000 1.004 0.3% 
PTV Inferior 0.934 0.982 0.961 0.959 2.5% 
Table 22: The reproducibility test results of two PTV TLD positions. The left column 
represents TLD locations for doses calculated on Monaco’s treatment planning software. 
The middle three columns represent the average TLD measured for each location and the 
percent standard deviation. The average ratios between measured and calculated dose are 
displayed in the right column. The TLD measurements were all within 4.1% of the reported 
TLD dose and the coefficient of variance was all within 2.5%. 
 
 
Institution Energy 
PTV 
Superior  
PTV 
Inferior  
Unity 1 7 MV 1.00 0.96 
ViewRay 2 6 MV 0.98 1.00 
ViewRay 3 60Co 1.03 1.00 
ViewRay 4 60Co  1.00 0.98 
Average -- 1.00 0.98 
Table 23: Feasibility study results for two TLD positions in the PTV for the MRgRT thorax 
phantom. The results display ratios between measured TLD dose and reported TLD dose 
from the institutions’ treatment planning software.   
 
IROC-Houston evaluated the treatment deliveries by performing an in-house 
gamma study on axial and sagittal films. The same gamma criteria (7%/5mm) used on 
IROC-Houston’s conventional thorax phantom was also used to evaluate the MRgRT 
thorax phantom. A film was said to pass the gamma analysis if more than 80% of the 
pixels passed each axial and sagittal plane and if the combined average between the two 
films (sagittal and axial) resulted in at least 85% of pixels passing. Table 24 and Table 
25 display the individual gamma pass rates for both the commissioning and the feasibility 
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study, respectively. The commissioning study had individual passing rates of 89.0%, 
96.8%, and 96.1% for axial films and 90.4%, 96.8%, and 90.9% for sagittal films. 
Individual passing rates for axial films were 97.9%, 96.7% and sagittal films were: 95.7% 
and 96.6% in the feasibility study. The combined average of pixels passing between axial 
and sagittal film in the commissioning study were 89.7%, 96.8%, 93.5% and were 96.8% 
and 96.7% in the feasibility study. Three dose profiles were generated in anterior-
posterior, left-right, and superior-inferior orientations during gamma analysis. A typical 
set of dose profiles generated from the study is shown in Figure 33. Qualitatively, film 
dose profiles in all studies were in excellent agreement with their calculated dose profiles.  
 
Institution 
% Pixel Passing 
[7%/5mm] 
Axial Sagittal Average Film Plane 
Unity 1-a 89.0 90.4 89.7 
Unity 1-b 96.8 96.8 96.8 
Unity 1-c 96.1 90.9 93.5 
Average 94.0 92.7 93.3 
Table 24:  The MRgRT thorax phantom was irradiated three times under a 1.5T Unity 
system. Axial and sagittal planes were evaluated based on 7%/5mm gamma criteria.  
 
 
Institution Energy 
 Pixel Passing 
Axial Sagittal Average 
Film 
Plane 
ViewRay 2 6 MV 97.9% 95.7% 96.8% 
ViewRay 3 Co-60 96.7% 96.6%  96.7% 
ViewRay 4* Co-60 - - - 
Average - 97.3% 96.2% 96.8% 
Table 25: The feasibility study were evaluated using the same passing criteria as the 
commissioning study. IROC-Houston gamma passing criteria required individual film planes 
to have a greater than 80% passing rate and an overall passing rate of 85%.  *Data 
unavailable from institution for analysis. 
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Figure 33: Dose profiles generated in the (a) anterior-posterior, (b) left-right, and (c) 
superior-inferior direction.  These graphs compare dose profiles generated on film to those 
generated from the treatment planning. These graphs were generated from institution 3, but 
resemble the typical dose profiles generated from both the feasibility and the commissioning 
studies. 
a. 
b. 
c. 
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5.5 DISCUSSION 
IROC-Houston’s conventional thorax phantom was originally designed for CT-
only workflows and was not intended to be used in MR environments. Two primary 
concerns with IROC-Houston’s conventional thorax phantom that rendered the phantom 
insufficient for MRgRT systems. These concerns were: 1) PTV and surrounding tissues 
were indistinguishable in MR images and 2) the motion table contained ferromagnetic 
materials that classified the motion system as MR unsafe. It was critical that the disease 
site and surrounding tissues were distinguishable from one another since on-board MR 
imagers can track tumors during treatment. Since IROC-Houston’s phantoms evaluated 
the institutions’ ability to accurately deliver radiation, it was also important that the 
MRgRT thorax phantom simulate patient breathing. Having motion during imaging and 
radiation delivery allowed institutions to perform their normal MR clinical workflows 
and allowed them to determine methods to mitigate motion uncertainties (i.e., gating, 
tumor tracking, free breathing).  
Several design modifications were performed to create an MRgRT lung insert 
which included: 1) creating four insert pieces, 2) equipping the insert with film pinpricks, 
and 3) construction of an exterior insert shell used to create a single unit. The MRgRT 
lung insert was constructed using a heterogeneous mixture which was composed of semi-
solid petroleum jelly and miniature styrofoam balls. Unlike IROC-Houston’s 
conventional lung insert, where the compressed cork was sculpted into place, the MRgRT 
lung insert could not simply be sculpted since the heterogeneous material was pliable. 
Each insert piece had an exterior shell constructed of HIPS and was used to create a rigid 
structure. The tumor was encapsulated in solid water to create a rigid structure. Solid 
water was used rather than HIPS for the tumor’s exterior shell since liquid PVC plastic 
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chemically reacted to HIPS. Film pinpricks are traditionally used in IROC-Houston’s 
phantoms to register the film’s orientation relative to the phantom’s position. Film 
pinpricks in IROC-Houston’s conventional lung insert are created by drilling small holes 
through compress cork. Drilling a hole through the MRgRT lung insert was not efficient 
since the insert was made with a semi-solid mixture which would make reproducing the 
same pinprick location difficult. The insert was modified by securing small fine needles 
inside the external HIPS part. When the insert’s pieces were combined, the small needles 
created small pinprick artifacts on the film which were used to register the film position. 
An exterior HIPS shell was created to combine the four individual lung insert pieces into 
a single unit. The exterior shell’s lid was made with an aluminum rod used to connect the 
cylinder to the lung insert.  
IROC-Houston is responsible for ensuring that quality is maintained within 
NCTN clinical trials. One-way IROC-Houston ensures quality is by sending off-site 
credentialing phantoms to test the cohesiveness between institutions. Since consistency 
is critical for the credentialing process, the MRgRT must use the same dose prescription 
and passing criteria as the conventional thorax phantom. Consistent dose prescriptions 
are also important when evaluating the treatment delivery. The commissioning study 
consistently showed larger discrepancies between inferior portions, most likely due to 
uncertainties occurring when creating the treatment plan. The thorax phantom only used 
free-breathing techniques and captured the PTV’s position at a single point in time. The 
treatment most likely did not capture the entire movement and caused greater 
uncertainties. 
The Unity system was not equipped with lasers inside the treatment vault. Rather, 
this MRgRT system captured MR images during every irradiation to account for any 
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setup discrepancies.  Unlike conventional linear accelerators, the normal workflow for 
the Unity system is to fuse an MR image to a CT image and re-optimize the treatment 
plan based on the anatomical structures captured in the MR image. In the commissioning 
study, the thorax phantom was removed from the MRgRT bore and the lung insert was 
uninstalled after each irradiation. These changes could have introduced setup 
uncertainties which included 1) the treatment couch potentially stopped at a different 
location inside the bore or 2) the thorax phantom shifted from the original position once 
reinstalling the insert and pneumatic system. Without lasers in the vault, it was difficult 
to quantify any noticeable shifts between irradiations. To account for any setup 
uncertainties and capture the entire end-to-end workflow, an MR imager was captured 
after every irradiation and the treatment plan was re-optimized according to any new 
shifts.  
Each part of the treatment workflow will have associated uncertainties. Since 
MRgRT and conventional linear accelerator systems have different workflows, they also 
will have different associated uncertainties. Some inherent uncertainties of an MRgRT 
system from treating a moving target on an MRgRT system would include: 1) MR/CT 
image registration, 2) potential minor MR effects on TLDs, 3) MR spatial accuracy, 4) 
real-time image guidance, and 5) re-optimization plans.  The purpose of this study was 
not to quantify the source of uncertainties, but to allow these end-to-end studies to have 
similar uncertainties found in the clinic. This study showed that the Unity, the MRIdian 
60Co, and the MRIdian Linac systems consistently deliver expected treatments despite 
having multiple sources of uncertainties associated to each MRgRT system. Even though 
there were associated uncertainties in each step of the treatment process, the gamma 
results showed that these uncertainties played a minor role in the overall dose delivery.   
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5.6  CONCLUSION 
In the future, NCI-sponsored clinical trials will begin to focus on the clinical 
impacts of MRgRT systems. The thorax region will be of particularly interest for MRgRT 
systems since new image guidance and online ART techniques could be used to improve 
lung tumor radiotherapy treatments. The MRgRT thorax phantom was carefully designed 
as a credentialing tool for MRgRT systems participating in NCTN clinical trials. OARs 
in the MRgRT thorax phantom were distinguishable in MR due to the contrast between 
the lack of signal from the internal structures and the surrounding MR signal from water. 
The MRgRT lung insert has a centrally located PTV surrounded by lung-mimicking 
tissue and was manufactured with tissue equivalent and MR/CT visible materials. 
Commissioning and feasibility studies were within IROC’s 7%/5mm passing criteria, 
thus, demonstrating that the MRgRT thorax phantom could be used as a credentialing 
tool for NCI clinical trials. This study also showed that various MRgRT systems could 
deliver comparable IMRT dose plans for moving targets. 
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Chapter 6: Summary 
 
6.1 GENERAL DISCUSSIONS AND CONCLUSIONS  
 
The main purpose of this study was to design a stationary H&N and dynamic 
thorax anthropomorphic QA phantom that could be used as an end-to-end tool to 
credential institutions wishing to use an MRgRT device to participate in NCI-sponsored 
clinical trials. This study was completed in four independent aims. The first two aims 
were designed to determine materials and radiation detectors used in the 
anthropomorphic MRgRT phantoms. Once materials were chosen and detectors were 
characterized in 0.35T and 1.5T magnetic field environments, then the next two aims 
focused on designing, manufacturing and evaluating the anthropomorphic thorax and 
H&N phantoms.  
The purpose of the first aim was to identify materials that could be used to 
manufacture the two MRgRT anthropomorphic phantoms. IROC-Houston had several 
material requirements which included: 1) simulate soft tissue or lung tissue 
dosimetrically, 2) have comparable HUs, 3) be visible in all aspects of the MRgRT 
workflow (i.e., MR and CT compatible), 4) endure harsh shipping conditions, 5) show 
longevity without additivities, 6) maintain physical structure over time (i.e., did not 
morph over time and had high melting points), 7) show ease in manipulating into tissue 
shapes and 8) hold radiation detectors in place. Before examining any dosimetric and 
imaging characteristics, all materials were first examined based on their physical 
characteristics. Materials that did not meet IROC-Houston’s practical characteristics (i.e., 
had low melting points, used preservatives, or required refrigeration) were eliminated as 
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potential MRgRT materials. The remaining 80 materials were analyzed based on IROC-
Houston’s radiotherapy criterion. Most of the materials evaluated in MR and CT imagers 
showed comparable HU values as human tissue but were not visible in both T1-weighted 
and T2-weighted MR sequences. Silicone-based and synthetic gel-based materials were 
the most promising materials since they were compatible in MR and CT. Silicone-based 
materials did not dosimetrically compare to either soft tissue or lung tissue. The 
dosimetric discrepancies found in silicone-based materials were attributed to their high 
effective atomic numbers. Synthetic gel-based materials showed similar effective atomic 
numbers and dosimetrically resemble human tissue. The first aim found four materials 
(ClearBallistic Gel #20, Liquid PVC plastics, Superflab and an in-house petroleum 
jelly/styrofoam ball mixture) that met all of IROC-Houston’s material requirements. Gel 
#20, and 100% Liquid PVC Plastic, and Superflab dosimetrically mimicked soft-tissue 
and the in-house petroleum jelly/styrofoam balls dosimetrically mimicked lung tissue 
(Figure 16 and Figure 17).  
TLD and radiochromic films were characterized in ViewRay’s MRIdian 60Co and 
Elekta’s Unity MRgRT systems in Aim 2. The same MRgRT system was used to 
characterize double-loaded TLD-100s and EBT3 film in the presence and absence of 
magnetic fields for the Unity and MRIdian configurations. TLDs were characterized in 
IROC-Houston’s homogenous acrylic output blocks and two geometrical phantom slabs. 
A lung and head geometrical slab phantom was manufactured from materials 
recommended in Aim 1. The TLD reproducibility study showed negligible differences 
of 0.6% and 0.5% between TLDs irradiated in the presence and absence of MRIdian and 
Unity configurations, respectively. Similarly, TLDs irradiated in geometrical phantom 
slabs also showed less than 1.4% differences. A larger discrepancy was seen in the 
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geometrical head phantom slab for the Unity configuration. This discrepancy resulted 
from having to change the HIPS exterior wall to solid water between irradiations. TLD 
comparisons using acrylic blocks and geometrical slab phantoms were all within the 
2.3% TLD uncertainty and were comparable to previous studies (Table 9)65. If a magnetic 
field dosimetrically affected the dose deposition in double-loaded TLDs, they were 
smaller than the 2.3% TLD uncertainty and were indistinguishable from the readout 
uncertainty.   
In addition to double-loaded TLDs, the geometrical phantoms were used to 
characterize EBT3 films in the presence and absence of a magnetic field for both 
MRIdian and Unity systems. Relative beam profiles were measured on the EBT3 films 
and were validated from virtual beam profiles generated on GEANT4. The DTA between 
measured and generated beam profiles were compared on the Unity system. The Unity 
configuration had excellent agreement between measured and generated film, thus 
demonstrating that a 1.5T magnetic field environment did not affect radiochromic EBT3 
film (Table 10 and Figure 21). The measured and simulated beam profiles on the 
MRIdian configuration had greater discrepancies than the Unity configuration.  Greater 
agreement was found on the Unity configuration since the point-source file was provided 
by Elekta. A generic 60Co phase-space data was used to simulate MRIdian’s proprietary 
system. Using a generic 60Co phase-space data caused greater discrepancies since the 
MRIdian treatment head could not be simulated completely due to unavailability of 
proprietary information. The greatest discrepancy between measured and simulated beam 
profiles were most apparent in the penumbra region. The simulated penumbra was 
broader due to only simulating a single MLC set. EBT3 was validated in a 0.35T 
environment by comparing the DTA between 0T/0.35T for measured beam profiles to 
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DTA between 0T/0.35T of Monte Carlo generated beam profiles (Table 11 and Figure 
22). This validation showed negligible differences between the film shift; thus, 
concluding that a 0.35T environment does not affect EBT3 films. 
Aim 3 used results from the previous two aims to construct anthropomorphic 
thorax and H&N phantoms using materials and dosimeters previously characterized in 
Aim 1 and Aim 2 (Figure 23 and Figure 28). Gel-based materials used in the MRgRT 
inserts were more difficult to manufacture than solid hydrogen-lacking materials used in 
IROC-Houston’s conventional inserts. Creating film pinprick locations and forming 
complex structures from gel-based materials was a challenging aspect during the 
manufacturing process. Film pinpricks were created by either drilling small holes into 
the insert’s thicker exterior wall or by attaching permeant fine needles into the insert’s 
exterior shell. Complex internal structures, constructed from gel-based materials, were 
manufactured in a multi-step process. The construction process consisted of melting the 
materials and pouring them into a pre-constructed custom mold. To eliminate bubbles 
induced in the pouring process, the molds were placed into a vacuum until the melted 
materials had solidified at room temperature. All gel-based materials were encapsulated 
with either solid water or HIPS to create a rigid and reproducible structure. Solid water 
was used to encapsulate materials that were shown to previously chemically react to and 
degrade HIPS. Due to the cost of solid water, materials that did not chemically react were 
encapsulated with HIPS rather than solid water. The MRgRT inserts’ hard exterior shells 
provided a rigid structure that could withstand hard shipping conditions.   
Designing and manufacturing a motion system used for the MRgRT thorax 
phantom was also included in Aim 3. The two MR safe motions systems considered for 
the MRgRT thorax phantom was to use either a piezoelectric motor or a pneumatic 
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system. MR safe piezoelectric motors were made with fragile ceramic materials that 
usually had a limited workload capability. Since IROC-Houston equipment frequently 
endures rough shipping and handling conditions it was not ideal to have a fragile motor 
that could easily break during transit. A pneumatic system was an appropriate motion 
system since it was durable and had a high workload capability. The pneumatic system 
was designed with two major sections: MR safe and MR unsafe components (Figure 30). 
The waveguide, built into all MRgRT suites, was used to separate the two sections. Thus, 
MR unsafe components were positioned outside and the MR safe parts were positioned 
inside the treatment room. The pneumatic system’s cylinder was an integral part of the 
motion system since it needed to be MR safe and was positioned at the center of the 
magnet. Commercially available aluminum cylinders were not completely MR safe since 
most were manufactured with a stainless steel piston. An aluminum cylinder was bought 
and the stainless steel piston was replaced with a custom made brass piston, thus, 
allowing to be used in center of the MR bore.  
After developing two phantoms in Aim 3, the MRgRT thorax and H&N phantoms 
were irradiated and their dose deliveries were evaluated in Aim 4. Evaluations were done 
by conducting a single institutional commissioning study and a multi-institutional 
feasibility study.  In these studies, TLDs and EBT3 films were used to compare the actual 
treatment to anticipated treatment and were evaluated using the same criteria used in 
IROC-Houston’s conventional phantoms. The passing criteria for the conventional 
thorax and H&N phantoms were 7%/5mm and 7%/4mm, respectively. All studies passed 
IROC-Houston’s criteria for the H&N (Table 15-Table 18)  and thorax (Table 22-Table 
25) phantom, thus demonstrating these phantoms were affective end-to-end QA tools 
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which could be used to credential institutions participating in NCI-sponsored clinical 
trials.   
The simplistic breathing pattern from the pneumatic system could have been a 
weakness in this work. The pneumatic system was designed such that every three seconds 
the phantom would move into either exhale or inhale positions. While this pneumatic 
system was used to represent lung breathing, it did not fully mimic breathing patterns 
from a lung cancer patient. To fully mimic breathing patterns from a typical lung patient, 
the pneumatic system would need to program a series of irregular lung movements. This 
pneumatic system was IROC-Houston’s first MR safe motion system and was originally 
designed with manual flow control knobs. The flow control knobs were physically 
adjusted to create the speed at which the lung insert would move. These manual flow 
control knobs could be replaced with programmable flow control knobs which could be 
used to create various breathing patterns.  
Another limitation of this work was the amount of institutions that participated in 
the feasibility studies. These studies were restricted to MRgRT systems in the United 
States, thus, reducing any time delays caused from shipping overseas and having to go 
through customs. At the time of this study there were only a few MRgRT systems in the 
United States which were fully installed and were working in the clinic. The feasibility 
study consisted of institutions who initially agreed to participate in both phantom studies. 
Some institutions, who had an MRgRT system, were not very receptive and either did 
not provide all necessary items (i.e., exported treatment plan, reported dose) for the 
evaluation studies, were undergoing an upgrade, was newly installed or had exported 
corrupted treatment data that could not completely be analyzed. Since the Unity system 
was new, only a handful of people were allowed to use the MRgRT system. The 
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feasibility study did not include MD Anderson since the same person who was required 
to operate the Unity system during the commissioning study was the same person who 
would have completed the feasibility study. Despite the small cohort, the ones that did 
participate in the feasibility studies passed IROC-Houston’s passing criterion.  
The goal of the MRgRT thorax and H&N phantom was to evaluate each 
institution’s complete MRgRT radiotherapy workflow.  Every component of the multi-
step treatment workflow had an associated uncertainty. The purpose of the end-to-end 
test was not to quantify or identify the source of each specific uncertainty but rather 
evaluate the overall radiotherapy process. Based on the phantom irradiations, the end-to-
end feasibility studies demonstrated that the MRIdian 60Co, MRIdian Linac and Unity 
MRgRT systems could accurately deliver radiation plans. These studies also showed that 
on-board MR imagers were able to verify treatment setup and track tumors on the 
MRgRT phantoms. Lastly, the phantom’s irradiation performance did not show a vendor 
dependence, thus demonstrating that the MRIdian and Unity systems can cohesively 
deliver IMRT plans to treat the MRgRT phantoms. 
The hypothesis of this project was that a homogeneous H&N and dynamic 
heterogeneous thoracic anthropomorphic phantom could be designed to evaluate MRgRT 
systems and would have agreements between the measured and calculated doses within 
±7%/4mm and ±7%/5mm, respectively. Based on the information obtained from this 
work the hypothesis was met by: 1) identifying tissue equivalent materials which were 
MR/CT visible, 2) characterizing EBT3 and TLDs in the presence of a 0.35T and 1.5T 
magnetic field 3) designing and manufacturing a homogenous H&N and a dynamic 
heterogeneous thorax anthropomorphic MRgRT phantom and 4) performing a 
commissioning and a feasibility study on both phantoms. 
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6.2 FUTURE WORK 
One potential avenue of future research would include modeling the MRIdian 
treatment head more realistically. While the treatment head configuration on the MRIdian 
60Co system is proprietary, one could attempt to mimic the treatment head by applying 
two MLCs within a generic 60Co Monte Carlo model. The user would have to estimate 
the location of the two MLCs within the model. Even with approximate MLC locations 
the simulated penumbra would better represent the actual penumbras seen on a MRIdian 
system. Potentially, one could simulate the beam profiles better by using a phase-space 
file provided by Viewray. While this would be the best scenario to simulate the MRIdian 
beam profiles this would be more difficult to achieve since this would require 
collaborating with ViewRay and asking them to provide the phase space data.  
Another broad area of future work would include making several other 
anthropomorphic phantoms for MRgRT systems. This future work could be completed 
by either: making modification to IROC-Houston’s phantoms to adjust for the MR 
component workflows or design new anatomical phantoms used for the MRgRT systems. 
IROC-Houston currently has a conventional pelvis phantom that is only visible in CT. 
This phantom could be constructed with materials suggested in the Steinmann et al. 2018 
study to create an MRgRT pelvic phantom.  Other anatomical phantoms could be created 
using MRgRT materials. For example, an MRgRT pancreas phantom could be extremely 
useful since ViewRay launched a multi-center prospective clinical trial for pancreatic 
tumors.  
Modifying the current MRgRT thorax phantom to address auto contouring and 
online ART techniques could also be another future research area. Rather than having a 
single insert, two inserts could be designed, manufactured and used in the credentialing 
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process. The original insert would represent a patient’s tumor in the beginning of 
treatment and the second insert would have a smaller PTV that represented the same 
tumor after several fractionations. The original insert would have the same end-to-end 
treatment methodology as the MRgRT thorax phantom and would be used to capture a 
CT image, create an IMRT plan accordingly, verify a treatment setup using an MR 
imager and irradiate the phantom. The second insert would be used to test automatic 
contouring and online ART techniques. After the original insert was irradiated, it would 
be removed and the second insert, with the smaller PTV, would be inserted into the 
phantom. While the phantom was on the treatment couch, the institution would perform 
their online ART workflow where they would have to auto contour the smaller PTV, 
adjust the treatment plan, re-calculate the treatment plan, verify treatment plan and 
irradiate the phantom with the new insert.  
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Appendix A: Beam Profile 
 
 
Figure 34: Beam profiles generated under the geometrical head phantom 0T configuration 
for the MRIdian beam. Averaged measured EBT3 beam profile compared to simulate beam 
profiles on Monte Carlo. 
 
 
Figure 35: Beam profiles generated under the geometrical head phantom 0.35T 
configuration for the MRIdian beam. Averaged measured EBT3 beam profile compared to 
simulate beam profiles on Monte Carlo. 
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Figure 36: Beam profiles generated under the geometrical lung phantom 0T configuration 
for the MRIdian beam. Averaged measured EBT3 beam profile compared to simulate beam 
profiles on Monte Carlo. 
 
   
 
 
Figure 37:  Beam profiles generated under the geometrical lung phantom 0.35T 
configuration for the MRIdian beam. Averaged measured EBT3 beam profile compared to 
simulate beam profiles on Monte Carlo. 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
-8 -6 -4 -2 0 2 4 6 8
N
o
rm
al
iz
ed
 D
o
se
Distance [cm]
ViewRay Lung- 0T Geant4 VS Film 
EBT3
Film
GEANT4
Point
Source
GEANT4
Co-60
phase
space
0.0
0.2
0.4
0.6
0.8
1.0
1.2
-8 -6 -4 -2 0 2 4 6 8
N
o
rm
al
iz
ed
 D
o
se
Distance [cm]
ViewRay Lung- 0.35T Geant4 VS Film 
EBT3
Film
GEANT4
Point
Source
GEANT4
Co-60
phase
space
  137 
Appendix B: Dose Profile 
6.2.1 MRgRT Head & Neck:  Left-Right 
 
Figure 38: Left-right dose profile from Unity 1-a (7MV/1.5T) of the commissioning study 
using the MRgRT H&N phantom. 
 
Figure 39: Left-right dose profile from Unity 1-b (7MV/1.5T) of the commissioning study 
using the MRgRT H&N phantom. 
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Figure 40: Left-right dose profile from Unity 1-c (7MV/1.5T) of the commissioning study 
using the MRgRT H&N phantom. 
 
 
Figure 41: Left-right dose profile from ViewRay2 (6MV/0.35T) of the feasibility study using 
the MRgRT H&N phantom. 
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Figure 42: Left-right dose profile from ViewRay3 (60Co/0.35T) of the feasibility study using 
the MRgRT H&N phantom. 
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6.2.2 MRgRT Head & Neck:  Anterior-Posterior  
 
Figure 43: Anterior-posterior dose profile from Unity 1-a (7MV/1.5T) of the commissioning 
study using the MRgRT H&N phantom. 
 
 
Figure 44: Anterior-posterior dose profile from Unity 1-b (7MV/1.5T) of the commissioning 
study using the MRgRT H&N phantom. 
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Figure 45: Anterior-posterior dose profile from Unity 1-c (7MV/1.5T) of the commissioning 
study using the MRgRT H&N phantom. 
 
 
 
Figure 46: Anterior-posterior dose profile from ViewRay2 (6MV/0.35T) of the feasibility 
study using the MRgRT H&N phantom. 
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Figure 47: Anterior-posterior dose profile from ViewRay3 (60Co/0.35T) of the feasibility 
study using the MRgRT H&N phantom.
0
2
4
6
8
-4 -3 -2 -1 0 1 2 3 4
D
o
s
e
 (
G
y
)
Distance (cm)
ViewRay 3: Anterior Posterior Profile
Film Institution Values
Primary PTVOrgan 
AnteriorPosterior
  143 
6.2.3 MRgRT Head & Neck:  Superior-Inferior 
 
Figure 48: Superior-inferior dose profile from Unity 1-a (7MV/1.5T) of the commissioning 
study using the MRgRT H&N phantom. 
 
 
Figure 49: Superior-inferior dose profile from Unity 1-b (7MV/1.5T) of the commissioning 
study using the MRgRT H&N phantom. 
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Figure 50: Superior-inferior dose profile from Unity 1-c (7MV/1.5T) of the commissioning 
study using the MRgRT H&N phantom. 
 
 
Figure 51: Superior-inferior dose profile from ViewRay2 (6MV/0.35T) of the feasibility study 
using the MRgRT H&N phantom. 
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Figure 52: Superior-inferior dose profile from ViewRay3 (60Co/0.35T) of the feasibility 
study using the MRgRT H&N phantom. 
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6.2.4 MRgRT Thorax: Left-Right Film Profiles  
 
Figure 53: Left-right dose profile from Unity 1-a (7MV/1.5T) of the commissioning study 
using the MRgRT thorax phantom. 
 
 
Figure 54: Left-right dose profile from Unity 1-b (7MV/1.5T) of the commissioning study 
using the MRgRT thorax phantom. 
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Figure 55: Left-right dose profile from Unity 1-c (7MV/1.5T) of the commissioning study 
using the MRgRT thorax phantom.  
 
 
 
Figure 56: Left-right dose profile from ViewRay2 (6MV/0.35T) of the feasibility study using 
the MRgRT thorax phantom. 
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Figure 57: Left-right dose profile from ViewRay3 (60Co/0.35T) of the feasibility study using 
the MRgRT thorax phantom.
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6.2.5 MRgRT Thorax:  Anterior-Posterior Film Profiles 
 
 
Figure 58: Anterior-posterior dose profile from Unity 1-a (7MV/1.5T) of the commissioning 
study using the MRgRT thorax phantom. 
Figure 59: Anterior-posterior dose profile from Unity 1-b (7MV/1.5T) of the commissioning 
study using the MRgRT thorax phantom. 
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Figure 60: Anterior-posterior dose profile from Unity 1-c (7MV/1.5T) of the commissioning 
study using the MRgRT thorax phantom.  
 
 
Figure 61: Anterior-posterior dose profile from ViewRay2 (6MV/0.35T) of the feasibility 
study using the MRgRT thorax phantom 
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Figure 62: Anterior-posterior dose profile from ViewRay3 (60Co/0.35T) of the feasibility 
study using the MRgRT thorax phantom 
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6.2.6 MRgRT Thorax:  Superior-Inferior Film Profiles 
 
 
Figure 63: Superior-inferior dose profile from Unity 1-a (7MV/1.5T) of the commissioning 
study using the MRgRT thorax phantom. 
 
 
 
Figure 64: Superior-inferior dose profile from Unity 1-b (7MV/1.5T) of the commissioning 
study using the MRgRT thorax phantom. 
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Figure 65: Superior-inferior dose profile from Unity 1-c (7MV/1.5T) of the commissioning 
study using the MRgRT thorax phantom. 
 
 
 
 
Figure 66: Superior-inferior dose profile from ViewRay2 (6MV/0.35T) of the feasibility study 
using the MRgRT thorax phantom. 
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Figure 67: Superior-inferior dose profile from ViewRay3 (60Co/0.35T) of the feasibility 
study using the MRgRT thorax phantom. 
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Appendix C: Gamma Analysis 
 
6.2.7 MRgRT Head & Neck:  Axial  
 
Figure 68: The commissioning study for the MRgRT H&N phantom. Unity 1-a axial film 
had 96.4% pixels passing.   
 
 
Figure 69: The commissioning study for the MRgRT H&N phantom. Unity 1-b axial film 
had 98.1% pixels passing.    
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Figure 70: The commissioning study for the MRgRT H&N phantom. Unity 1-c axial film 
had 99.1% pixels passing.   
 
 
Figure 71: The feasibility study for the MRgRT H&N phantom. ViewRay 2 axial film had 
97.9% pixels passing.   
 
 
  157 
 
Figure 72:  The feasibility study for the MRgRT H&N phantom. ViewRay 3 axial film had 
96.7% pixels passing.   
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6.2.8 MRgRT Head & Neck:  Sagittal  
 
Figure 73: The commissioning study for the MRgRT H&N phantom. Unity 1-a sagittal film 
had 89.9% pixels passing.     
 
 
Figure 74: The commissioning study for the MRgRT H&N phantom. Unity 1-b sagittal film 
had 89.9% pixels passing.     
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Figure 75: The commissioning study for the MRgRT H&N phantom. Unity 1-c sagittal film 
had 89.2% pixels passing.     
  
 
 
Figure 76: The feasibility study for the MRgRT H&N phantom. ViewRay 2 sagittal film had 
95.7% pixels passing.   
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Figure 77: The feasibility study for the MRgRT H&N phantom. ViewRay 3 sagittal film had 
96.6% pixels passing.   
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6.2.9 MRgRT Thorax:  Axial  
 
Figure 78: The commissioning study for the MRgRT Thorax phantom. Unity 1-a axial film 
had 89.0% pixels passing.  
 
 
Figure 79: The commissioning study for the MRgRT Thorax phantom. Unity 1-b axial film 
had 97.2% pixels passing.  
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Figure 80: The commissioning study for the MRgRT Thorax phantom. Unity 1-c axial film 
had 96.1% pixels passing.   
 
 
Figure 81: The feasibility study for the MRgRT Thorax phantom. ViewRay 2 axial film had 
96.8% pixels passing.   
  163 
 
Figure 82: The feasibility study for the MRgRT Thorax phantom. ViewRay 3 axial film had 
93.1% pixels passing.   
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MRgRT Thorax: Sagittal  
 
Figure 83: The commissioning study for the MRgRT Thorax phantom. Unity 1-a sagittal 
film had 90.4% pixels passing.    
 
 
Figure 84: The commissioning study for the MRgRT Thorax phantom. Unity 1-b sagittal 
film had 95.4% pixels passing.     
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Figure 85: The commissioning study for the MRgRT Thorax phantom. Unity 1-c sagittal film 
had 90.9% pixels passing.    
 
 
Figure 86: The feasibility study for the MRgRT Thorax phantom. ViewRay 2 sagittal film 
had 94.6% pixels passing.   
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Figure 87: The feasibility study for the MRgRT Thorax phantom. ViewRay 3 sagittal film 
had 92.5% pixels passing.  
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